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Future physicians may laugh at our mixing of 
primitive cocktails of poisons to kill the most 
elemental and magisterial disease known to our 
species. But much of this battle will remain the same: 
the relentlessness, the inventiveness, the resilience, 
the queasy pivoting between defeatism and hope, the 
hypnotic drive for universal solutions, the 
disappointment of defeat, the arrogance and hubris. 
 
- Siddhartha Mukherjee 
“The Emperor of All Maladies: A Biography of Cancer” 
 
Generalizations in biology are almost invariably of a 
probabilistic nature. As one wit formulated it, there 
is only one universal law in biology: ‘All biological 
laws have exceptions.’ 
 
- Ernst Mayr 
“The Growth of Biological Thought” 
 
Peace of mind isn’t at all superficial to technical 
work. It’s the whole thing. 
 
- Robert M. Pirsig 
“Zen and the Art of Motorcycle Maintenance” 
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 1. Summary 
 
Sarcomas comprise of a diverse set of neoplasms that present with features of mesenchymal and 
neural crest lineages and can occur in various anatomical sites. Although quite rare in adults, they 
represent the third most common cancer type in the pediatric population. Current clinical 
management involves a multimodal approach that consists of high-dose conventional 
chemotherapy, surgery and/or radiotherapy. Significant improvement in survival outcomes was 
initially noted upon implementation of these modalities but the clinical benefits have now reached a 
plateau. The outcome for patients with recurrent or metastatic disease is still very poor. Additionally 
systemic treatment with conventional cytotoxic drugs and radiotherapy cause severe acute and 
chronic morbidity and could lead to secondary neoplasms later in life. Therefore there is an urgent 
need for rationally selected therapeutic avenues and improved treatment protocols.  
 
It is becoming increasingly apparent that intra-tumoral heterogeneity is a key determinant of clinical 
outcome. Based on the source of heterogeneity two major models of tumor progression have been 
proposed: clonal evolution model and the cancer stem cell (CSC) model. The former is based on 
cancer being purely a disease of the genome, wherein stochastic genetic events give rise to a 
genetically heterogeneous tumor with diverse subclones that follow Darwinian laws of natural 
selection to aid in tumor progression and recalcitrance and importantly are equipotent in their 
tumorigenic capacity in xenotransplantation assays. In this case the cancer-initiating cell (CIC) 
population would be characterized by a genetic lesion alone. The ‘cancer stem cell’ model on the 
other hand views cancer as a developmental disease and therefore as a hierarchically organized 
mass following the principles of organogenesis. It seeks to incorporate the phenotypic and 
functional heterogeneity within tumors and postulates that tumorigenic behaviour is 
compartmentalized to a rare de-differentiated CIC population. Using high-throughput next-
generation sequencing recent studies are beginning to show that the two models of tumor 
development may not be mutually exclusive. 
 
The studies presented in this thesis investigate the cellular organization of the most common 
pediatric sarcoma, Rhabdomyosarcoma (RMS), in order to offer improved clinical management. 
RMS presents as two major histological subtypes – Embryonal (ERMS) and Alveolar (ARMS). 
ERMS account for 70% of diagnosed RMS cases and have a relatively more complex genome. 
ARMS on the other hand have fewer mutations and in about 80% of the cases present with a 
chromosomal translocation that leads to the expression of a potent oncogenic fusion transcription 
factor PAX3/7-FOXO1. In brief, using in vitro sphere formation assay and in vivo 
1 
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xenotransplantation we show that human ERMS cancer cell lines possess subpopulation of 
primitive CICs. Furthermore we present evidence that ERMS CICs are maintained by hedgehog 
signaling and importantly the hedgehog-active ERMS CICs could have prognostic value. Therefore 
ERMS tumors seem to be hierarchically organized wherein a subpopulation of cells have enhanced 
self-renewal and tumor initiation capacity. On the contrary, our investigations in ARMS show that 
the majority of the tumor population possesses CIC properties which are ultimately defined by the 
activity of the fusion protein PAX3-FOXO1.  
 
Although many studies have reported functional heterogeneity within different pediatric sarcoma 
entities there has been no significant breakthrough in terms of targeting sarcoma CICs. Our studies 
offer targeting hedgehog signaling as means to inhibit ERMS CICs and further highlight that novel 
rationally selected treatment strategies in ERMS need to take into account not only the mutational 
background but also the hierarchical organization of the tumor. Furthermore the two histological 
subtypes, which are currently treated with similar protocols in the clinics, seem to follow different 
organizational principles and hence would need tumor type specific treatment strategy. Therefore 
our attempts to identify and characterize RMS CICs not only led to significant advances in 
experimental RMS disease modeling but also have important clinical implications. Overall our 
studies underscore the importance of assessing intra-tumoral heterogeneity in pediatric sarcomas to 
identify key targeting nodes for a lasting cure. 
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 2. Zusammenfassung 
 
Sarkomas sind eine heterogene Gruppe von Krebskrankheiten welche Eigenschaften 
mesenchymaler und neuralleisten Abstammung aufweisen. Sie können an verschiedenen 
anatomischen Stellen auftreten. Obwohl sie im Erwachsenenalter eher selten sind, repräsentieren sie 
die dritthäufigste Tumorgruppe in Kindern. Die klinische Behandlung erfolgt in einem 
multimodalen Ansatz mittels Hochdosis Chemotherapie, Operation und/oder Bestrahlung. Nachdem 
dadurch die Überlebensrate ursprünglich signifikant verbessert werden konnte, haben wir nun ein 
Plateau in der Behandlung erreicht. Die Überlebensrate für Patienten mit Metastasen oder 
Rückfällen ist deshalb immer noch sehr gering. Zusätzlich sind die Behandlungen mit zytotoxischen 
Medikamenten und Radiotherapie akut toxisch und können sekundäre Tumore im späteren Leben 
auslösen. Deshalb besteht ein dringender Bedarf an neuen, sinnvoll ausgewählten therapeutischen 
Strategien, um bestehende Behandlungsprotokolle zu verbessern.   
 
Es wird immer deutlicher, dass intra-tumorale Heterogenität ein wichtiger Faktor für den klinischen 
Erfolg darstellt. Darauf basierend wurden zwei hauptsächliche Modelle des Verlaufs der 
Tumorerkrankungen vorgeschlagen: das klonale Evolutions- sowie das Krebsstammzellen Modell. 
Das erste basiert auf der Annahme, dass Krebs ausschliesslich eine Krankheit der Gene darstellt. 
Stochastisch auftretende genetische Ereignisse führen demnach zu einem genetisch heterogenen 
Tumor in welchem die Zellen natürlicher Selektion nach Darwinunterliegen. Alle Tumorzellen 
haben dabei eine ähnliche Fähigkeit, neues Tumorwachstum in Xenotransplantationen zu initiieren. 
Diese sind durch genetische Läsionen charakterisiert. Dem gegenüber steht das Krebsstammzellen 
Modell, welches Krebs als eine Krankheit betrachtet, die hierarchisch organisiert ist und den Regeln 
der Organogenese folgt. Hier wird postuliert, dass eine seltene Population von Zellen für das 
tumorigene Verhalten verantwortlich ist. Durch neue Sequenziermethoden wird zunehmend auch 
klar, dass sich die beiden Modelle nicht unbedingt ausschliessen müssen. 
 
Die Untersuchungen, welche in dieser Arbeit vorgestellt werden, haben die zelluläre Organisation 
des häufigsten kindlichen Sarkomas, des Rhabdomyosarkoms (RMS), charakterisiert. RMS zeigt 
sich klinisch in zwei Hauptgruppen – embryonal (ERMS) und alveolär (ARMS). ERMS ist 
verantwortlich für 70% aller Fälle und weisen ein verhältnismässiges komplexes Genom auf. 
ARMS auf der anderen Seite hat weniger Mutationen und ist in ca. 80% der Fälle durch eine 
chromosomale Translokation charakterisiert, die zur Expression eines onkogenenFusionsprotein 
führt, PAX3/7-FOXO1. Wir konnten nun erstmals durch Bildung von Sphären und 
Xenotransplantationenzeigen, dass ERMS Tumorzellen eine kleine Population von 
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Krebsstammzellen aufweisen.Wir zeigen, dass diese Population mittels aktivem Hedgehog 
Signalweg gesteuert wird, und dass ihre Anwesenheit von prognostischer Bedeutung ist. Daher ist 
ERMS ein hierarchisch organisierter Tumor. Auf der anderen Seite zeigen unsere Untersuchungen 
an ARMS, dass die Mehrheit der Tumorzellen dieser RMS Gruppe Eigenschaften einer Stammzelle 
aufweisen, welche ultimativ durch das Fusionsprotein PAX3/FOXO1 gesteuert werden. 
 
Obwohl ähnliche Untersuchungen schon funktionelle Heterogenität in verschiedenen kindlichen 
Sarkomen nachgewiesen haben, konnten diese Erkenntnisse bis jetzt klinisch nicht genutzt werden. 
Unsere Untersuchungen heben nun den Hedgehog Signalweg als mögliche therapeutische Option 
hervor. Dies zeigt, dass sinnvoll ausgesuchte neue Therapien nicht nur den Mutationshintergrund 
sondern auch die hierarchische Organisation des Tumors berücksichtigen müssen. Die beiden 
histologischen RMS Untergruppen, welche bis anhin mit ähnlichen Protokollen behandelt werden, 
weisen demnach eine unterschiedliche zelluläre Organisation auf und brauchen in Zukunft 
möglicherweise unterschiedliche Behandlungsstrategien. Deshalb haben unsere Untersuchungen 
über die Krebsstammzellen nicht nur das Verständnis zur Tumororganisation signifikant verbessert, 
sondern implementieren auch wichtige klinische Konsequenzen. Sie zeigen zudem, dass der 
Tumorheterogenität in pädiatrischen Sarkomen eine Schlüsselrolle auf dem Weg zu einer 
langfristigen Heilung zukommt. 
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 3. List of Abbreviations
 
ABCG2  ATP-binding cassette sub-family G member 2 
ALK   Anaplastic Lymphoma Kinase 
AKT   AK – mouse strain, T – Thymoma; also called Protein Kinase B (PKB) 
ARF   Alternate Reading Frame; part of CDKN2A gene locus 
CCND1  Cyclin D1 
CDK   Cyclin-dependent kinase 
CD[number]  Cluster of Differentiation 
cDNA   complementary Deoxyribonucleic acid 
CI   Confidence Interval 
CK1   Casein Kinase 1 
c-KIT cellular Tyrosine protein KInase; also called CD117 or Stem Cell growth 
Factor Receptor (SCFR) 
c-MET  cellular Mesenchymal-Epithelial Transition factor; also called Hepatocyte 
Growth Factor Receptor (HGFR) 
CMV   Cytomegalovirus 
DAPI   4’,6-Diamidino-2-Phanylindole 
DMEM  Dulbecco’s Minimum Essential Medium 
DMSO  Dimethylsulphoxide 
EDTA   Ethylene diamine tetraacetic acid 
ERK   Extracellular signal Regulated Kinase 
FBS   Fetal Bovine Serum 
FOS   Finkel-Biskis-Jinkins murine Osteogenicsarcoma 
FOXO  Forkhead box O 
GLI   Glioma-associated 
GSK3β  Glycogen synthase kinase-3 beta 
GTPase  Guanosine triphosphate hydrolase 
HES   Hairy and Enhancer of Split 
HHIP   Hedgehog interacting protein 
HIF   Hypoxia inducible factor 
h-TERT  human telomerase reverse transcriptase 
INK4   Inhibitor of cyclin-dependent kinase 4 
qRT-PCR  quantitative Real-Time Polymerase Chain Reaction 
LGR5   Leucine-rich G-coupled Receptor 5 
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MAPK  Mitogen-Activated Protein Kinase 
MDM2  Mouse double minute 2 homolog 
MDR1  Multidrug resistance protein 1; also called Permeability-glycoprotein 1 (P-gp) 
MEK MAPK/ERK Kinase; also called mitogen-activated protein kinase kinase 
(MKK; MAP2K) 
MSC   Mesenchymal Stem Cell 
mRNA  messenger ribonucleic acid 
mTOR  mammalian Target of Rapamycin 
MYC (C-, N-) Myelocytomatosis oncogene (C-cellular, N-neuroblastoma) 
MYF   Myogenic factor 
NANOG  Tír na nÓg 
NF1   Neurofibromatosis 1 
NGS   Next-generation sequencing 
NOD   Non-Obese Diabetic 
OCT4   Octamer-binding transcription factor 4 
P53   Protein 53; also called Transformation-related protein 53 (TRP53) 
PARP   Poly (ADP-ribose) polymerase 
PAX   Paired box protein 
PI3K   Phosphoinositide-3-kinase 
PKC   Protein Kinase C 
PTEN   Phosphatase and tensin homolog 
RAS   Renin-Angiotensin System 
ROS   Reactive Oxygen Species 
Sca-1   Stem cell antigen-1 
SCID   Severe combined immunodeficiency 
SDF1α  Stromal derived factor-1 alpha 
SEER   Surveillance, Epidemiology, and End Results 
shRNA  short hairpin RNA 
siRNA   small interfering RNA 
SOX2   SRY (sex determining region Y)-box 2 
Stro-1   Stromal precursor antigen-1 
VEGF   Vascular Enodthelial Growth Factor 
Wnt   Wingless related integration site; a combination of Wingless (Wg) and Int1 
 
 
 
  
6 
 4. Introduction1 
 
4.1. Cancer: A brief introduction 
Cancer is a group of diseases characterized by uncontrolled proliferation of atypical cells that 
eventually develop the ability to invade surrounding normal tissues and spread to other organs in 
the body. It is the second most common cause of death worldwide, after heart disease [3]. Cancers 
are histologically classified based on the embryonic origin of the normal tissue they most closely 
resemble: carcinomas (epithelial tumors), sarcomas (mesenchymal tumors), neuroectodermal 
tumors (occurring in tissues derived from outer cell layer of early embryo) and hematological 
tumors (blood cancers). 
The relative incidence of cancer types changes remarkably across different population age 
groups (Fig. 1A; [1]). Carcinoma is the most commonly diagnosed cancer types in the world; 
accounting for 80% of all cancer-related deaths and occurs mainly in adults. Children (0-14 years) 
develop primarily hematological malignancies, neuroectodermal tumors and sarcomas. The 
distribution of cancer entities diagnosed in children also changes with increasing age (Fig. 1B; [2]). 
The cancer incidence and observed survival in 0-14 year age group in Switzerland is depicted in 
Fig. 1, C and D. 
.  
Figure 1. Cancer incidence by type in European 
populations. (A) Data derived from a total of 53,717 
cases for age 0–14 years, 282,042 cases for age 15–29 
years, and 5,950,220 cases for age 30+ years; obtained 
from cancer registries. Adapted from [1]. (B) Relative 
frequencies for the main International Classification of 
Childhood Cancer-3 diagnostic groups by indicated age 
groups. Adapted from [2]. (C) Incidence of cancer types in 
0-14 year age group in Switzerland standardized to world 
standard population reported by Automated Childhood 
Cancer Information System (ACCIS; International Agency 
for Research on Cancer, World Health Organization). (D) 
Estimate of five-year observed cumulative survival for 
Switzerland and Europe for 0-14 age group, reported by 
ACCIS. Error bars represent 95% C.I. Graphs for (C) and 
(D) were constructed using data available at 
http://acciss.iarc.fr (Last updated on: 11/03/2003; 
accessed 3 March 2014, 17:37)  
 
1 Many sections within the Introduction have been adapted from the published book chapter:  
Satheesha, S. and Schäfer, B.W., Cancer Stem Cells in Pediatric Sarcomas, in Stem Cells and Cancer Stem Cells: 
Therapeutic Applications in Disease and Injury, M.A. Hayat, Editor. 2014, Springer: Dordrecht. p. 111-126. 
Introduction 
The cancer-causing or etiological factors can be broadly classified as Intrinsic or Extrinsic, 
based on their source. Intrinsic factors primarily include inherited or acquired genetic mutations. 
Extrinsic factors could be chemical (such as asbestos, tobacco etc.), physical (ionising and non-
ionising radiation) or biological (viruses, bacteria and other parasites). Other risk factors that 
contribute to cancer have also been identified such as age, lifestyle (exercise, diet, alcohol 
consumption) and geographical location (pollution, parasite prevalence). The causative factor for 
most pediatric tumor types is unknown and the risk factors are unclear.  
Cancer initiates as a monoclonal disease following a genetic mutation. The development of 
cancer is a multi-step process in which normal cells accrue genetic and epigenetic alterations that 
progressively leads to their conversion into a pre-neoplastic, and finally a highly malignant state 
(Fig. 2A) [4-5]. Normal cellular machinery maintains homeostasis by employing evolutionarily 
conserved signaling networks that are extensively inter-linked and possess intricate feedback 
mechanisms. The genetic mutation and loss of epigenetic identity of normal cells has a cascading 
effect on cell transcriptional profiles which translates to altered protein expression and function. 
The mutations that initiate (‘gatekeeper’ mutations) and cause cancer progression (‘driver’ 
mutations) occur in key nodes that affect cellular genome maintenance, cell fate or cell proliferation 
(Fig. 2B). This culminates in a cancer cell acquiring functional features that makes it resourceful, 
versatile, labile and hence difficult to kill. The features possessed by a cancer cell have been 
codified as the ‘Hallmarks of Cancer’ (Fig. 2, C and D) [6-7]. Also, cell extrinsic factors such as the 
tumor cell microenvironment have been recently identified as an important determinant of cancer 
cell behavior. 
 
Figure 2. Current understanding of the molecular and cellular biology of cancer. (A) The concept of the 
multi-step nature of carcinogenesis depicted as a lineage of mitotic cell division from fertilized egg to a single cell within a 
cancer, which is applicable to most adult cancers and specifically proven in the case of colorectal cancer development. 
While driver mutation leads to cancer progression a cancer cell possesses many ‘passenger’ mutations that do not 
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contribute to cancer cell function. Adapted from [4]. (B) The driver genes identified from cancer sequencing studies can 
be classified into one or more of the 12 pathways (middle ring) that confer a selective growth advantage (inner circle). 
These affect major cellular processes (outer ring). Detailed explanation in [5]. (C) The first described six ‘core’ acquired 
functional capabilities of cancer cells. Adapted from [7]. Detailed explanation in [6] (D) Two additional hallmarks yet to be 
generalized and therefore referred to as ‘emerging’: altered cellular metabolism and evasion of immune surveillance 
seem to support neoplastic progression. Two consequential characteristics of cancer: genomic instability and 
inflammation facilitate acquisition of ‘core’ and ‘emerging’ hallmarks and have been described as ‘enabling’ hallmarks [7]. 
 
4.2. Sarcoma 
4.2.1. Diagnosis 
Sarcomas comprise a heterogeneous group of rare malignancies (5.9 cases per 100,000 
inhabitants) with features of mesodermal or neural crest origin [8]. They consist of a large number 
of histological variants with differing clinical behavior [9]. Sarcomas usually present as enlarging 
mass lesions, deep within tissues, without any characteristic clinical symptoms. The patient 
experiences physical symptoms only if the lesion is compressing adjacent structures and hence 
making early detection problematic. They do not seem to be associated with a particular organ 
system like carcinomas and can occur in any part of the body, most commonly in the extremities, 
followed by the trunk and intra-abdominal sites. However some histological variants seem to show 
a predilection to certain sites and gender, the reasons for which is still unclear. 
Certain broad classification principles are used in sarcoma biology; i) based on the closest 
immunotypic and cellular resemblance to an adult mesenchymal tissue (e.g. smooth or skeletal 
muscle, vasculature, fibrous tissue, adipose or 
chondro-osseous tissue), ii) based on cellular 
morphology (e.g. small round blue cells, spindle 
cells, pleomorphic or epithelioid cells), iii) based 
on genetic lesions (e.g. chromosome translocation-
positive or –negative) and iv) based on clinical 
behavior determined retrospectively (e.g. benign, 
locally invasive or rarely metastasizing 
intermediate or malignant). Over the past two 
decades molecular genetics has played an 
increasingly important role in correct diagnosis of 
sarcomas as a significant number of them possess 
characteristic chromosome translocations (Table 
1); encoding for either aberrant transcription 
factors, for example alveolar rhabdomyosarcoma 
(ARMS), Ewing sarcoma and primitive neuroectodermal tumors (PNETs) and synovial sarcoma or 
leading to constitutive growth factor signaling as in dermatofibrosarcoma pertuberans (DFSP) [10]. 
 
Table 1. Chromosomal translocations in sarcomas. [9] 
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4.2.2. Epidemiology 
Sarcomas pose a unique challenge to researchers and clinicians alike as they cross the age 
spectrum. Although in total numbers more adults are diagnosed with sarcoma its relative incidence 
is higher in the pediatric populations, accounting for 7.4% of all pediatric malignancies. Significant 
differences have been noted in the occurrence pattern with age (Fig. 3A). The incidence of 
sarcomas in infants (<1 year old) was found to be higher than in older children [11]. Congenital 
fibrosarcoma and hemangiopericytoma are peculiar to infants while RMS is the most common 
sarcoma in the first two decades of life (median age of 15 years). In children <10 years of age the 
embryonal RMS (ERMS) is more common followed by malignancies of fibroblastic histologies 
such as UPS (previously referred to as malignant fibrous histiocytoma or MFH) and fibrosarcoma 
[8]. In young adolescents (age 10-14 years) ARMS becomes more common and in older patients the 
pleomorphic subtype is the most often diagnosed RMS [12]. In the second decade of life non-RMS 
sarcomas occur more frequently and eventually become the most common sarcomas diagnosed in 
adults. These include osseous tumors such as Ewing sarcoma and osteosarcoma, fibroblastic tumors 
such as DFSP and UPS, chondrosarcoma, synovial sarcoma, malignant peripheral nerve sheath 
tumor (MPNST) and desmoplastic small round cell tumor (DSRTC). In young adults (age 20-39 
years) Kaposi sarcoma is the most frequent sarcoma since the dominant causal mechanism requires 
HIV infection [13]. Synovial sarcoma, Ewing sarcoma, DFSP and alveolar soft parts sarcoma 
(AFPS) could be considered as transitional tumor types as they overlap the pediatric and young 
adult age groups [8, 14-15]. Older adults (>40 years old) have increased propensity for 
leiomyosarcoma, liposarcoma and blood vessel tumours. Osteosarcoma has its second incidence 
peak in people above 60 years of age as a consequence of treatment for a different cancer or 
secondary to Paget’s disease [16]. 
Within a sarcoma histotype predilection to site of occurrence also changes with age. Ewing 
sarcoma in children is predominantly diagnosed in the bone while in adults it manifests itself in the 
soft tissues [14]. Embryonal RMS the predominant histology in children shows a preference for the 
head and neck regions and the adult pleomorphic RMS occurs in the extremities [8]. In the case of 
osteosarcoma, children develop sarcoma in the lower long bones during the growth spurt and in 
adults the pelvic region is more commonly afflicted than in children [16]. Survival of sarcoma 
patients decreases with advancing age (Fig. 3B).  
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Figure 3. Sarcoma incidence and survival pattern in different age groups. (A) Distribution of histological 
subtypes in 10-year age groups determined from 48,012 cases collected from the SEER database (1973-2006) [8]. (B) 
Reported survival rate of pediatric-type sarcomas for adult and pediatric patients. Table adapted from [17].  
 
Whether age is a prognostic factor is under discussion and is critically reviewed for Ewing 
sarcoma family of tumors [14]. The difference in survival could be due to the dissimilar clinical 
management strategies used for adult and pediatric sarcoma patients. There may additionally be 
inherent differences in the tumor biology but the data is too limited to draw conclusions [8, 14, 18-
19].  
Since the experimental work performed for the present doctoral thesis focuses on pediatric 
rhabdomyosarcoma the following sections will focus and elaborate on sarcoma histotypes and sub-
histotypes which are most common in the pediatric population or are in the transitional zone 
between children and young adults. These include ERMS, ARMS, UPS, osteosarcoma, Ewing 
sarcoma and synovial sarcoma.  
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4.2.3. Treatment of pediatric sarcomas 
Treatment approach to sarcomas is multimodal and includes surgery, conventional anti-mitotic 
combinatorial chemotherapy and optional radiotherapy (Fig. 4).  
 
Figure 4. Current multimodal treatment approach in sarcomas based on histology [15]. Solid boxes 
represent standard of care whereas dotted lines may not apply to all or are still in clinical trials. Dotted lines represent 
possible recurrence. DSRCT and synovial sarcoma are represented with a gradient because they have features of both 
pediatric type and adult-type sarcomas. 
ESFT, Ewing Sarcoma Family of Tumors (Ewing sarcoma and PNETs); Ifos/Dox, ifosfamide and doxorubicin; IRS, 
Intergroup Rhabdomyosarcoma Study; IVA, ifosfamide, vincristine, and actinomycin; IVA(Do), IVA plus doxorubicin, RT, 
radiotherapy; STS, Soft-tissue Sarcoma; VAC, vincristine, actinomycin-D, and cyclophosphamide; VDC_IE, vincristine, 
doxorubicin, and cyclophosphamide plus ifosfamide and etoposide; VIDE, vincristine, ifosfamide, doxorubicin, and 
etoposide. Also see text. 
 
Although pediatric sarcomas are generally considered as chemosensitive and radiosensitive 
tumors surgery with negative margins is the only way to achieve complete remission. Local control 
is the major cause of treatment failure. In case of synovial sarcoma it was noted that positive margin 
was an independent predictor of local recurrence [20]. Surgery is performed after chemotherapy in 
some European protocols to ensure better local control. If complete resection is possible for a low-
grade or low-risk tumor type only then radiotherapy is avoided. However RMS occurs mainly in 
sites where surgery is either unfeasible or would lead to severe cosmetic consequences, in which 
case radiotherapy and chemotherapy are the only hopes for local and systemic control [21-22]. 
The treatment of RMS has improved over the past decades by the implementation of multi-
institutional co-operative risk-adapted trials. The groups conducting these trials are the Soft tissue 
Sarcoma committee of the Children’s Oncology Group (STS-COG, formerly Intergroup RMS 
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Study Group, IRSG) in the United States, and the recently formed European pediatric Soft tissue 
Sarcoma Study Group (EpSSG). The latter was formed by the joining of International Society of 
Pediatric Oncology-Malignant Mesenchymal Tumor committee (SIOP-MMT), the German Soft 
tissue co-operative study (CWS) and the Italian Co-operative Group (ICG; Associazione Italiana 
Ematologia Oncologia Pediatrica-Soft Tissue Sarcoma Committee, AIEOP-STSC). Based on 
clinical parameters at the time of diagnosis RMS patients are divided into clinical groups. The 
clinical groups are then used as prognostic indicators to divide the patients into ‘risk groups’. The 
intensity of treatment is predicated on the risk stratification since the staging system closely relates 
to outcome. The clinical grouping and risk-based staging systems are not uniform across the two 
trial leaders making comparisons difficult (Table 2). 
 
Table 2. Risk stratification used in Soft tissue sarcoma co-operative groups with concurrent 
treatment and estimated survival. [18]  
 
NOS: not otherwise specified. Favourable sites include: urogenital (non-bladder, non-prostate), head and neck (non-
parameningeal), orbit, unfavourable includes all other sites. N0: lymph node involvement absent; N1: positive lymph 
nodes; and Nx: unknown involvement lymph nodes. M0: no distant metastases; and M1: distant metastases present. I: 
ifosfamide; Do: doxorubicin; V: vincristine; A: d-actinomycin; C: cyclophosphamide; Topo: topotecan; CPT-11: irinotecan; 
and RT: radiotherapy. *Post-surgical clinical grouping system 
 
Despite the initial successes of the multimodal treatment strategies in childhood solid cancers 
there has been little improvement on mortality in recent years [23]. It seems that 30-40% of children 
and young adults with sarcoma, irrespective of histology and regimens used, will develop recurrent 
or metastatic disease and <25% of them will survive in the recurrent setting [15]. About 50% of 
ERMS cases are considered low risk with a majority having long term event-free survival at 85-
95% even with reduced therapy intensity. However there is a minority of low risk patients that still 
require high-dose chemotherapy and have lower survival. The intermediate risk ERMS patients 
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consisting of about 40% of ERMS cases have an event-free survival of about 75% which has not 
improved with either dose intensification or changing therapy agents. The situation is dismal for the 
high risk metastatic ERMS patients and patients with progressive or recurrent disease, with a five 
year survival estimate at 35% and 17% respectively [24-25]. At present 30% of osteosarcoma 
patients do not survive the disease and there has been no significant improvement in the treatment 
of metastatic disease [16]. The scenario is similar for Ewing sarcoma [26]. 
Additionally the high cure rates for pediatric sarcomas come at a high cost since severe 
treatment-related morbidity has been associated with the current regimens [21]. Pediatric patients 
are treated with high dose systemic chemotherapy, which is not tolerated by adult patients. There is 
greater than 80% chance of having at least one drug-related side-effect that is severe, life-
threatening or fatal during the course of therapy [27]. The VAC protocol which is the mainstay in 
RMS treatment is associated with considerable acute toxicity [22]. The alkylating drugs such as 
ifosfamide and cyclophosphamide cause gonadal toxicity, ifosfomide can cause acute neurologic 
complications, anthracycline drugs such as doxorubicin cause cardiotoxicity, d-actinomycin can 
cause hepatotoxicity (especially in infants) and vincristine induces peripheral neuropathies. There is 
a significant risk of late effects such as cardiac dysfunction and coronary heart disease, cognitive 
impairment, renal insufficiency, endocrinopathies, including infertility, and secondary malignant 
neoplasms such as leukemia, which are not clinically evident until many years later [23, 28-29]. The 
late effects of radiotherapy are staggering. The survivors of childhood cancers treated with direct 
abdominopelvic irradiation have a risk of developing colorectal cancer that is comparable to that of 
individuals with a strong family history of colorectal cancer [30]. Radiotherapy also causes bone 
growth arrest, muscle atrophy, bladder dysfunction and infertility in childhood RMS survivors [22, 
31]. Recent EpSSG-led trials seeking to reduce or even omit radiation modality showed that 
although this led to slightly higher relapse risk the overall survival was comparable to the COG 
trials [32]. These recurrent tumors seem to be amenable to re-treatment; however the effect of 
increased hospitalization on patient quality of life and morbidity in the long-term needs further 
investigation.  
Due to the aforementioned inadequacies and limitations of current modalities there has been an 
emphasis on understanding the molecular biology of pediatric sarcomas to tailor personalized 
rationale-based therapies. To do so, one would need to answer three important interrelated 
questions,  
 What causes sarcomas? – etiological factors that could provide targeting options 
 Where do sarcomas originate? – ‘cell of origin’ to design efficient models for drug testing 
 How do sarcomas develop? – models of sarcomagenesis to delineate targeting strategies 
These questions will be briefly discussed in the following sections. 
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4.2.4. Etiology 
The etiology of sarcomas is under extensive investigation which has led to the identification of 
many important oncogenic drivers [33]. Interestingly pediatric cancer contain very few mutations 
compared to adult cancer entities and are therefore considered as genetically simple tumors to study 
(Fig. 5) [5]. Even so, the ‘magic bullet’ to completely cure the disease is elusive. 
 
Figure 5. The median number of non-synonymous mutations per tumor in a variety of tumor types. 
Horizontal bars indicate the 25 and 75% quartiles. MSI, microsatellite instability; SCLC, small cell lung cancers; NSCLC, 
non–small cell lung cancers; ESCC, esophageal squamous cell carcinomas; MSS, microsatellite stable; EAC, 
esophageal adenocarcinomas. Adapted from [5]. 
 
Many pediatric sarcomas contain chromosomal translocations (Table 1) which are necessary for 
the survival of the cancer cell but they seem not be sufficient for tumorigenicity in most cases; 
synovial sarcoma being a key exception [34-35]. Usually additional secondary mutations are 
necessary to fully transform cells [33, 36-37]. For instance, for complete transformation of skeletal 
myoblasts into ARMS in vitro, the initial hit of PAX3-FOXO1 expression needed to be coupled 
with loss of INK4A pathway, N-MYC amplification and stabilization of h-TERT [38] and 
disruption of p53 or p16Ink4a pathway was required in vivo [39-40]. The translocation-positive 
sarcoma have a near-diploid karyotype which is in mark contrast to the relatively more complex 
karyotypes found in the translocation-negative sarcoma subtypes (ERMS, osteosarcoma and UPS). 
Recent NGS studies in RMS could reliably quantify this difference between fusion positive and 
negative RMS [41-42].  
Certain congenital syndromes and birth defects seem to be significantly associated with risk of 
developing translocation-negative sarcomas (Fig. 6). Many of the genetic syndromes associated 
with sarcoma development disrupt genes involved in genome maintenance. Additionally mice 
deficient in DNA repair mechanism with an Ink4a mutant background were shown to develop 
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ERMS, fibrosarcoma and UPS [43]. These observations have led to improved disease modeling and 
identification of tumor initiating lesions important in sporadic sarcomas. 
 
 
Figure 6. Congenital disorders associated with (A) rhabdomyosarcoma (Adapted from [44]) and (B) 
osteosarcoma [16].  
 
Loss of cell cycle checkpoints seems to be a recurrent theme in sarcomagenesis, including 
mutation of Retinoblastoma (RB1), deletion of CDKN2A (INK4A locus), PTEN mutations and 
amplification of CDK4. Loss of p53 activity has been widely reported in various sarcoma subtypes 
through different mechanisms. Almost all transgenic sarcoma mouse models require p53 
(homozygous or heterozygous) mutation, Ink4a mutation and/or disruption of the Rb pathway to 
initiate tumor formation or improve phenotype penetrance. Interestingly mice with p53 or Ink4a 
null mutation alone developed sarcomas with relatively lower penetrance. The most penetrant 
osteosarcoma mouse models involve the co-operative effect of p53 and Rb1 mutations [45-46]. In 
case of ERMS mouse models loss of Rb1 seems to act a genetic modifier by de-differentiating the 
tumor phenotype [47]. It is important to acknowledge and factor in the difference between mouse 
models of sarcomagenesis and the human situation. Human RB1 loss of function mutations 
translates to some residual activity unlike in the mouse where the entire gene is lost. Also p53 
mutations in humans have gain of function phenotype but in mouse they are null mutations. 
Commonly found activated oncogenic pathways include MYC (osteosarcoma and RMS), RAS 
(synovial sarcoma and RMS) and FOS (osteosarcoma and ERMS). RAS pathway has now been 
unequivocally identified as the most commonly activated oncogenic pathway in RMS [41-42]. RAS 
activation led to ERMS formation in zebrafish [48]. KRAS activation in mice with p53 null 
background leads to UPS formation [49-50]. Various growth factor receptors are either amplified or 
the signaling pathways have been shown to be activated in different sarcoma subtypes [35-37, 51]. 
These include Epidermal Growth Factor Receptor (EGFR) in ERMS, UPS and osteosarcoma; 
Insulin Growth Factor Receptor (IGFR) and Fibroblast Growth Factor Receptor (FGFR) in RMS 
and osteosarcoma; Platelet Derived Growth Factor Receptor (PDGFR) in RMS, Connective Tissue 
Growth Factor (CTGF) in osteosarcoma and Hepatocyte Growth Factor Receptor (HGFR or c-
MET) in ERMS, synovial sarcoma and osteosarcoma. Epigenetic changes such as Loss of 
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Heterozygosity at 11p15.5, which includes the IGF2 locus, are commonly observed in ERMS 
tumors. 
Lately the importance of developmental pathways such as Wnt (canonical and non-canonical), 
Hedgehog, Notch and Transforming Growth Factor β (TGFβ) in tumor initiation and differentiation 
has been shown in diverse sarcomas [51-52] (discussed later). Other cellular processes that play 
critical roles in maintaining cancer cell functions such as epigenetic regulation of gene expression, 
apoptotic pathway regulation, post-transcriptional regulation of RNA via non-coding RNAs, protein 
translation regulation (mTOR pathway), protein post-translational regulation (protein folding, 
ubiquitination, phosphorylation), metabolism (ROS generation), angiogenesis induction (VEGF 
production) seem to aid in sarcomagenesis and are also being actively scrutinized for targeting 
options in pediatric sarcomas [37, 41-42, 51, 53-57]. Overall it is apparent that pediatric sarcoma 
cells despite harboring few mutations are successful in possessing many of the cancer hallmarks. 
Apart from the fusion proteins in the translocation positive sarcomas, it is not yet clear which of the 
aforementioned node(s) is central to the sarcoma phenotype. A bottom-up way of addressing this 
quandary would be to establish a faithful sarcoma model that would recapitulate the tumor 
phenotype. To do so, we would need to know the sarcoma ‘cell of origin’. 
 
4.2.5. Sarcoma ‘cell of origin’ 
Improved gene targeting methods in mice which allow for spatial and temporal control of gene 
expression and gene expression profiling have made it possible to rigorously interrogate the ‘cell of 
origin’ for different sarcomas (Fig. 7). 
 
4.2.5.1. Multi-lineage stem cell origin 
It was postulated decades ago that mesenchymal neoplasms could have a stem cell origin based 
on ultrastructural and immunophenotyping studies [58]. Accordingly, results from in vitro 
experiments and gene expression profiling and also extrapolations from clinical presentations have 
led researchers to postulate mesenchymal stem cell (MSC) as the ‘cell of origin’ for many of the 
pediatric sarcoma entities, including osteosarcoma, Ewing sarcoma, ARMS, UPS and synovial 
sarcoma [45, 59-64]. This has been successfully established in vivo for osteosarcoma, where tumors 
arose from mesenchymal progenitor lineage upon homozygous p53 deletion and Rb1 deletion [65]. 
Interestingly, the authors describe a large percentage of sarcoma entities in the mesenchymal 
lineage model as ‘poorly differentiated soft tissue sarcoma’ which could be a UPS phenotype. 
Ewing sarcoma cells seem to possess features of MSCs [66]. However when EWS-FLI1 expression 
was introduced in the mesenchymal progenitor compartment it led to increased incidence of ‘poorly 
differentiated sarcoma’ with high expression of EWS-FLI1 specifically in the tumor cells but it is 
  
17 
Introduction 
unclear how much this model resembles the human situation [67]. In general, the expression of 
EWS-FLI1 alone has been found to be insufficient to completely transform MSCs in vivo. 
A neural crest-derived (pre-myogenic) stem cells compartment has been propounded as a 
possible origin for ERMS since it is known to occur in body parts where no known skeletal muscle 
cells are present. Indirect evidence has also been provided by ERMS development in mice with NF1 
mutation [68]. Recent efforts to identify the ‘cell of origin’ in Ptch1 mutant mouse model of ERMS 
revealed that a prenatal activation of the hedgehog pathway in a pre-somitic compartment rather 
than the muscle lineage is required for tumor formation [69]. Additionally, a rare sarcoma entity, 
Ectomesenchymoma, intriguingly and most commonly, presents with intermixed areas of neuronal 
and rhybdomyosarcomatous differentiation and is thought to arise from a multipotent neural crest 
cell [70-71]. A neural crest origin has also been posited for Ewing sarcoma due to the presence of 
primitive neuroectodermal features within the tumors [72]. Recently it was shown that EWS-FLI1 
expression was tolerated by human neural crest stem cells and their MSC progeny; however, the 
tumorigenic capacity of these cells has not been reported [73]. 
 
4.2.5.2. Lineage-restricted stem cell and progenitor origin 
Adipocyte stem cells could be chemically transformed to give rise to sarcomas with synovial 
sarcoma or UPS histology [74]. Recently hedgehog activated ERMS (restricted to the head and 
neck region) were shown to arise from the adipocytic lineage [75]. The adipocyte stem cells 
however seem not be conducive to osteosarcoma formation [76]. Instead osteosarcomas develop 
with high penetrance when tumor suppressors were ablated in the osteoblast lineage-restricted 
cellular compartments [45-46].  
The ERMS ‘cell of origin’ has been investigated by targeted ablation of Ptch1, p53 and Rb1 
activities in a range of cells in the myogenic lineage [47]. These studies showed that ERMS arose 
from the more differentiated compartments, while UPS arose from the undifferentiated 
compartments (satellite cell) showing that these two major sarcoma subtypes could lie in a 
continuum. Also activation of hedgehog signaling in Myogenin (committed muscle progenitor) 
expressing cells led to formation of ERMS in the tongue. When the oncogenic insults were altered 
to activate Kras and ablate Tp53 then the undifferented muscle stem cell compartment 
(Pax7+MyoD-) gave rise to mostly RMS and some UPS but the more differentiated compartment 
(Pax7+MyoD-) gave rise to exclusively UPS tumors. Intramuscular origin for UPS has been reported 
previously [49-50]. Interestingly, osteosarcomas can also arise from Myf5 (activated muscle stem 
cell) expressing compartment upon homozygous p53 knockout [47].  
UPS has also been shown to arise from other mesenchymal lineages. UPS could also be induced 
from mouse embryonic fibroblasts reprogrammed by homozygous knockout of Rb1 [77]. In the 
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various models of osteosarcoma UPS incidence has also noted, in particular when p53 was ablated 
in pre-osteoblasts. It is unclear if the molecular features of the UPS in all these different lineage 
models are similar.  
The mature myoblasts expressing Myf6 were reported as the origin of fusion positive ARMS. 
The compartment seems to de-differentiate upon expression of Pax3-Foxo1, but this was possible 
only in a p53 or Ink4a null background [39]. Synovial sarcomas have uncertain differentiation but 
their origin seems to be from the Myf5 expressing myogenic compartment [34]. 
It should be noted that the characterization of sarcomas modeled in vivo has mainly included 
histological analysis and gene expression profiling. However relevance to the human situation in 
clinically important aspects such as latency of the tumor model, which is especially important when 
studying childhood cancers, and site of incidence has not been taken into account. Additionally, 
single sarcoma histological entities have been shown to have different ‘cell of origin’ but it is as of 
yet unknown if the sarcomas of similar histologies generated from different cellular compartments 
in different studies are also similar at the molecular level.  
 
 
Figure 7. Current understanding of the origins of RMS, UPS and osteosarcoma. (A) RMS and UPS can 
arise from mutli-potent mesodermal cells and also various compartments committed to the muscle lineage. ERMS and 
UPS are thought to be at different ends of the differentiation spectrum within the same tumor phenotype since UPS 
tumors can originate from the muscle lineage. ARMS can develop from differentiated muscle through ‘de-differentiation’. 
Adapted from [78]. (B) Osteosarcoma mainly initiate from the osteogenic-committed lineage. *Some of the models also 
presented with multiple tumor types for example – ‘poorly differentiated soft tissue sarcoma’ (UPS?), adipogenic tumors, 
RMS. Adapted from [46]. (C) Transdifferentiation seen in ERMS development. Activation of the hedgehog pathway by 
different oncogenic hits (Ptch1 mutation or Smo activation) leads to ERMS development from different mesodermal 
lineages. Adapted from [79]. 
 
Taken together it is clear that single sarcoma entities could have multiple cells of origin 
depending on the oncogenic hit since the cell differentiation status would confer different 
permissive states. Conversely the same cell type can give rise to different sarcomas based on the 
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mutational profile. Although specific lineages are targeted in the tumor-initiation studies the effect 
of the tumor-initiating lesion on cell fate/differentiation (either de-differentiation or 
transdifferentiation; Fig 7C) could finally determine the tumor phenotype. Taken together this 
implies that the final tumor phenotype is not indicative of the ‘cell of origin’ for many sarcomas. 
For example, ERMS tumors have an activated satellite cell profile even though the cell of origin 
need not be a muscle stem cell [47-48, 80]. These principles seem to be universally applicable in 
cancer biology [81].  
Once a causative hit has initiated a lesion the question remains as to how it progresses to form 
the heterogeneous malignant tumor mass which is encountered in the clinics. Different models of 
tumor development have been postulated which could also be applied to sarcoma progression. 
 
4.3. Models of sarcomagenesis 
Initially tumor development was thought to be a product of genetic clones of cancer cells following the 
Darwinian laws of natural selection; however, experimental and clinical evidence gathered over past couple 
of decades has made researchers and clinicians refine this model to also explain features of tissue hierarchy 
observed within heterogeneous masses of certain cancer entities (Fig. 8). 
 
Figure 8. Models of tumor development. (A) Timeline highlighting the major discoveries in the development of the 
clonal evolution (right) and cancer stem cell (left) models [82]. (B) Schematic representation of the tumor development 
models. Clonal evolution: Sarcoma formation could be modeled based on selection of the ‘fittest’ clone. Upon the primary 
genetic disruption the ‘cell of origin’ becomes neoplastic and forms a homogeneous tumor mass which increases in 
heterogeneity, albeit with the persistence of a dominant clone. Therapeutic intervention leads to a selective sweep of a 
pre-existing or de novo drug resistant mutant that initiates tumor growth. Cancer Stem Cell model: Sarcomas could also 
be hierarchically arranged where the initiating oncogenic change causes the ‘cell of origin’ to assume a stem cell-like 
phenotype that is able to divide asymmetrically to give rise to the heterogeneous tumor bulk. Upon therapeutic 
intervention the cancer stem cells (CSCs) persist and reform a heterogeneous tumor which is identical to the primary 
tumor. The genetic and functional heterogeneity of sarcoma cells could be explained by considering an evolutionary 
model of CSCs where genetic and epigenetic changes lead to a co-existence of different CSC populations that respond 
to selective pressures. Adapted from [83]. 
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4.3.1. Clonal evolution model 
The widely accepted model of oncogenesis was posited by Peter C. Nowell in 1976 where he 
described the evolution of a tumor at clonal level in response to selective pressure, making it more 
aggressive with time by stochastic accumulation of genetic lesions that confer the cells a selective 
growth advantage (Fig. 8B; Top panel) [84]. The evidence for the clonal evolution in solid tumors 
has largely been gathered using cytogenetic analysis. Although mesenchymal tumors are thought to 
follow this model the evidence has been mostly gathered from adult sarcomas wherein mutational 
burden has the possibility to increase with time [85-87]. But pediatric sarcomas are diagnosed very 
early in life which leaves a very narrow window for extensive clonal evolution but the genetic 
instability inherent in pediatric sarcomas could account for the genetic clonal heterogeneity [33, 
88]. Although increased karyotypic complexity is seen as sarcomas progress it is unclear if this 
altered karyotype is what drives the progression [89-90]. The most telling evidence of clonal 
evolution in disease progression would involve cytogenetic analysis of multiple samples of primary 
lesion, local recurrences and metastasis. Such longitudinal sampling of clonal aberrations has rarely 
been done for pediatric sarcomas and, the few studies that did so in the past, fail to show direct 
clonal evolution due to extensive intratumoral genetic heterogeneity which cannot be covered by 
traditional cytogenetic methods [85]. The use of NGS technologies with their potential for in-depth 
genomic coverage could offer novel insights. Accordingly a recent NGS study of ERMS tumors 
could reliably demonstrate clonal evolution in disease progression whereupon the relapsed and 
metastatic lesions were genetically different from the primary tumors [41]. However, to date, no 
specific genetic change has been shown to be necessary for recurrence or relapse in sarcomas. 
 
4.3.2. Cancer Stem Cell models 
The Cancer Stem Cell (CSC) hypothesis postulates that analogous to normal regenerating organs 
tumors are hierarchically organized containing a subset of undifferentiated multipotent self-
renewing stem-like cells while the bulk of the tumor consists of differentiated cells incapable of 
long-term sustenance of tumor growth (Fig. 8B; Middle panel). The model is especially attractive as 
it seeks to explain tumor relapse through the intrinsic resistance offered by CSCs to anti-mitotic 
drugs [82, 91-97].The origin of CSCs is under speculation. Initially they were implicitly understood 
as cells resembling the ‘cell of origin’ of the tumor which in most cases has been thought to be a 
transformed stem cell that has continued to persist in limited numbers in a progressing tumor [95]. 
However recent evidence suggests that differentiated cells could reacquire properties of stem cells 
due to epigenetic changes or oncogenic hits. It is also possible that CSCs emerge as a tumor 
progresses from a benign lesion to a malignant one. Currently CSCs are considered to be only 
phenotypically different from their non-CSC counterparts; investigations into the genetic or 
  
21 
Introduction 
epigenetic differences between these populations have begun [96-97]. The CSC phenotypes need 
not be stable and could be a purely epigenetic phenomenon based on niche factors. Also there might 
not be just one CSC phenotype but multiple which are either selected depending on the need of the 
tumor or are generated de novo. This latest, more complex notion, is an amalgamation of the clonal 
evolution and CSC models where CSCs obey Darwinian rules of evolution (Fig. 8B; Bottom panel). 
This latter model confers versatility to a progressing tumor, explaining many of the clinical 
phenomena observed and additionally accounting for the multi-functional heterogeneity within 
tumors [82, 97]. The surge in studies exploring the CSC model of disease progression has led to 
many controversies in the field, especially with regards to the immunophenotype markers of CSCs 
[92, 94]. Researchers have begun to standardize the ideas and terminologies associated with the 
‘CSC field’ in order to streamline interpretations [91]. Thus, the model is a work in progress which 
in itself is likely to evolve with time. Studies in various cancers reveal that the type of tumor model 
followed could be dependent on the cancer entity and hence the validity of the CSC model would 
need to be empirically determined on a case-by-case basis [96].  
There is biological and clinical circumstantial evidence for the presence of CSCs in pediatric 
sarcomas. The presence of undifferentiated multipotent cells was noted in sarcomas long before the 
CSC concept took shape [58]. Pediatric sarcomas have an extensively phenotypically heterogeneous 
cellular milieu with often a clear differentiation hierarchy irrespective of the genetic background. 
Osteosarcomas have been known to possess areas of ‘dedifferentiation’ that can emerge de novo 
with an abrupt transition from the differentiated areas [9]. Osteosarcoma tumor cells show 
similarities to primitive osteoblasts and the aggressiveness of the disease seems to correlate with the 
osteogenic differentiation status of the tumors [98]. Ewing sarcoma cells seem to have a potential 
for multidirectional differentiation [72]. RMS tumors have features of halted skeletal muscle 
differentiation [99]. Synovial sarcomas, although of mesodermal origin, also present with co-
expression of epithelial markers [35]. 
Clinical data suggests that osteosarcoma tumors consist of chemoresistant cellular populations 
since when patients are treated only with conventional chemotherapy the survival rate is only 20% 
[100]. In case of synovial sarcomas, even though the tumor entity is considered to be 
chemosensitive the early benefits from therapy seem to dissipate over time and there is also high 
likelihood of late metastasis [101]. Recent clinical effort in the treatment of metastatic childhood 
sarcoma showed that while the high-dose therapy was unsuccessful an oral maintenance therapy 
with lower drug dose showed a high efficacy; which raised the possibility of slow cycling long-
living stem cell-like cells being present within sarcomas [102].  
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Recently efforts have been made towards validating the CSC hypothesis in pediatric sarcomas. 
These primitive stem cell-like cellular compartments will henceforth be referred to as sarcoma or 
cancer initiating cells (CICs) to better define their function. 
 
4.4. Identification of sarcoma initiating cells 
Sarcoma initiating cells have been isolated using different methods which either employ a 
phenotypic trait such as cell surface antigen or a functional property such as self-renewal [100, 103-
107]. Specifically the CSC model has been most widely studied in osteosarcoma [100, 104]. 
 
4.4.1. Cell surface markers 
4.4.1.1. CD133 
CD133 (Prominin 1) is the most promiscuous CIC marker. It has been used to isolate CICs in 
colon neoplasia, brain cancer and many other epithelial cancers [92, 96]. CD133 is known to exist 
in different glycosylated forms of unknown functional significance [108]. Similarly its expression 
has been documented in many pediatric sarcomas such as ERMS, osteosarcoma, Ewing sarcoma 
and synovial sarcoma [109-117]. CD133 expression was found to be variable between patients with 
the same tumor type and there was no specific correlation with pediatric or adult origin of the cell 
line or tumor [109-110, 112, 118]. 
The most commonly used glycosylated epitope of CD133 in epithelial cancers is CD133/1 or 
AC133. Accordingly in Ewing sarcoma AC133 has been used to isolate a self-renewing 
tumorigenic subpopulation from primary patient tumors [116]. However, the applicability of CD133 
as a single marker of Ewing sarcoma stem cells has not been unequivocally established [105]. In 
ERMS CD133/2 or AC141 was found to be enriched in the sphere cultures and was subsequently 
used for isolating ERMS stem cells from human cell lines [114]. In studies where only polyclonal 
CD133 antibodies were used the reconciliation with previous publications is difficult. Interestingly 
it was noted by Sana et al. that the total CD133 expression was rare in primary embryonal and 
alveolar RMS tumors but increased in the corresponding tumor derived cell lines [112]. Importantly 
the proportion of total CD133 did not change during the progression of ARMS from primary lesion 
to recurrence and relapse, even under the influence of chemotherapeutics. The CD133/2 epitope 
was expressed in synovial sarcoma cell lines and tumor samples, although most of the samples were 
from adult patients [110, 119]. Naka et al. studied primary synovial sarcoma derived cell lines that 
possessed a high degree of self-renewing capacity in vivo but sparse CD133/1 expression [120]. The 
expression level of CD133/2 was not evaluated however CD133/2 expression seems to reduce 
tumorigenecity of synovial sarcoma cells [121]. Tirino et al. have specifically shown that the 
CD133/2 epitope is expressed in pediatric osteosarcoma cell lines and in pediatric and adult 
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osteosarcoma tumor biopsies [109-110]. However, in many studies involving osteosarcoma the 
epitope status of CD133 has not been mentioned [111, 115, 122] or total CD133 expression is 
evaluated [113].  
 
4.4.1.2. Others 
CD117 (c-kit), in combination with Stro-1, was found to enrich for CICs in osteosarcoma mouse 
and human cell lines [123]. However, other studies have found primary bone sarcomas and 
osteosarcoma cell lines to be negative for CD117 expression [110, 124]. Interestingly Stro-1 was 
initially found to be expressed by osteosarcoma spheres [125]. More recently, work by Zhang et al. 
has shown that osteosarcoma spheres were in fact CD117 and Stro-1 positive [126]. 
Another potential surface marker that needs further assessment in osteosarcoma is the primitive 
mesenchymal marker Sca-1. It was observed in a transgenic mouse model that a small population of 
tumor cells expressed Sca-1 which correlated with increased tumorigenicity [127]. Sca-1 is in fact 
expressed in early mesenchymal progenitors and it appears that some committed progenitors regain 
the expression of Sca-1 to accelerate tumor formation. The self-renewal property of the Sca-1+ 
population was not addressed and it is yet to be studied in human samples. 
In the case of ERMS it was shown that FGFR3 could be a candidate marker to isolate CICs. 
FGFR3 positive cells were capable of tumor formation at lower cell numbers than the FGFR3 
negative cells [128]. But FGFR3 expression was not enriched in ERMS sphere cultures which were 
shown to have increased tumorigenicity [114]. Additionally, Pressey et al. have reported that most 
of the FGFR3+ cells from RMS cell lines of ERMS and ARMS origin were also positive for CD133 
[129]. 
The expression of neural crest marker CD57 (HNK-1; Human Natural Killer-1) was found to 
identify population of highly self-renewing tumorigenic cells in Ewing sarcoma [130]. The 
expression of CD57 did not correlate with CD133 expression. 
It has also been recently highlighted that the somatic stem cell marker LGR5 is heterogeneously 
expressed among different Ewing sarcoma cell lines and patient samples but it is still not clear if it 
marks a self-renewing population [131]. It is a very interesting marker for further investigation 
since the functional role of LGR5 in development and in the CSC research field has been firmly 
established [132-133]. 
 
4.4.2. Assays based on functional properties 
4.4.2.1. Self-renewal in vitro and in vivo 
Developed as a method to isolate neural stem cells, the neurosphere assay has also been used to 
enrich for primitive long term self-renewing cells from solid cancers. Tumor cells are allowed to 
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form clonal spherical colonies in suspension in serum-deprived media containing specific growth 
factors and maintained in long-term cultures. Spheres are thought to arise from primitive cells and 
although are generally enriched for CICs they are considered to be heterogeneous [134]. In sarcoma 
stem cell research sphere assay (sarcosphere formation) has been primarily used to indicate the 
presence of primitive cells in osteosarcoma, ERMS, Ewing sarcoma, synovial sarcoma and UPS cell 
lines of human and animal origin [106, 114, 120, 125-126, 130, 135-137]. Sphere formation 
efficiency in osteosarcoma cell lines correlated with tumorigenicity in vivo and it was noted that 
osteosarcoma patient tumor cells from pulmonary metastasis formed larger spheres than primary 
tumor cells [124]. The sarcosphere assay can be used for identification of cell surface markers that 
could be used to prospectively sort cellular subpopulations from heterogeneous cell lines and 
primary tumor material as was done for ERMS [114]. Conversely cellular subpopulations sorted 
using surface antigens can be cultured as sarcospheres to evaluate and compare the self-renewing 
capacity in vitro and consequently validating the utility of the surface antigen as a ‘stemness’ 
marker. 
Tumor cells with high self-renewal capacity can also be isolated based on their tumorigenic 
capacity in vivo and/or expression of genes known to be important for conferring ‘stemness’. 
Recent work in synovial sarcoma showed that primary tumor derived cell lines (of unspecified 
patient age) could be serially transplanted in immunocompromised mice. Heterogeneous expression 
of the embryonic transcription factors Oct4 and Nanog was seen within the tumor. Although no 
definitive surface marker was found for prospective isolation of the CIC populations, the self-
renewal capacity was imparted by the de-differentiation function of the oncogenic fusion protein 
SS18-SSX [120]. In a zebrafish model of ERMS a subpopulation of tumor cells resembling 
activated satellite cells was identified based on increased self-renewal capacity in vivo [48]. All 
reports that have studied CIC populations in osteosarcoma note that the pluripotency genes Nanog, 
Oct4 and Sox2 were enriched in the self-renewing tumorigenic subpopulations [104, 126]. 
Functionally Oct4 and Sox2 have been validated as maintaining CICs in osteosarcoma by different 
studies [138-139]. Interestingly, Sox2 expression correlated with the previously described Sca-1 
marker. Whether the Sox2 expressing cells are also Oct4 positive has not been investigated. 
 
4.4.2.2. Quiescence 
Analogous to most normal stem cells, CICs could be quiescent and hence not affected by drugs 
that target actively proliferating cells. Quiescent cells can be identified by their retention of 
lipophilic membrane dyes such as PKH26. It was observed in osteosarcoma cell lines that 8-25% of 
the total population consisted of quiescent cells that were capable of long-term sphere formation 
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and in vivo tumor formation at lower numbers. However drug resistance was not directly addressed 
[124].  
 
4.4.2.3. Drug resistance 
Clinically relevant cancer stem cells could express membrane proteins that are able to efflux 
drugs or enzymes that are capable of drug detoxification. Therefore the property of drug resistance 
could be used to identify CIC populations.  
 
Side Population analysis 
Cells that express the drug efflux protein family including ABCG2 and MDR1 can be isolated 
by their property to efflux the DNA binding dye Hoechst 3342 using flow cytometry. These cells 
are labeled as ‘Side Population’ (SP) and have been shown to have stem cell-like properties. 
Although isolation of SP cells has been carried out in various sarcoma entities of pediatric and adult 
origin their stem cell characteristics have not been proven in all cases [140-144]. This could be due 
to the various technical aspects of SP analysis which makes reproducibility difficult, for example 
Ewing sarcoma cell line SK-ES-1 was shown to contain 1.2% SP cells in one study [143] which is 
ten times greater than what was previously reported [142]. Also the inherent toxicity of the Hoechst 
dye labeling skews the read out of tumorigenicity in vivo. Recently, using primary osteosarcoma 
cells from an undefined age group Yang et al. showed that the isolated SP cells were capable of 
higher tumorigenicity in vivo and more resistant to commonly used chemotherapeutics such as 
doxorubicin, cisplatin and methotrexate [122]. The SP cells have been reported to be heterogeneous 
in their tumor initiating capacity indicating that there could be room for further enrichment by 
combining with other CIC markers and features [109, 145-146]. However none of the previously 
identified osteosarcoma CIC markers, such as CD133 and CD117, segregated with the SP cells 
[122].  
 
Aldehyde dehydrogenase activity 
A method to identify cellular populations that would be resistant to alkylating drugs measures 
the activity of a detoxification enzyme Aldehyde Dehydrogenase 1 (ALDH1) using flow cytometry. 
Recently, a population with high activity of ALDH1 (ALDH1high) was identified in pediatric OS99-
1 osteosarcoma cell line which was tumorigenic at lower numbers than the low ALDH1 activity 
cells and could additionally self renew in vivo [147]. Interestingly it was shown that the proportion 
of ALDH1high population increased in xenotransplanted tumor in comparison to cell lines which 
highlights the importance of in vivo niche-dependent effects. In Ewing sarcoma cell lines and early 
passage primary xenografts a small population of ALDH1high cells was noted. When the cells with 
high and low ALDH1 activity were isolated and injected in immunocompromised mice only 0.6% 
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of the ALDH1high cells were capable of tumor formation [117]. Similar to SP analysis not all 
ALDH1high cells were capable of tumor initiation. The authors also used CD133/2 to isolate 
tumorigenic population and concluded that ALDH1 activity was a better marker. However, the 
CD133/1 epitope has been established as a Ewing sarcoma stem cell marker and hence it is still 
unclear whether CD133/1 expression or ALDH1 activity marks stem cell-like cells. Interestingly 
the ALDH1high cells were shown to be resistant to doxorubicin, a characteristic which has not yet 
been proven for CD133/1+ cells.  
 
Selection under drug treatment 
Drug treatment could also be used to enrich for tumor cells with resistance capacity, and 
consequently responsible for tumor relapse [148]. Therefore to select for cells with drug resistance 
properties osteosarcoma cell line MG63 was treated with a PARP inhibitor [149] or grown as 
spheres in media containing vincristine, a commonly used drug in clinics [111]. Treatment with 
PARP inhibitor led to the formation of a heterogeneous cell line with high sphere forming capacity 
and differentiation potential. The spheres formed under vincristine selection were enriched for total 
CD133 and drug efflux proteins. A non-tumorigenic pediatric osteosarcoma cell line HOS and 
ARMS cell line Rh4 were selected for cisplatin resistance and it was found that the resistant cells 
had an increased SP profile. Interestingly cisplatin treated HOS SP cells were capable of tumor 
formation in vivo [146]. Similarly, the SP proportion within UPS xenotransplanted tumors increased 
considerably when treated with conventional chemotherapeutics in vivo [144].  
 
Motility and hypoxia 
It is also possible that the CIC property is a function of the environment and hence recreating an 
appropriate niche could select for cells with self-renewal capacity. Side population cells were 
collected from ARMS cell line Rh4 and allowed to migrate to media containing high levels of 
SDF1α. The cells were found to have higher migration capacity and also increased tumorigenicity 
in mice. Also the migratory SP fraction increased when cells were briefly exposed to hypoxia. 
Interestingly the tumorigenicity of the migratory hypoxic SP cells was increased by 4000 fold 
[145]. Simulation of bone hypoxic environment led to increased osteosarcoma sphere formation 
[126]. 
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4.5. Characterization of sarcoma initiating cells 
The primitive cellular subpopulations, once identified and isolated, must fulfill certain functional 
criteria before being designated as bona fide stem cell-like CIC population. 
 
4.5.1. Tumor initiation and self-renewal in vivo 
One of the key properties that a CIC population must possess is that of long-term self-renewal. 
Although the in vitro sphere formation assay is indicative of a self-renewing population it is not 
always definitive [81, 110, 134]. Therefore higher propensity for tumor initiation must be shown in 
vivo by limiting dilution and preferably the self-renewing capacity of the subpopulation elucidated 
by serial transplantation. Earlier studies on osteosarcoma stem cells did not include in vivo 
validation [125]: either the experiments were not attempted or the tumor cells were deemed to be 
graft resistant [109]. However recent work has shown that it is indeed possible to grow 
osteosarcoma cell lines and even primary cells in immunocompromised mice [122-124, 139, 146, 
150]. Importantly some of these studies also showed that the subpopulations could self-renew in 
vivo [122-123, 139, 150]. Similar results have been obtained for ERMS [48, 114], ARMS [145-
146], Ewing sarcoma [116-117, 130], and UPS [144]. 
 
4.5.2. Stem cell phenotype and differentiation potential 
Osteosarcoma, Ewing sarcoma and synovial sarcoma initiating cells have been shown to possess 
mesenchymal stem cell features [104, 107, 120]. The gene expression profile of ERMS spheres 
resembled that of neurospheres and glioma patient samples indicating a neural background [114]. 
ERMS stem cells have also been known to possess a more lineage restricted phenotype. ERMS 
sarcospheres were enriched for neural crest and myogenic lineage-specific stem cell genes such as 
PAX3 and PAX7 while downregulating genes important in myogenic differentiation [114] and 
similar results observed for the CD133+ ERMS cells [129]. The ERMS stem cells identified from 
RAS-dependent sarcomas were noted to have an activated satellite cell gene expression profile. 
Sarcoma initiating cells have been shown to be enriched for various genes that are important for 
embryonic stem cell self-renewal including Oct3/4, Nanog and Sox2. These transcription factors are 
enriched in sarcospheres and in sorted CIC populations from various sarcoma entities. Although 
Oct4 expressing cells were specifically shown to have CIC properties in osteosarcoma the role of 
Oct4 in sarcoma biology has not been established due to experimental and biological limitations 
[100]. Sox2 expression in osteosarcoma seems to maintain Sca-1 expression and the 
undifferentiated state of the tumor-initiating population [138]. In Ewing sarcoma it was shown that 
expression of Sox2 had a functional consequence in tumorigenicity of cell lines and that Sox2 is a 
target gene of EWS-FLI1 [151]. The fusion protein in synovial sarcoma seems to also confer 
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‘stemness’ to the tumor cells [120]. The expression level of PAX3-FOXO1 determined the 
tumorigenicity capacity of ARMS cells [40, 152]. Thus in the case of the translocation-positive 
sarcomas the oncogenic fusion proteins could orchestrate the stem cell phenotype in tumor cells. 
Other stem cell associated genes used to characterize sarcoma stem cells are Bmi-1, Stat3, 
Nucleostemin, Msx1 and Nestin [106].  
Functionally, a stem cell possesses the ability to differentiate into various lineages. The multi-
potential characteristic of sarcoma initiating cells could explain the observed heterogeneous cellular 
populations within the tumor that display immunophenotype of different germ layers. Accordingly 
many reports have shown that sarcospheres are capable of differentiating into multiple lineages 
[114, 116, 123, 125]. 
 
4.5.3. Quiescence and rarity 
These properties of CSCs are not directly implied by the CSC model [94]. CICs could boast 
higher proliferation in order to increase tumor aggressiveness. The CD133+ cells from osteosarcoma 
cell lines were shown to have a higher rate of proliferation [109]. The pediatric sarcoma fusion 
proteins, that mediate ‘stemness’, are intrinsically necessary for cancer cell proliferation. The rarity 
of CICs has also been questioned. Contextual factors such as genetic heterogeneity, depth of 
differentiation hierarchy and microenvironment could influence the proportion of CICs within a 
tumor. The large proportion (45%-75%) of osteosarcoma cells was found to be Sox2-Sca-1high 
[138]. 
 
4.5.4. Drug resistance 
The clinically relevant property of CICs is their acquired resistance to conventional drug 
onslaught. This has been shown conclusively in a variety of adult cancer entities (Fig. 9).   
 
Figure 9. Timeline of milestone studies that demonstrate how CSCs (CICs) contribute to the 
acquisition of chemotherapy resistance: first shown in leukemia (red box) and consequently demonstrated in a 
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variety of tumor types (black box). AML, acute myeloid leukemia; CML, chronic myeloid leukemia; GBM, glioblastoma 
multiforme. Adapted from [153].  
 
In pediatric sarcomas: osteosarcoma, Ewing sarcoma and ERMS initiating cells isolated using 
different techniques have been reported to be resistant to commonly used therapeutics such as 
cisplatin, doxorubicin, daunorubicin, methotrexate, etoposide, vincristine and chlorambucil [114, 
117-118, 122-123, 135, 143, 154-155]. The use of conventional chemotherapy decreased UPS 
tumor growth in vivo but it did not affect the ability of the cells to form tumors upon serial 
transplantation [144]. Stro-1+ human osteosarcoma cells were specifically found to be enriched for 
the drug efflux protein ABCG2 [123]. The theoretical consideration earlier was that a stem cell 
nature implied quiescence and hence only a minimal effect of a DNA damaging agent. However 
most reports on sarcoma initiating cells have not specifically highlighted a slower cell cycle kinetic 
for the CIC compartment. An alternative explanation for resistance to replication stress inducing 
drugs could be efficient DNA repair mechanisms. It was shown that osteosarcoma and Ewing 
sarcoma sphere cells over-express DNA mismatch repair genes MLH1 and MSH2 [135]. Gene 
ontology analysis of ERMS spheres showed that DNA mismatch repair pathway was significantly 
overrepresented (Satheesha S., unpublished data). Anti-apoptotic pathways have also been shown to 
be activated in osteosarcoma cell line selected for resistance to PARP inhibition [115]. 
 
There are some limitations and caveats to the studies discussed above. Since pediatric sarcomas 
are rare malignancies most of the data collected have been from cell lines or their xenografts in 
immunocompromised mouse models. However, wherever possible the existence of sarcoma 
initiating cells needs be directly validated using primary patient material and/or transgenic animal 
models. Alternatively the identified marker or pathway could also be validated retrospectively on a 
large cohort of patient samples as was done for CD133 in ERMS where high CD133 expression 
significantly associated with lower overall survival [114] and in osteosarcoma where CD133 
expression positively correlated with lung metastasis and proved to be an independent prognostic 
marker [156]. Technical caveats such as limited reproducibility of the SP analysis or lack of 
adherence to the CD133 epitope status across studies makes generalizations difficult at the moment. 
Also, care must be taken as to the use of the most stringent mouse model. It is interesting to note 
that the site and media composition of tumor cell engraftment had a critical role in not only primary 
tumor generation but also formation of metastasis, especially in osteosarcoma [124, 149]. This 
highlights the importance of niche factors in the tumorigenicity of cells and consequently the 
significance of orthotopic engraftment routes. Technical aspects of primary tumor tissue handling, 
such as enzymatic digestion and engraftment media composition, could have profound effects on 
tumor formation in vivo and therefore affect the robustness and reproducibility of the CIC marker.  
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Despite these concerns, the data taken together seem to indicate that many pediatric sarcoma 
entities contain a subpopulation of highly tumorigenic cells that are multipotent and capable of self-
renewal in vitro and in vivo. It is possible that the property of quiescence cannot be universally 
applied to all sarcoma initiating cell populations and the proportion of cells within a tumor that 
possess stem cell-like properties is unclear as this appears to depend on the isolation technique used. 
Along with intra-tumoral, inter-tumoral heterogeneity will play an important role in dissecting the 
sarcoma stem cell biology and also establish its clinical significance [157]. Nonetheless, researchers 
have already begun to analyze pathways that are activated in the sarcoma initiating cells in order to 
present novel targeting options. 
 
4.6. Targeting sarcoma initiating cells 
4.6.1. Pathways conferring growth advantage 
Oncogenic pathways that provide the sarcoma initiating cells with their increased tumorigenic 
capacity are largely unresolved. Most commonly cell cycle and DNA repair regulatory pathways 
have been identified as being important. In osteosarcoma and Ewing sarcoma sphere cells it was 
noted that the expression of p14INK4a/p19ARF was reduced [135]. Also pediatric MSCs had a 
decreased expression of p14INK4a which could account for the higher cellular proliferation and 
possibly the permissiveness for EWS-FLI1 expression [151]. The expression of enzyme RECQL 
involved in DNA repair was downregulated in the quiescent osteosarcoma stem cell population 
implying higher genetic instability within this population [124]. Patients with loss of function 
mutations in RECQL have a higher incidence of osteosarcoma than the general population but as of 
yet the role of RECQL in sporadic osteosarcoma has not been established.  
Growth factor pathways have also been implicated in sarcoma initiating cell maintenance. 
Cisplatin resistant osteosarcoma and ARMS SP cells displayed autocrine VEGF signaling which 
was dependent on increased MAPK-ERK pathway activity and therefore sensitive to MAPK or 
VEGF inhibition [146]. Also RAS-dependent ERMS initiating cells were shown to express high 
levels of c-MET/HGFR. Ewing sarcoma stem cells have been shown to employ microRNAs 
(miRNA) to sustain a stem cell phenotype [158-159]. The expression of EWS-FLI1 in pediatric 
MSCs led to reprogramming of the cells to assume a primary Ewing sarcoma phenotype by 
repressing the expression of miRNA-145 [107]. Further investigations revealed that the CD133/1+ 
fraction of Ewing sarcoma cells show disrupted TARBP2-depedent miRNA processing which 
seems to be important for the CIC-like nature of the cells [158]. By increasing the activity of 
TARBP2 using enoxacin, an antibacterial agent of the fluoroquinolone family, the in vitro 
spherogenicity and in vivo tumor growth of Ewing sarcoma xenografts was reduced. Alternatively 
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the fusion protein activity or expression could be directly inhibited to attenuate the CIC phenotype 
[117, 135]. 
 
4.6.2. Developmental pathways affecting differentiation and survival 
The course of organ development seems to be closely linked with tumorigenesis [160] and 
therefore pathways playing important roles in organismal development such as Wnt, Hedgehog, 
Notch and TGFβ have now been linked to initiation and progression of different cancer entities. It is 
becoming increasingly apparent that these pathways could affect tumor cell differentiation and 
thereby modulate CIC properties [161-170]. 
 
4.6.2.1. Wnt signaling pathway 
Wnt signaling dictates cell fate determination, polarity and adhesion and development of various 
organ systems and tissue self-renewal in certain adult organ systems [171]. In mammals Wnt 
proteins consists of 19 highly conserved glycoproteins that serve as secreted ligands for the Frizzled 
(Fz 1-10) receptors. Depending on the combination of Wnt-Fz receptor complex formed receptor 
could initiate two signaling cascades (Fig. 10): canonical (Wnt/β-catenin) and non-canonical 
(Wnt/Ca2+ or planar cell polarity; PCP).  
 
 
Figure 10. Schematic representation of the Wingless/Wnt signaling network. (A) Major arms of the Wnt 
signaling system. Adapted from [172]. (B) Recent studies show that the seemingly distinct Wnt pathways behave as a 
network. Adapted from [170]. 
 
In the canonical pathway binding of ligand to receptor complex of Fz and LRP5/6 (member of 
the LDL receptor family) leads to stabilization of β-catenin whereupon it translocates to the nucleus 
to form a transcription activator complex with T-cell factor/lymphois-enhancer factor (TCF/LEF). 
The target genes include MYC, CCND1 among others. In the absence of the ligand β-catenin is 
phosphorylated by GSK3β and CK1 within the ‘destruction’ complex formed by Adenomatous 
polyposis coli (APC) and Axin proteins. The phosphorylation primes β-catenin for proteosomal 
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degradation. The ligand binding inhibits the activity of GSK3β via Dishevelled (DSH). The non-
canonical pathway is considered to be β-catenin independent. It involves signaling via receptor 
tyrosin kinases (RTKs) such as Ror and Ryk, small Rho GTPases, c-Jun N-terminal Kinase (JNK) 
and induction of intra-cellular Ca2+ fluxes to affect organ morphogenesis. Recent data shows that 
the two seemingly distinct pathways could behave as an integrated network fine-tuned to the 
demands of the environmental context [170]. 
 
4.6.2.2. TGFβ signaling pathway 
TGFβ plays an important role in, germ layer specification, vertebrate patterning, and 
organogenesis during embryonic development, and in the homeostatsis and regeneration of adult 
tissues [165]. The ligand families that can activate the TGFβ superfamily include TGFβ (1-3), bone 
morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), anti-Müllerian 
hormone (AMH), Activins and Nodal (Fig. 11). The secreted ligands bind and bring together two 
transmembrane serine-threonine kinases, known as receptor types I (also called Activin-receptor 
like kinases, ALKs; 1-7) and II (5 types). Upon ligand activation type II receptor phosphorylates 
type I receptor, which then leads to phosphorylation of regulatory Smads (1, 2, 3, 5 and 8). The type 
of Smad phosphorylated is again specific to the ligands that initiate the signal. The phosphorylated 
Smads generally complex with a common mediator, Smad4, translocate to the nucleus and bind to 
other transcription factors and nuclear co-factors for context-specific gene expression [162]. 
 
 
Figure 11. Canonical signaling pathways of the TGFβ supefamily. [165] 
ECM, extracellular matrix; R-Smads, Regulatory Smads; I-Smads, Inhibitory Smads 
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4.6.2.3. Notch signaling pathway 
Notch signaling is evolutionary conserved pathway with critical roles during embryogenesis and 
development of various organ systems; in cell communication, differentiation, proliferation and 
survival [163]. The pathway is activated via cell-cell contact mediated though ligand-receptor 
binding. Mammalian membrane-bound Notch ligands occur is two distinct families: Delta-like 
ligands (DLLs -1, 3 and 4) and Jagged (JAGs: 1 and 2) (Fig. 12). There are four Notch receptors 
(NOTCH 1-4) that bind to the ligands via extracellular domain with EGF-like repeats. Upon ligand 
binding, proteolytic cleavages by metalloprotease and gamma.secretase lead to the release of active 
Notch intra-cellular domain (NICD) into the cytoplasm. NICD translocates to the nucleus and binds 
to CSL (CBF1/Suppressor of Hairless/LAG1)/RBPJ transcription factor complex to activate or 
derepress via binding of mastermind-like proteins (MAMLs 1-3) to transcribe of target genes. The 
downstream targets include HES family of transcription factors, PI3K, AKT, MYC, p21 among 
others. 
 
Figure 12. Overview of the Notch pathway. [52] 
ICN: Intra-cellular Notch (referred to as NICD in the text) 
 
4.6.2.4. Hedgehog signaling pathway 
The hedgehog pathway plays an important role in tissue patterning and stem cell maintenance 
during embryogenesis. It is essential for the development of epidermal and neural tissues [173]. The 
hedgehog signaling pathway outcome is determined by balance between the activator and repressor 
functions of the GLI transcription factors – GLI1, GLI2 and GLI3 (Fig. 13). GLI1 is the most potent 
transactivator without a repressor function, GLI2 can act as an activator or repressor and GLI3 is 
mainly a repressor with weak transactivating potential. The pathway is activated by binding of 
secreted ligands – Sonic (SHH), Indian (IHH) or Desert (DHH) – to the inhibitory transmembrane 
receptor Patched (PTCH1/2) which causes its internalization and thereby allowing the translocation 
of Smoothened (SMO) to the primary cilium. Once SMO is in the primary cilium it initiates 
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downstream events, that are not yet fully characterized, which finally culminate in the dissolution of 
the inhibitory Suppressor of Fused (SUFU)-GLI complex leading to the formation and stabilization 
of transactivated GLI transcription factors. The target genes of the pathway include GLI1, GLI2, 
PTCH1, HHIP, CCND1 and others. 
 
 
Figure 13. Overview of the hedgehog signaling in mammals. [173] 
 
 
The effect of these pathways has been better established in adult CICs than pediatric (Table 3); 
although the signaling systems have been shown to be active and functionally important in pediatric 
cancers.  
Recently, activation of canonical Wnt pathway across the sarcoma spectrum was reported [174]. 
The study concluded that the effect of Wnt signaling in initiating a stem cell-like phenotype was 
overshadowed by other mutations within the cells; however this was not directly addressed. In 
Ewing sarcoma it was recently shown that canonical Wnt signaling pathway can be activated using 
Wnt ligands and further potentiated by R-spondin which is known to bind LGR5. Activation of Wnt 
signaling or LGR5 overexpression had no effect on proliferation; however it remains to be seen if it 
could enhance self-renewal [131]. On the other hand, activation of canonical Wnt signaling seemed 
to differentiate osteosarcoma stem cells [104, 138]. Recently it was shown that in osteosarcoma the 
switch from canonical Wnt signaling to non-canonical Jun-based signaling by secretion of DKK1 
(Dickkopf-related protein 1) led to the upregulation of CIC marker ALDH1 [175]. Activation of 
non-canonical Wnt signaling was necessary for derivation of UPS from MSCs [61, 64]. The 
upregulation of receptors for non-canonical Wnt signaling, FZD2 and FZD3, was observed in 
ERMS sphere cells [114]. Recently, inhibition of canonical Wnt signaling using GSK3β inhibitors 
was shown to suppress ERMS self-renewal and tumor growth [176]. 
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Table 3. Developmental pathways shown to be important for adult CICs and pediatric cancers. 
Developmental 
pathway Adult CICs* 
Pediatric sarcomas Other pediatric solid cancers 
Associated CIC Associated CIC 
Wnt 
Canonical 
Breast, CRC, 
GBM, CML, 
AML, 
cutaneous 
cancers [153, 
167-168, 177] 
Sarcoma in general 
[174], subset of 
ERMS [41-42, 178], 
pro-differentiation 
in RMS and OS [52, 
98, 178-181], ES 
[131, 182], SS [183] 
Pro-
differentiation 
in OS [104, 
138] and 
ERMS [176] 
Subset of MB, 
Wilms’ tumor, 
ependymoma, 
hepatoblastoma, 
PNETs [184-185] 
Not 
reported 
Non-
canonical 
 UPS** [61] OS [175]   
TGFβ 
Breast, CML, 
pancreas, Pro-
differentiation 
in SCC, GBM 
and CRC [153, 
165] 
RMS [186], Pro-
differentiation in OS 
[98], SS [187], ES 
[37] 
OS [126] 
Subset of MB 
[188], 
ependymoma, 
PNETs [189], 
Wilms’ tumor [190] 
Not 
reported 
Notch 
GBM, breast, 
NSCLC, 
prostate, CRC 
[153, 166, 168] 
RMS [52, 181, 191-
192], UPS** [193], 
OS [194-195], ES 
[37], SS [196] 
UPS** [144] 
Ependymoma, 
MB, NB [197] 
MB [184] 
Hedgehog 
Multiple 
myeloma, 
GBM, breast, 
prostate, CML, 
CRC, 
melanoma, 
pancreas [153, 
164, 168, 198] 
ES [37], ERMS [52, 
181], OS [98, 199-
200] 
UPS** [144] 
Ependymoma, 
hepatoblastoma, 
Wilms’ tumor, 
subset of MB, NB 
[106, 185, 199-201] 
MB [184], 
NB [201], 
DIPG [202] 
* Primary studies within the referenced reviews 
** Relevance to pediatric UPS unclear 
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CRC, colorectal cancer; DIPG, diffuse intrinsic pontine 
glioma; ES, Ewing sarcoma; GBM, glioblastoma multiforme; MB, medulloblastoma; NB, neuroblastoma; NSCLC, non-
small cell lung cancer; OS, osteosarcoma; PNETs, primitive neuroectodermal tumors; SCC, squamous cell carcinoma; 
SS, synovial sarcoma 
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TGFβ signaling has been shown to be an important mediator of self-renewal in osteosarcoma 
[104]. Osteosarcoma ALDH1high cells overexpressed BMP receptors and BMP-2 treatment led to a 
decrease in tumorigenicity of ALDH1high cells in vivo [150]. Furthermore TGFβ1-induced 
dedifferentiation of osteosarcoma cells led to the upregulation of various components of the Notch, 
IGF and PDGF pathways, making it a very interesting signaling node for future studies [126]. The 
gene expression profiling of osteosarcoma stem cells isolated based on their property of quiescence 
also revealed upregulation of IGF1 and IHH [124]. The importance of IGF, Hedgehog and TGFβ 
pathways has been previously implicated in osteosarcomagenesis [98]. Wang et al. have observed 
that SP cells from primary UPS samples expressed higher levels of Hedgehog and Notch pathway 
components. Inhibition of these pathways in vivo decreased the tumor growth and also markedly 
reduced the tumor initiation capacity of these cells upon serial transplantation in secondary and 
tertiary recipients [144]. Studies on the roles of Notch and hedgehog signaling in muscle 
differentiation and RMS tumorigenesis have revealed that their targeting could offer clinical 
benefit; however their effect on RMS ‘stemness’ has not been directly investigated [52, 181]. 
Overall, the function of developmental pathways in sarcoma initiating cells is slowly being 
elucidated and is a prime avenue for future research. The study of such pathways not only offers 
rationale for CIC-appropriate treatment but also presents insights into the origins of sarcoma 
initiating cells. 
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 5. Subject of Investigation 
 
Rhabdomyosarcoma is the most common pediatric soft tissue cancer which is currently treated 
using conventional multimodal strategies that entail severe acute and chronic morbidity. 
Furthermore under recurrent and metastatic setting these treatments are ineffective. Therefore there 
is an urgent need to find rationale-based novel treatment avenues to ensure a long-term cure for the 
patients with minimal impact on quality of life. Our main aim was to understand the biology of 
RMS initiation, maintenance and progression to offer new perspectives for translational medicine. 
To this end we set out the following aims, 
 
1. To elucidate if RMS tumors were hierarchically organized. 
 
2. To characterize the signaling mechanism(s) and/or genes that could contribute to the 
maintenance of self-renewal and tumor initiating capabilities of the cancer initiating 
populations. 
 
It would be important to understand if RMS tumors contained tumor cell compartments with 
enhanced ‘stemness’ and tumorigenic potential since clinical intervention would then need to 
include drugs that could specifically target these populations. The immunophenotype of the RMS 
stem cell-like CICs could be used for prognostic risk stratification and as biomarkers during clinical 
trials. Furthermore the developmental hierarchy of RMS could also provide insight into its origins, 
which would have significant impact on disease modeling. 
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 6. Results 
 
6.1. CD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell 
Population Is Enriched in Rhabdospheres 
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D’Alessandro, Susanne M. Oesch, Hubert Rehrauer, Ivo Leuschner, Ewa Koscielniak, Carole 
Gengler, Holger Moch, Michele Bernasconi, Felix K. Niggli and Beat W. Schäfer. Part of this study 
was conducted in cooperation with the CWS Study Group 
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Summary 
 
We show that highly tumorigenic stem cell-like cells could be enriched from human ERMS cancer 
cell lines using the neurosphere assay. In an orthotopic tumor model 100 fold less sphere cells were 
required for tumor initiation compared to adherent cells. The expression of stem cell genes like 
OCT4, NANOG, SOX2 and C-MYC was increased in the sphere cultures (rhabdospheres). The 
sphere cells were capable of differentiation into mesenchymal and neuronal lineages. The gene 
expression profile of rhabdospheres was more similar to that of neural stem cells and glioma 
patients than mesenchymal stem cells. Rhabdospheres contained a greater number of CD133 
expressing cells compared to the adherent cells. Adherent ERMS cell expressing CD133 were more 
chemoresistant in vitro and more tumorigenic in vivo. The expression of CD133 in ERMS patient 
samples predicted worse overall survival. 
 
Conclusions and significance 
 
ERMS tumors seem to be hierarchically organized wherein a subpopulation of cells have enhanced 
self-renewal and tumor initiation capacity. The optimized rhabdosphere culture system, described 
here for the first time, provides an easy method evaluate and enrich for self-renewing cells. The 
neural crest phenotype of rhabdospheres indicates a pre-myogenic origin for ERMS. The report is 
also the first to show that CD133 expression could be used prospectively to isolate functionally 
important cells in ERMS. Additionally CD133 expression could be used as a prognostic marker in 
ERMS. Overall, the report presents novel insight into the biology of ERMS. Its findings have been 
reproduced and expanded upon by an independent study [129]. 
 
For contribution and detailed information see attached manuscript (section 11). 
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6.2. Targeting hedgehog signaling reduces self-renewal in  
Embryonal Rhabdomyosarcoma 
 
Sampoorna Satheesha, Amandine Bovay,* Gabriele Manzella,* Elisa A. Casanova, Peter Bode, 
Réka Belle, Simone Feuchtgruber, Patricia Jaaks, Nurhak Dogan, Ewa Koscielniak, and Beat W. 
Schäfer 
 
Manuscript under review at Stem Cells (submitted April 2014). * Equal contribution 
 
Summary 
 
Using clinically relevant synthetic small molecules and genetic loss- and gain-of-function 
approaches we show that active hedgehog pathway is necessary for self-renewal in vitro and in vivo 
tumor initiation. We provide novel mechanistic insights into ligand-based activation of hedgehog 
signaling in sporadic ERMS. Additionally we describe novel roles for hedgehog pathway in 
determining ERMS cell motility, differentiation status and chemoresistance to anti-proliferative 
drugs currently used in ERMS clinical management. Our data provides the first indications of novel 
cross-talk between hedgehog pathway and other developmentally important pathways, such as 
Notch, TGFβ-BMP and Wnt in ERMS. We identify NANOG as a key downstream effector for 
hedgehog pathway-mediated stemness, previously unknown in any soft tissue sarcoma. Importantly 
we could demonstrate translational relevance of our findings by showing that functional intra-
tumoral heterogeneity measured by the presence of hedgehog-active CICs (GLI1+ and NANOG+) in 
ERMS patients has significant prognostic impact. 
 
Conclusions and significance 
 
Our study identifies the hedgehog pathway as being instrumental in maintaining the stem cell 
functions of ERMS CICs. This pathway has been implicated in ERMS tumorigenesis previously 
[52]; however its specific function was unknown. This is the first report to show that the hedgehog 
pathway could control CIC properties in a pediatric sarcoma. Also, our data suggests that a 
combinatorial approach using hedgehog inhibitors would increase treatment efficacy. SMO 
targeting for progressive rhabdomyosarcoma is already in clinical trial as a single agent 
(clinicaltrials.gov; NCT01125800). Additionally, ERMS patients are currently stratified for risk of 
relapse based on clinical parameters only. We present evidence that evaluating the presence of 
hedgehog-driven CIC populations within ERMS patients can offer better means of risk stratification 
which has not yet been possible with mutational status. Our study also emphasizes that novel 
rationally selected treatment strategies need to take into account not only the mutational background 
but also the hierarchical organization of the tumor. Furthermore, CIC-targeting requires updating 
the current clinical trial management protocols since the biomarkers and end points used to estimate 
treatment efficacy would be conceptually altered. Therefore our findings not only advance our 
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perceptions on the functional role of hedgehog pathway in ERMS but are highly relevant to the 
current and future clinical management of ERMS patients. 
 
For contribution and detailed information see attached manuscript (section 11). For the purposes of 
the present thesis the ‘long form’ of the manuscript is attached which includes a more in-depth 
description and discussion of the study results. 
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6.3. PAX3-FOXO1 increases fibroblast reprogramming efficiency and 
drives self-renewal in alveolar rhabdomyosarcoma 
Elisa A. Casanova, Melanie Generali, Sampoorna Satheesha, Peter K. Bode, Paolo Cinelli, Beat 
W. Schäfer 
 
Manuscript in preparation 
 
Summary 
 
Multiple ARMS cell lines were analyzed using common CSC assays such as tumorsphere 
formation, ALDH activity and stem cell surface marker expression. However we were unable to 
identify de-differentiated, self-renewing subpopulations. ARMS cell lines expressed all core stem 
cell factors (OCT4, SOX2 and NANOG) but surprisingly the alteration in the expression of these 
stem cell genes has minimal effect on ARMS pathophysiology; which is in mark contrast to the 
dramatic effect of altering the levels of PAX3-FOXO1 – the key oncogenic fusion protein in 
ARMS. Interestingly, PAX3-FOXO1 expression increases the efficiency of reprogramming human 
fibroblasts into induced pluripotent stem (iPS) cells and could also impede the differentiation ability 
of iPS cells in vitro and in vivo indicating that PAX3-FOXO1 could promote stem cell behavior. 
Furthermore, RH30 ARMS cells were capable of tumor initiation at limiting dilutions and RH30 
single cell clones had equal capacity to initiate tumors highlighting that probably all ARMS cells 
behave as cancer stem/initiating cells. 
 
Conclusions and significance 
 
In this study we present evidence that fusion-positive ARMS, contrary to ERMS, does not possess 
an exclusive subpopulation of CICs but rather each ARMS cell exhibits similar tumorigenic 
potential that is strictly PAX3-FOXO1 dependent. The effects of the PAX3-FOXO1 on iPS 
generation and differentiation indicate that the fusion protein controls mechanisms that can confer 
de-differentiated self-renewal phenotype to all cancer cells. Our study suggests that all ARMS cells 
would need to be targeted by inhibiting the activity of PAX3-FOXO1 to ensure a cure. This has 
immense implications for ARMS treatment strategies and additionally underscores the biological 
difference between the two RMS histotypes. Our study also presents a novel disease model to study 
the function of PAX3-FOXO1 without the transcriptional noise that is usually present within a 
cancer cell. Even though the PAX3-FOXO1 iPS cells do not form true ARMS tumors in vivo, the 
model system could be used to verify the genetic or epigenetic hits that are further required to 
completely transform the cells. 
 
For contribution and detailed information see attached manuscript (section 11). 
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 7. Discussion and outlook 
7.1. The hierarchical organization of RMS tumors 
In our studies we used in vitro self-renewal assays and in vivo xenograft formation to assess the 
presence of functional heterogeneity within RMS tumors. The data presented in articles 1 and 2 
indicate that ERMS tumors seem to the follow the cancer stem cell model of tumor progression. 
ERMS cell lines having a common genetic background contain phenotypically distinct 
subpopulations of primitive, multi-potential cells with enhanced self-renewal, tumorigenicity and 
chemoresistance. Additionally we show that the heterogeneous activation of hedgehog pathway 
within ERMS cell lines and patient samples has functional and clinical consequence. Active 
hedgehog pathway is necessary to maintain ERMS self-renewal while pathway inhibition leads to 
ERMS cell differentiation, reduction in tumorigenic potential and increase in sensitivity to 
conventional chemotherapeutics. Overall our studies show that ERMS tumors possibly present with 
a ‘steep’ hierarchical organization, with a minority of primitive/de-differentiated CICs forming the 
apex while cells with early and late progenitor phenotype contributing to the majority of the tumor 
bulk (Fig. 14A). On the contrary, the translocation-positive ARMS tumors are composed of a 
majority of tumorigenic cells with equal propensity for tumor initiation (article 3). The expression 
of PAX3-FOXO1 within ARMS tumors de-differentiates the cells; determining self-renewal and 
tumor initiation. Since PAX3-FOXO1 is ubiquitously expressed in majority of ARMS cells the 
hierarchy is either ‘shallow’ (determined by PAX3-FOXO1 expression gradient) or non-existent 
altogether (Fig. 14B).   
 
 
Figure 14. Summary of the RMS tumor progression models elucidated by our studies. (A) ERMS tumors 
contain a subpopulation of hedgehoghigh compartment characterized by GLI1 and NANOG expression which are 
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important for tumor maintenance. Thus ERMS tumors could be sustained by a steep hierarchy where majority of tumor 
cells which are hedgehoglow and therefore non-tumorigenic. Drugs indicated in bold are small-molecule inhibitors used in 
our study. (B) ARMS tumors are maintained by PAX3-FOXO1 activity which confers all cells with tumor-initiating 
features. Thus ARMS tumors could present with either shallow hierarchy based on PAX3-FOXO1 activity or no hierarchy 
at all. Images on the right side depicting hierarchy adapted from [96].  
 
7.1.1. Markers for ERMS CICs and their regulation 
7.1.1.1. GLI1-NANOG 
We identified GLI1-NANOG axis as a key determinant of hedgehog-driven ERMS CICs (article 
2). GLI1 is considered to be the most reliable marker for active hedgehog signaling [173]. This 
particular signaling node has been shown to be functionally important in the self-renewal of normal 
neural, glioma and medulloblastoma stem cell [203-204]. NANOG is part of the core transcriptional 
factor network, including OCT4 and SOX2, which is essential for the establishment of pluripotency 
in embryonic stem (ES) cells. These three genes regulate each others’ expression and thereby are 
maintained at defined expression levels leading to an optimal self-renewal phenotype [205]. 
Interestingly, although the expression of OCT4 and SOX2 is uniform across all ES cells, NANOG 
expression seems to be heterogeneous – similar to what we have noted in ERMS cells and tumors. It 
appears that ES cells with lower NANOG expression have a greater propensity to differentiate 
allowing for important cell fate decisions [206-207]. Navarro et al. reported that NANOG 
heterogeneity in ES cells is mediated by an auto-repression mechanism through unknown binding 
sites which is OCT4/SOX2 independent [208]. However recent work has shown that heterogeneous 
expression of NANOG may be a cell culture artifact with little effect on in vivo cell fate decisions 
for ES cells [209]. Even so, heterogeneous expression of NANOG has been noted in multiple 
cancer types and therefore could be specifically important for CIC functions [210-211].  
With the increasing evidence for the important role for NANOG function in cancer it has 
become imperative to understand NANOG regulation and downstream targets. Embryonic genes are 
subject to transposition and therefore apart from the embryonic NANOG gene (NANOG1; Chr. 12) 
eleven pseudogenes have been reported in the human genome [212]. Of these only one psuedoegene 
(NANOGP8; Chr. 15) possesses a complete open reading frame and gives rise to a functional 
protein with one amino acid different (Q253H) from embryonic NANOG. In ES and teratoma cells 
NANOG protein is derived from NANOG1 mRNA, however in carcinomas and glioblastoma it 
seems to be derived either predominantly from NANOGP8 or from both loci [204, 213-214]. The 
determination of the loci contributing to the expressed NANOG protein becomes important when 
investigating gene expression regulation: since the cis and trans genomic elements associated with 
either loci would be different. Moreover a recent study in ES cells suggests that the NANOG1 locus 
itself is involved in genome-wide chromatin interaction that has functional consequences [215]. Our 
efforts to identify the mRNA variant expressed in ERMS revealed that NANOG1 could contribute to 
the majority of NANOG protein expressed (data not shown). Although it is assumed that NANOG1 
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regulation could be important in ES cells and NANOGP8 is important in tumorigenesis the 
regulation of NANOG expression in cancer seems to have been largely centered on the NANOG1 
locus leading to elucidation of many upstream regulators of unclear significance (Fig. 15A). 
However, in the context of hedgehog signaling GLI binding elements are present in the promoter 
region of NANOG1 and NANOGP8 [204]. Therefore, at least in the system that we describe, 
NANOG protein expression need not be subject to differential gene loci regulation. 
 
 
Figure 15. Pathways converging on NANOG. (A) Upstream regulators of NANOG. (B) Schematic representation 
of the central role of NANOG in signaling networks perpetuating many cancer hallmarks. Figures adapted from [211]. E-
cad, E-cadherin; Esrrb, estrogen-related receptor β; GDF3, growth differentiation factor-3; STAT3, signal transducer and 
activator of transcription 3; Ezh2, enhancer of zeste homolog 2; Tcl1a, T-cell leukemia/lymphoma protein 1A; TLR4, toll-
like receptor 4. 
 
Investigation into the biochemical differences between the proteins encoded from the two loci 
indicated that NANOG1 and NANOGP8 proteins possibly assume different conformations [216]; 
however there seem to be no major functional differences between them. Currently available 
antibodies detect total NANOG protein and therefore for functional analysis most studies do not 
make a distinction between the two forms. NANOG controls the expression of various genes in 
cancers that are known to contribute to the acquisition of different cancer hallmarks leading to 
tumor progression (Fig. 15B; [210-211]). Specifically in hedgehog signaling NANOG regulates the 
expression of GLI1 and GLI2 and thereby creating a feedforward loop ([203-204] and our study) to 
maintain ‘stemness’. Additionally we observed a GLI1-independent regulation of the hedgehog 
pathway by NANOG (data not shown) and therefore it is possible that other genes within the 
pathway could be affected by NANOG. Also, we were unable to generate a stable NANOG over-
expression cell line while hedgehog-activated cell lines could be easily produced; highlighting that 
NANOG could have additional hedgehog-independent functions within ERMS. Since the role and 
targets of NANOG seem to be cancer cell-context specific it would be important to further 
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characterize the functional importance of NANOG in ERMS. Recently developed transgenic mouse 
models that allow temporal and spatial control of NANOG expression [217-219] could be used in 
conjunction with the plethora of ERMS mouse models [220] for a thorough investigation of the 
importance of NANOG in ERMS.  
 
7.1.1.2. CD133 
The use of CD133 as a sarcoma stem cell marker has been previously described in section 
4.4.1.1. However there have been no studies examining the regulation or function of CD133 in 
sarcomas. Most studies, including in adult cancer entities, which describe alteration in CD133 
expression by cell extrinsic or intrinsic factors do not demonstrate direct transcriptional regulation. 
For instance, in Ewing sarcoma CIC modeling, expression of EWS-FLI1 in pediatric human MSCs 
led to increased CD133/AC133 expression but no direct regulation was described [151]. Additional 
analysis using Ewing sarcoma patient samples and cell lines revealed a cell-context specific 
expression [118]. Higher expression of hedgehog pathway components has been noted in CD133+ 
compartment of glioblastoma and medulloblastoma samples [203-204, 221]. Similar results were 
obtained in ERMS cells [129]; however we were unable to confirm this (data not shown). Although 
CD133 and GLI2 (but not GLI1 or GLI3) mRNA expression correlated significantly in ERMS 
patients (data not shown), we could not find evidence for positive regulation of CD133 expression 
by the hedgehog pathway. On the contrary CD133 (protein) expression was highest in the 
hedgehog-inhibited ERMS cells lines. Studies in other cancer types which show a positive 
correlation between CD133 and hedgehog pathway expression, do not address direct regulation. 
There has been increasing evidence supporting epigenetic and niche-dependent regulation of 
CD133, which could explain the cell-context dependent expression patterns [222-228]. 
We and others have described that the ERMS CD133+ population is more chemoresistant to 
conventional therapies that affect DNA replication although the populations did not proliferate 
differently (article 1 and [129]). The CD133+ populations in glioma and colon cancer cell lines, 
upon therapeutic insult (radiation/chemotherapy), seem to preferentially activate DNA repair 
pathways highlighting a mechanism for their treatment resistance [229-230]. Although we did not 
directly assess the expression of DNA repair pathway components in the CD133+ population, DNA 
repair was noted to be the most highly represented upregulated pathway upon gene ontology 
analysis of ERMS spheres expression profiles (data not shown). 
CD133 can be phosphorylated by Src proteins. A recent study in glioma cells has shown that 
phosphorylated CD133 interacts with p85 subunit of PI3-kinase to activate Akt leading to increased 
‘stemness’ [231]. Activated Akt has been previously noted in hepatocellular and neuroblastoma 
CD133+ populations [231]. Interestingly Akt pathway was shown to be preferentially activated in 
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the synovial sarcoma CD133- (AC141-) population [121]. It would be interesting to determine if 
Akt activation is heterogeneous in other sarcoma types and/or preferentially associated with CIC 
markers since it is a key node for therapeutic intervention.  
 
7.1.1.3. FGFR3 
The role of FGFR3 has been mainly described in bone and connective tissue development. Its 
transcription has been shown to be positively regulated by Sp1 family of transcription factors, AP2δ  
and E2F-1 [232-234]. It has been postulated that majority of FGFR3 expression, at least in 
chondrocytic cells, is due to Serum Response Factor (SRF) transcriptional activity. Consequently 
FGFR3 expression could be increased by the addition of serum or cytoskeletal changes [235]. 
However in ERMS cells FGFR3 expression was highest in media without serum [236]. FGFR3 
expression could also be controlled by the microenvironment: FGFR3 expression was induced in 
hypoxic conditions in a HIF1α-dependent manner [237]. Binding sites for other transcriptional 
regulators have been identified, although not functionally characterized [235], and could mediate 
cell-context specific regulation.  
FGFR3 was found to be part of the RAS signature that could be used to predict drug sensitivity 
in zebrafish ERMS model [53]. Functionally FGFR3 can trigger MAPK and Akt pathways [235]; 
however this has not been directly addressed in ERMS cells. The use of FGFR3 expression as 
ERMS CIC marker has been established mainly using an obscure ERMS cell line, KYM-1 [128]. 
The expression of survivin, an apoptosis regulator, has been noted to be higher in FGFR3 
expressing KYM-1 cells and the use of oncolytic adenovirus to target survivin expression reduced 
tumor growth [236]. It is unclear if survivin is a robust marker correlating with FGFR3 expression 
or stem cell activity. It is equally likely that survivin affects ERMS pathogenesis by inducing 
apoptosis without affecting ‘stemness’. We noted FGFR3 expression to be positively regulated by 
hedgehog pathway in RD cells and negatively regulated in RH36 cells (data not shown). Therefore 
FGFR3 could mark active hedgehog phenotype depending on ERMS cell-context. In the commonly 
used ERMS cell lines majority of FGFR3 expressing cells co-expressed CD133 [129]. Furthermore, 
FGFR3 expression was not enriched in ERMS sphere cells (article 1). It would be useful to assess if 
combinatorial use of the markers would improve ERMS CIC detection. 
 
7.1.1.4. MYF5 
Extensive investigations in skeletal myogenesis using transgenic mouse models have revealed 
the key roles played certain basic helix-loop-helix (bHLH) transcription factors which are now 
referred to as muscle regulatory factors (MRFs). These MRFs control muscle stem cell specification 
(early MRFs) and differentiation (late MRFs) [238]. Myf5 is an early MRF expressed in activated 
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muscle stem cell. It transcribes MyoD (an early and late MRF) and Myogenin (a late MRF) which 
together with other transcription factors, epigenetic regulators and miRNAs lead to muscle cell 
commitment and terminal differentiation [238-239]. Myf5 expression is regulated through different 
lineage-specific enhancers, minimal promoters and transcription balancing sequences. During 
myogenesis exogenous signaling pathways such as hedgehog, Wnt (β-catenin-mediated and PCP 
pathways) and BMP control the expression of Myf5 spatially and temporally. Specifically 
transcription factors such as Gli2, Gli3, β-catenin, Pax3 (directly and indirectly via Dmrt2), Pax7 
(in complex with histone methyltransferases), Six1/Six4 (with Pax3) have been shown to bind to 
various Myf5 enhancers to initiate expression [238-244]. Recently post-transcriptional regulation of 
Myf5 expression by miR-31 has been documented in adult myogenesis adding another facet to the 
complex and intricate regulation of myogenesis [245]. 
The effect of individual Gli proteins on Myf5 expression and/or myogenic processes in general 
seem to be dependent on experimental context, such as, in vitro vs. in vivo, embryonic myogenesis 
vs. postnatal/adult muscle regeneration and normal vs. pathological conditions [243, 246-250]. For 
instance, hedgehog inhibition during in vitro muscle stem cell activation did not affect Myf5 
expression [250], however, hedgehog inhibition and specifically loss of Gli3 reduced Myf5 
expression, attenuated muscle regeneration and associated angiogenesis in vivo [248-249]. Also in 
normal myogenesis hedgehog signaling, primarily via Gli2 and (activated) Gli3, is required for 
Myf5 expression and myotome patterning but in pathological conditions, such as ERMS, Gli1 and 
Gli2 (but not Gli3) seem to de-differentiate the cells by inhibiting the activity of MyoD and Myf5 
[243, 247].  
Myf5 has been identified as a component of the ERMS signature from transgenic mouse models 
and CIC marker in the RAS-activated zebrafish model of ERMS [47-48, 251]. We could not detect 
Myf5 expression in ERMS cells lines used in our study (data not shown) indicating that Myf5 
activity was not necessary for human ERMS cell survival or hedgehog-driven self-renewal, at least 
in vitro. Myf5 mRNA expression level was noted to be higher in ERMS patient samples with high 
Gli1 mRNA expression [252] and increased Gli3 expression, along with Myf5 expression, was 
reported in the self-renewing zebrafish ERMS cell compartment [48]. However we did not find a 
correlation between expression of Myf5 and any of the Gli transcription factors within our cohort of 
patients. Although this maybe due to the small sample size, it is also possible that Myf5 expression 
is controlled by hedgehog-independent mechanisms in ERMS. 
 
7.1.2. Novel hedgehog-modulated genes in ERMS 
Our study identified transcription factors PITX2, LMX1B and PAX6 as being positively 
regulated by the hedgehog pathway in ERMS cells (article 2). PITX2 is expressed in cranial tissues 
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derived from the neural crest and mesoderm [253]. PITX2 has been identified as the master 
regulator of myogenesis in the head and neck region: extraocular, tongue, laryngeal and other 
muscles derived from the branchial arches [238]. LMX1B is expressed in the mesenchyme where it 
integrates signals from different pathways (including hedgehog signaling) to affect dorsal-ventral 
patterning during limb development [254-255]. It is also known to play a role in kidney and brain 
development [256]. The expression and function of LMX1B seems to be imperative in the 
development of neural crest derived-periocular mesencyme which affects the anterior segment of 
the vertebrate eye [257]. Intriguingly the investigators also noted the expression of LMX1B in the 
posterior periocular mesenchyme resembling nascent muscle masses derived from the mesoderm. 
The function of LMX1B in extraocular muscle development has not been further studied. PAX6 
plays an important role in the development of neuroectoderm and endocrine lineages. In the retina, 
PAX6 is required for the maintenance of multi-potential status of stem cells. It is expressed in 
cerebellar precursors and prepancreatic endoderm [258].  
Both PITX2 and LMX1B have been implicated in ovarian cancer progression [259-260]. PAX6 
expression has been noted in breast cancer, pancreatic cancer, astrocytic glioma, glioblastoma and 
medulloblastoma [261-262]. In glioma and glioblastoma PAX6 expression correlates with favorable 
outcome [263] while its ectopic expression leads to the development of pancreatic cystic adenoma 
[264]. During development a negative feedback exists between hedgehog signaling and PAX6; 
similar to the regulation noted in astrocytic glioma cells [258, 265]. However in medulloblastoma 
PAX6 expression is positively regulated by the hedgehog pathway [265]. Therefore the regulation 
and function of PAX6 in cancer seems to be cell-context dependent. 
There have been no previous indications of oncogenic roles for these genes in ERMS. However, 
interestingly, majority of ERMS develop in the anatomical sites wherein the expression and/or 
function of PITX2 and LMX1B have been previously reported. In renal cancer PITX2 seems to 
protect the cells from doxorubicin mediated toxicity by upregulating multidrug transporter ABCB1 
[266]. We also observed increased resistance to doxorubicin in the PITX2-expressing hedgehog-
activated ERMS cells. Overall it would be highly informative to further characterize the importance 
of these novel genes as they could help unravel mechanisms of hedgehog-driven CIC functions in 
ERMS. 
 
7.1.3. Novel cross-talk between developmental pathways in ERMS and possible lineage 
relationships within CIC markers 
There is emerging evidence of cross-talk between developmental pathways in sustaining 
different cancer entities. The means of regulation and the final outcome on the activity of the 
pathways involved seem to depend on the type of cancer studied. For instance, in breast cancer, 
  
49 
Discussion & Outlook 
Wnt, Notch and hedgehog pathways collaborate to maintain breast CICs [267], while in gastric 
cancer hedgehog pathway inhibits Wnt signaling to exert a pro-tumorigenic effect [268]. In RMS 
these pathways have been studied independently (Table 3). Our study (article 2) shows for the first 
time that activation of the hedgehog pathway in ERMS cells inhibits pathways associated with the 
myogenic lineage: Notch, Wnt and TGFβ-BMP. Antagonistic regulation between hedgehog 
signaling and these pathways has been previously reported also in other cell types [269-272]. It was 
unexpected to find that de-differentiated (hedgehog-active) ERMS cells downregulated Notch (RD 
cells; data not shown) and TGFβ pathways since inhibition of these pathways in known to 
differentiate ERMS cells [186, 273]. Wnt pathway activation seems to promote RMS differentiation 
[52, 178]. Concordantly we observed increased expression of Wnt pathway components in the 
differentiated hedgehog-inhibited cells. Recently activation of canonical Wnt signaling in ERMS 
using GSK3β inhibitors was shown to decrease ERMS self-renewal primarily by inducing 
differentiation [176]. These new insights are highly instructive since pro-differentiation strategies 
are a key area of interest in RMS and myopathies. Therefore it would be worthwhile to 
mechanistically characterize these interactions further under pathological conditions [274]. 
Based on the data and known regulatory mechanisms in myogenesis we can formulate a 
hypothetical lineage hierarchy within ERMS tumors (Fig. 16).  
 
Figure 16. Hypothetical lineage hierarchy in ERMS. GLI1-NANOG expressing cells could possess a pre-
myogenic mesenchymal phenotype occupying the apex of the hierarchy with the highest hedgehog pathway activity and 
self-renewal function. Activity of pro-myogenic developmental pathways (Notch, TGFβ and Wnt) is low. We observed cell 
line-specific regulation of certain markers by hedgehog signaling: CMYC and SOX2 were positively regulated in RD and 
RH36 cells respectively by the hedgehog pathway. Also, the expression of CXCR4 and FGFR3 was positively regulated 
by the hedgehog pathway in RD cells and negatively regulated in RH36 cells. Although we observed upregulation of 
CXCR4 expression in RD GLI1 over-expressing cells the reduction upon hedgehog inhibition was minor indicating a 
hedgehog-independent regulation. The transient amplifying population could be characterized by high Notch, TGFβ, 
GLI2/GLI3-mediated moderately active hedgehog signaling and possibly R-spondin-LGR5-Wnt signaling. It could be 
marked by the expression of CD133, FGFR3, MYF5 and LGR5. We found the expression of muscle stem cell markers C-
KIT and C-MET to be highest in the hedgehog-inhibited RD cells (data not shown). It is possible that different ERMS CIC 
phenotypes with varying differentiation potentials are concomitantly present within tumors. It is likely that, GLI 
transcription factors could play non-redundant roles in determining ERMS CIC phenotype and tumor differentiation 
status, similar to what is seen during normal development. Importantly, if the hypothesis holds true then hedgehog 
pathway inhibition could affect both apical and transient-amplifying ERMS CICs. Myogenin expressing cells comprise the 
majority of ERMS cell population and these cells are considered to be lineage-committed. The terminally differentiated 
cells express myosin fibres. See text for further details. HH, Hedgehog signaling; MyHC, Myosin Heavy Chain 
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Hedgehog signaling is important for myogenesis ([241, 246-247, 249-250]) but functionally the 
GLI transcription factors seem to play non-redundant, context-dependent and marginally 
compensatory roles, with GLI2 and GLI3 in general being important for myogenesis than GLI1 
[243, 248]. Our study shows that particularly when GLI1 is over-expressed ERMS cells 
downregulate pathways necessary for myogenic lineage specification and rather express genes that 
are commonly found in neural crest-derived mesenchyme and neuroectoderm. Therefore hedgehog-
active compartment that expresses GLI1 could possess a pre-myogenic mesenchymal phenotype; 
probably occupying the apex of the hierarchy. Furthermore, the induction of NANOG expression by 
GLI1 in ERMS cells could potentiate the pre-myogenic phenotype [275-276]. Our analysis for the 
expression of known ERMS CIC markers and other candidate markers revealed that GLI1 and 
NANOG expressions appear to the most reliable marker for hedgehog-active pre-myogenic 
phenotype (discussed above).  
The pathways repressed by GLI1 over-expression in ERMS play important roles in skeletal 
muscle specification and differentiation. Notch activation is necessary during myogenesis for 
specification, self-renewal and maintenance of muscle stem cells [163]. During postnatal 
myogenesis BMP signaling co-operates with Notch pathway to maintain quiescence of stem cells 
and block terminal differentiation [163, 277-278]. BMP signaling in particular has been shown to 
increase the number of fetal muscle progenitor cells and adult satellite cells [279-280]. Positive 
interactions between TGFβ and Notch signaling have been documented in other tissues as well 
[269]. We found CD133 expression to be highest in ERMS cells with a more myogenic 
background. CD133+ cells isolated from blood and skeletal muscle have been used to regenerate 
muscle in dystrophic muscle mouse models [281] and CD133+ ERMS cells are reported to have 
higher expression of muscle stem cell markers [129]. Therefore CD133 could be marker for early 
pro-myogenic precursors in ERMS tumors. FGFR3 is expressed in quiescent muscle stem cells 
[282] and concordantly FGFR3+ ERMS cells were reported to show increased expression of 
quiescent muscle stem cell markers CD34 and PAX3 [128]. Myfhigh ERMS CIC compartment 
showed increased expression of muscle stem cell genes, c-met and m-cadherin and also bmp3 [251]. 
Expression of Notch2 and GIi3, along with Myf5, was found to be highest in the self-renewing 
‘activated stem cell’-like CIC compartment in the RAS-activated zebrafish ERMS model [48]. As 
previously discussed Myf5 is a Gli2/Gli3 target gene during myogenesis. The mRNA expression of 
GLI2 and CD133 correlated within ERMS patients. In several cancer types TGFβ2/Smad3 induces 
GLI2 expression [283]. 
Wnt signaling plays different roles in the various stages of myogenesis [284]. During embryonic 
myogenesis Wnt signaling is required for specification of muscle progenitor cells while in adult 
myogenesis a temporal switch from active Notch to Wnt is required for terminal differentiation 
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[285]. However a positive regulation between Wnt and Notch signaling is also possible and has 
been noted in other cell systems and cancers [181]. We also analyzed LGR5 expression, a Wnt 
target gene and pathway component [286], which was enriched in ERMS spheres and 
heterogeneously expressed within cell lines (data not shown). Similar to what we observed for other 
Wnt pathway components: the expression of LGR5 was increased in the more differentiated 
compartment. Interestingly, Wnt-β-catenin signaling through R-spondin (an LGR5 ligand) 
increased Myf5 expression in myoblasts [242, 286]. Therefore Notch, TGFβ, GLI2/GLI3-mediated 
hedgehog signaling and possibly Wnt signaling could control the self-renewal of the transient 
amplifying population which is characterized by a myogenic lineage phenotype and could be 
identified by CD133, FGFR3, MYF5 and LGR5 expression status. Upon inhibition of hedgehog, 
Notch, TGFβ or activation of Wnt signaling ERMS cells seem to increase the expression of 
myogenin which signifies commitment to differentiation (this study and [176, 178, 186, 273]) and 
eventually leads to terminal differentiation as assessed by the expression of myosin fibers.  
So far our knowledge about the hierarchical organization in ERMS is elucidated from the 
‘potential’ of various cell types to initiate tumor formation. However this may not be the actual 
‘fate’ of the cell type during tumor growth in vivo [96]. Therefore lineage tracing experiments using 
ERMS mouse models should be able to not only concretely prove the application of the CSC model 
in ERMS progression but also clarify the hierarchy of the CIC markers. Further progress in 
understanding the developmental biology of the neural crest, mesoderm and skeletal muscle could 
shed more light on CIC regulation in ERMS and in general improve disease modeling [287]. 
 
7.2. Factors that could influence sarcoma hierarchical organization 
7.2.1. Non-genetic determinants 
Studies in several cancer types show that the CIC phenotype is not a static entity. The plasticity 
of CIC phenotype may be determined by epigenetic modulators, niche factors such as hypoxia, 
inverse-paracrine pathway activation and genotypic background of the mouse strain used for 
xenograft studies; and noisy cellular gene expression leading to stochastic state transitions [96-97]. 
It is possible that some, if not all, of these factors put pressure on cell fate decisions and therefore 
could determine the CIC phenotype. Additionally the efficiency of the interconversions between the 
CIC and non-CIC state would influence the functional readouts in CIC assays and impact clinical 
outcome (Fig. 17 and 18). In ERMS we have shown that hedgehog pathway can be modulated 
leading to alteration in cellular differentiation states. Therefore the hierarchy in ERMS is clearly not 
static. However under basal conditions we detect only rare cells expressing high levels of GLI1-
NANOG indicating that the interconversion between the GLI1-NANOGhigh and GLI1-NANOGlow 
may be inefficient. In osteosarcoma hypoxia seems to play a major role in determining 
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differentiation status of CICs indicating a more dynamic regulation of this population than 
previously appreciated [126]. Although our study shows that ARMS does not present with a ‘steep’ 
hierarchical organization hypoxic conditions could induce phenotypic alteration in cells to increase 
their tumorigenicity [145]. 
 
Figure 17. Impact of cell plasticity on sarcoma stem cell modeling. If the CIC phenotype is static then non-
CIC cells will not be capable of tumor initiation in transplantation assays and CIC-directed therapies will not lead to tumor 
shrinkage but will not allow tumor relapse. However if the CIC phenotype is reversible, either due to cell intrinsic or 
extrinsic factors, then some or many tumors will form when non-CIC cells are xenotransplanted and importantly the CIC-
directed therapies will not be beneficial. Adapted from [96]  
 
7.2.2. Genetic determinants 
7.2.2.1. Mutations in oncogenes and tumor suppresors 
The effect of genotypic insult on the functionality of CIC markers has been shown in lung cancer 
mouse models where Sca-1+ cells were shown to have enriched tumorigenic properties in Kras and 
p53 mutant background but not when Kras was mutated alone [288]. Recent studies show that 
oncogenes, such as Pten, Ras, Rb1 and Myc, also play an important role in self-renewal and/or 
transformation of normal cells into cancer stem cell-like cells [77, 289-291]. Specifically, p53 - the 
most commonly mutated tumor suppressor in sarcoma models, plays complex context-dependent 
roles in the maintaining mesenchymal lineage phenotypes [292]. Rb1 has been identified a modifier 
of the sarcoma phenotypes generated in osteosarcoma and RMS mouse models [45, 47]. Overall 
genetic alterations could influence the sarcoma ‘cell of origin’ (summarized in section 4.2.5) and 
consequently also the sarcoma CIC markers and lineage phenotypes (Fig. 18).  
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Figure 18. Impact of genetic and non-genetic determinants on sarcoma CIC phenotypes. Sarcoma 
stem/initiating cells could be persistent clones of the ‘cell of origin’ which could be a neoplastic stem cell or a de-
differentiated mature cell. Sarcoma stem cells could also be tumor cells that have acquired the stem cell properties to 
either resemble the ‘cell of origin’ or other stem cells within the tumor histogenic lineage. However it is also possible that 
the sarcoma stem cell phenotype resembles a stem cell that has no direct bearing on the lineage of tumor development 
(transdifferentiation). Genetic, epigenetic and cell extrinsic factors could affect cell fat decisions and thereby alter CIC 
phenotypes. Adapted from [83].  
 
Recent NGS studies found that the RAS pathway is most commonly de-regulated in ERMS [41-
42]. The cell lines used in our study also possess activating RAS mutations (RD -NRAS Q61H and 
RH36 -HRAS Q61K). Interestingly RAS pathway activation is known to increase hedgehog 
signaling strength [293]. RD cells also possess p53 mutation (R248V) and disruption of the p53 
pathway has been documented in sporadic ERMS tumors [41-42]. Rubin et al. reported that 59% of 
ERMS patients in their cohort had a mutant p53 signature and majority of patients with hedgehog-
active signature (29% of total) also possessed a mutant p53 signature [47]. p53 has been known to 
repress NANOG expression and loss of p53 increases hedgehog-NANOG signaling strength [203-
204, 211]. Therefore it is likely that the hedgehog-active CIC phenotype may be a common feature 
in sporadic ERMS cancer.  
In case of ARMS PAX3/PAX7-FOXO1 is the main oncogenic mutation in the tumor 
accompanied by very few additional mutations [41-42]. Our study (article 3) shows that PAX3-
FOXO1 can confer ‘stemness’ to cells. Apart from being necessary for tumor initiation it is also 
necessary for cell survival and proliferation. Furthermore it blocks differentiation and thereby keeps 
all PAX3-FOXO1 expressing cells (majority of the tumor) in an undifferentiated state. The de-
differentiation function of PAX3-FOXO1 that we observed across various lineages in PAX3-
FOXO1 expressing iPS cells implies that a non-skeletal muscle origin could be envisioned for 
ARMS [60]. Also in other fusion-positive sarcomas it is the fusion oncogenes that provide the cues 
for ‘stemness’ [120, 151]. However in contrast to our findings in ARMS, Ewing sarcoma tumors 
have been determined to contain functionally distinct subpopulations [107]. 
Also it is possible that only a subset of sarcomas, depending on the genotype, present with 
hierarchical organization. Wnt pathway activating mutations have been recently identified in a 
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subset of ERMS patients; however nuclear β-catenin accumulation is heterogeneous among the 
tumor cells [41, 294]. Wnt pathway activation as discussed earlier has a pro-differentiation 
consequence in ERMS cells. Therefore further studies are needed to characterize the nature of these 
tumors and if they are also hierarchically organized. 
 
7.2.2.2. Intra-tumoral genetic heterogeneity 
Deep sequencing and data analysis with improved bioinformatic methods show that tumor 
entities are often composed of a dominant genetic clone and minor genetically distinct subclones 
[295]. Extensive genetic heterogeneity within tumors could obscure isolation of truly functionally 
distinct cellular populations since cellular compartments isolated for enriched tumorigenicity could 
be endowed with such a property due to their mutational background [96-97]. Combining functional 
studies, such as clonal xenografting and sphere formation, with deep sequencing could test if 
functional heterogeneity is present within subclones and also amongst them [296-297]. ERMS and 
ARMS tumors have considerable genetic heterogeneity. Clonal evolution of subclones in ERMS 
tumors has been documented during tumor progression [41]. However NGS data alone cannot 
directly test the cancer stem cell model. Given the evidence for hierarchical organization in ERMS 
tumors we predict that ERMS CICs undergo clonal evolution during tumor progression to generate 
relapse and metastasis. Therefore future studies would need to incorporate genetic analysis and 
functional assays using patient material wherein the genetic heterogeneity is maintained. In ARMS 
we show that single cell clones had equal propensity for tumor initiation despite presenting with 
phenotypic heterogeneity. Therefore, although it remains to be determined using primary tumors, 
intra-tumoral genetic heterogeneity possibly has little effect on CIC properties which seem to be 
mainly determined by PAX3-FOXO1 activity. 
 
7.3. Treatment implications and impact on clinical care 
Understanding the hierarchical organization, or lack thereof, in RMS tumors has significant 
implications for therapeutic strategies. At present E- and ARMS patients are treated with similar 
drugs regimens; with just therapy ‘intensity’ being altered based on clinically determined 
parameters. Our studies show that although RMS tumors present with markers of halted skeletal 
muscle differentiation, the fusion-negative and fusion-positive RMS tumors are in fact very 
different in their cellular organization. Therefore our studies add to the increasing weight of 
evidence that the histological subtypes should be treated as distinct molecular and biological 
entities. Recently the RAS pathway has been proposed as a common therapeutic target axis across 
the histological subtypes [42]; however our data argues against similar treatment of the RMS 
variants. Instead we propose that therapies against ERMS tumors should include hedgehog 
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inhibitors to debilitate the hierarchical organization of the tumor while in fusion-positive ARMS 
tumors the need of the hour would be to target the fusion protein activity [298].  
 
7.3.1. Targeting hedgehog signaling 
Several means of hedgehog pathway activation has been noted in cancers [161] and in order to 
target it effectively it would be important to elucidate the mechanism of pathway activation that is 
prevalent in ERMS. To this end, we show for the first time in ERMS that autocrine ligand-based 
signaling via IHH and DHH occurs in ERMS. We detected increased stromal ligand expression 
within xenografts compared to normal mouse muscle indicating a minor contribution from inverse-
paracrine activation. Also we clarified that the contribution of SMO-independent GLI activation is 
minor within ERMS. Therefore using SMO inhibitors would be effective in ERMS.  
The targeting of hedgehog pathway in RMS xenografts has been previously reported however 
there are serious concerns regarding their validity for interpreting treatment efficacy. Two of the 
studies use non-specific drugs: Betulinic acid [299] and Forskolin [300]. Importantly betulinic acid 
was shown to induce regression in GLI1 amplified ARMS xenografts. In ERMS, although 
administration of forskolin led to reduced tumor growth, the specific inhibition of hedgehog 
pathway was not reported either in vitro or in vivo. The use of SMO inhibitor cyclopamine in Ptch1 
mutant ERMS tumors in vivo did not induce tumor regression leading the authors to conclude that 
hedgehog signaling is important for tumor initiation but not maintenance [301]. However the 
efficacy of the drug was found to be low and severe toxicities were associated with cyclopamine 
treatments. Recently a chemical screen conducted by an independent study group to identify drugs 
that could inhibit ERMS self-renewal also identified cyclopamine as a potent tumor inhibitor in vivo 
[176]. Evidence from clinics shows that cyclopamine has low affinity for SMO, poor oral 
bioavailability, suboptimal pharmacokinetics and low metabolic stability and hence studies 
performed using this drug could give spurious results [161, 302]. Therefore new studies are required 
to assess the effect of using clinically relevant hedgehog inhibitors on ERMS tumors in vivo.  
There are some additional key issues to consider before using SMO inhibitors in ERMS,   
1. In hedgehog-dependent cancers where mutational activation has been noted, the use of SMO 
inhibitor as a single therapeutic agent has led to the development of SMO activating mutations 
which render the patients insensitive [161]. Since the activity of GLI transcription factors could be 
increased in the absence of SMO signaling it is possible that tumor cells could compensate for SMO 
inhibition by activating other pathways that directly regulate the GLI code [303]. Therefore it would 
be more prudent to test combination treatment strategies, preferably using GLI inhibitors rather than 
SMO inhibitors, to avoid compensatory mechanisms. Many of the oncogenic pathways that have 
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been reported to increase ERMS tumor aggressiveness also could positively influence GLI activity 
(Fig. 19).  
 
 
Figure 19. Crosstalk between hedgehog signaling and oncogenic pathways. Details of the studies 
documenting the activation of the depicted pathways in ERMS are presented in reference [55]. The crosstalk 
mechanisms have been reviewed in [303-304]. Additional references: [305-308] 
 
2. Importantly our studies present hedgehog inhibition as means to reduce self-renewal in 
ERMS. Therefore measuring the efficacy of hedgehog inhibitors on tumor regression as primary 
treatment endpoint could lead to erroneous interpretations. Strategies that are directed against self-
renewal of a cellular subpopulation rather than tumor bulk would imply that the treatment efficacy 
should measure long-term disease-free survival and not just short-term effects on tumor growth. 
Hence translational research in ERMS evaluating hedgehog inhibitors need to have an altered 
design that would accommodate the cancer stem cell model. A possible strategy of how we could 
assess hedgehog inhibition in combination with other treatment options as an anti-CIC therapy in 
experimental laboratory and clinical trial situation has been depicted in Fig. 20. 
Our study presents GLI1 and NANOG expression as biomarkers to assess hedgehog-driven self-
renewal in ERMS. Expression of GLI1 and NANOG within sporadic ERMS patients could predict 
worse overall and event-free survival. Although high CD133 expression seems to predict worse 
overall survival in ERMS its dynamic regulation and unclear function in self-renewal limits its use 
as a CIC biomarker [108, 309]. So far the importance of FGFR3 or MYF5 expression for ERMS 
patient outcome has not been established. Importantly mutational status or signatures have not been 
successful in prospectively stratifying patients to predict outcome [41, 47]. Therefore combining 
genetic information with CIC biomarkers could offer improved insight for patient recruitment in 
trials, combinatorial treatment options and efficacy endpoint evaluations. 
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Figure 20. Hedgehog inhibition to reduce self-renewal in pre-clinical and clinical settings. (A) 
Treatment-naïve and post-treatment biopsies from patients could be used for in vitro (sphere assay) and in vivo (patient-
derived xenograft) studies that assess hedgehog-driven self-renewal. **Characterization of tumor biopsies would involve 
analysis of self-renewal marker expression (such as GLI1 and NANOG) and genome sequencing to evaluate effects on 
mutational spectra and subclonal architecture. Adapted from [310]. (B) During clinical trials surrogate end points that 
involve genetic, phenotypic and functional analyses would need to be used to assess the effectiveness of combination 
strategies involving standard treatment with hedgehog inhibitors (anti-CSC therapy) [153]. 
 
3. The use of SMO inhibiting drugs systemically in growing children could lead to premature 
dwarfism since bone growth plate development depends on IHH signaling [311]. In infants less than 
six months old hedgehog inhibition could affect cerebellar development [312]. Clinical trials are 
ongoing to assess the optimal therapeutic dosage for SMO inhibitor LDE225, as a single agent, in 
medulloblastoma and other refractory solid tumors in children (including RMS). The safety profiles 
generated from these trials should be helpful in making treatment decisions in children. Even so, it 
would be useful to identify ways in which hedgehog inhibitors could be targeted to the tumor site 
instead of systemic application. Issues with drug-targeting in children are not unique to hedgehog 
inhibition: a developing child would be much more vulnerable to developmental side-effects of any 
targeted drug compared to adult patients [23, 313]. Therefore apart from novel targeting agents we 
would also need efficient targeted-delivery modes to improve patient quality of life. 
 
Current treatment modalities entail severe side-effects (discussed in section 4.2.3). Our data 
shows that using hedgehog inhibitors not only reduces self-renewal but also sensitizes ERMS cells 
to normal chemotherapeutics, thereby allowing a reduction in standard therapy length and dosage. 
Other pro-differentiation strategies could be combined with hedgehog inhibition to terminally 
differentiate ERMS cells. This would especially be beneficial in reducing the chance for metastasis 
since non-CIC committed progenitor cells possess higher invasiveness (article 2 and [251]). These 
principles could be extended to other pediatric sarcoma entities (Fig. 21A). 
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The clinical benefit from conventional treatment of childhood sarcomas has reached a plateau 
[23]. Local recurrence and its refractoriness is still a major problem for sarcoma patients. Therefore 
the need of the hour in the sarcoma stem cell research field is not only identification of tumor 
sustaining subpopulations but also the mechanisms that are necessary for the survival of these cells, 
be it cell intrinsic or extrinsic, in order to target them efficiently. Overall, research and development 
in sarcoma stem cell modeling promises to have an impact in all aspects of patient care (Fig. 21B). 
 
 
Figure 21. Translational relevance of sarcoma stem cell research. (A) Sarcoma CIC-inhibiting 
pathways/drugs which could be combined with the inhibition of other pro-differentiation pathways. **relevance to pediatric 
UPS is unclear. [104, 117, 120, 158, 176] Other references are listed in Table 3. (B) Perceived impact of sarcoma stem 
cell research in clinical management of patients [83]. 
 
7.4. Conclusion 
It is becoming increasingly apparent that tumor heterogeneity is an important factor that impedes 
successful treatment in the clinics [7]. Genetic, epigenetic and/or tumor microenvironment collude 
to generate not just intra-tumoral heterogeneity but also contribute to inter-tumoral heterogeneity 
[97]. The heterogeneity determines ‘stemness’ features of cancer cells, which has significant impact 
on clinical outcome and provides novel therapeutic options. In certain cancer entities, like ERMS, 
functional heterogeneity is in a steep hierarchy where rare primitive tumorigenic cells, akin to 
normal stem cell behavior, would give rise to many phenotypically distinct non-tumorigenic cells. 
In other cancer types, like ARMS, shallow or no hierarchy is observed despite being a 
phenotypically heterogeneous tumor mass and therefore tumorigenic cells are common. In the latter 
scenario usually genetic determinants (for example PAX3-FOXO1) provide ‘stemness’ 
characteristics to cancer cells and inter-tumoral differences could be attributed to varying PAX3-
FOXO1 transcriptional signatures. In conclusion our studies incorporate the latest models of tumor 
progression to provide novel perspectives to RMS tumor biology which will aid in designing 
optimum therapeutic strategies against these deadly childhood cancers.  
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Abstract
Cancer stem cells (CSCs) have been identified in a number of solid tumors, but not yet in rhabdomyosarcoma (RMS), the
most frequently occurring soft tissue tumor in childhood. Hence, the aim of this study was to identify and characterize a CSC
population in RMS using a functional approach. We found that embryonal rhabdomyosarcoma (eRMS) cell lines can form
rhabdomyosarcoma spheres (short rhabdospheres) in stem cell medium containing defined growth factors over several
passages. Using an orthotopic xenograft model, we demonstrate that a 100 fold less sphere cells result in faster tumor
growth compared to the adherent population suggesting that CSCs were enriched in the sphere population. Furthermore,
stem cell genes such as oct4, nanog, c-myc, pax3 and sox2 are significantly upregulated in rhabdospheres which can be
differentiated into multiple lineages such as adipocytes, myocytes and neuronal cells. Surprisingly, gene expression profiles
indicate that rhabdospheres show more similarities with neuronal than with hematopoietic or mesenchymal stem cells.
Analysis of these profiles identified the known CSC marker CD133 as one of the genes upregulated in rhabdospheres, both
on RNA and protein levels. CD133+ sorted cells were subsequently shown to be more tumorigenic and more resistant to
commonly used chemotherapeutics. Using a tissue microarray (TMA) of eRMS patients, we found that high expression of
CD133 correlates with poor overall survival. Hence, CD133 could be a prognostic marker for eRMS. These experiments
indicate that a CD133+ CSC population can be enriched from eRMS which might help to develop novel targeted therapies
against this pediatric tumor.
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Introduction
The cancer stem cell hypothesis suggests that a small
subpopulation of cells sharing common characteristics with nor-
mal stem cells (SCs) - such as capacity to self renew, potential
to differentiate, extensive proliferation in vivo, and resistance
to chemotherapeutics - is responsible for tumor development
[1] and that tumors are organized hierarchically. This concept
was first established in acute myeloid leukemia (AML) [2] and
subsequently also in a number of solid tumors such as breast
cancer where a CD44+/CD242/low CSC population was iden-
tified [3], in brain tumors [4], colon cancer [5], and mela-
nomas [6]. Additionally, CSCs are postulated to be more resistant
to standard chemotherapy [7,8,9,10,11] and might be responsible
for tumor recurrence usually observed in the clinics. However,
the concept is still controversial and the frequency of CSCs
might vary between tumor entities. Some tumors might not be
hierarchically organized at all. Therefore, the existence of such a
cellular subpopulation most likely has to be established for each
tumor type [12].
Rhabdomyosarcoma (RMS) is the most common soft tissue
tumor in childhood representing 5 to 8% of all pediatric ma-
lignancies [13]. RMS is a member of the small blue round cell
tumors additionally comprised of neuroblastoma, non-Hodgkin’s
lymphoma, Ewing’s sarcoma and Wilm’s tumor [14]. It occurs in
most parts of the body, but more frequent sites are spaces
surrounding the brain, the trunk and genitourinary tract [15]. It
has been suggested that mesenchymal stem cells (MSCs) might be
the origin of rhabdomyosarcomas and accordingly the origin of
a potential rhabomyosarcoma stem cell might also be a mesen-
chymal one [16,17]. However, some reports indicate that also
neuronal cells can transform into malignant myogenic cells after
activation and a large number of neuronal genes are expressed in
RMS. Hence the origin of potential RMS stem cells remains to be
determined [18,19].
CD133, also known as Prominin1, is a five transmembrane
protein with eight potential N-glycosylation sites. It was first
described in murine neuroepithelial cells and was recognized as a
human hematopoietic SC marker, because hematopoietic CD34+
progenitor cells express CD133 [20]. CD133 has been suggested
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as CSC marker in brain tumors [21], breast [3], colon [22],
pancreatic [23], liver [24], skin [25], prostate cancers [26] and
Ewing’s sarcoma [27]. Furthermore, CD133+ glioma stem cells are
more resistant to chemotherapy and radiation than bulk and the
CD133 negative population [8]. Moreover, CD133 downregula-
tion induced differentiation in neuroblastoma cell lines and thus
increased sensitivity to drug treatment [28]. Therefore, CD133
could by itself also represent a potential marker for targeted
therapy. Nevertheless, CD133 positive CSC populations in
melanoma and prostate cancer are still controversially discussed
[29,30].
Here, we enriched for a CSC population in rhabdosphere
cultures which are 100 fold more tumorigenic than adherent cells
in xenograft experiments. This subpopulation expressed the stem
cell genes sox2, oct4, nanog, c-myc and pax3 to significantly higher
levels and retains the capability to differentiate into adipocytes,
myocytes and neuronal cells. Furthermore, the known stem cell
marker CD133 was upregulated in rhabdospheres. CD133+ cells
characterize a subpopulation which is more tumorigenic and
resistant to chemotherapy than the negative population. In ad-
dition, high CD133 expression in human eRMS samples cor-
related with a poor overall survival.
Thus, our study demonstrates for the first time that rhabdo-
spheres can be formed from eRMS cells which are enriched in a
CD133+ CSC population.
Materials and Methods
Cell culture methods
Rh36 (kindly provided by Peter Houghton (St Jude Children’s
Hospital, Memphis, TN, USA)), RD, U87MG and MRC5
(purchased from the American Type Culture collection (LGC
Promochem, Molsheim Cedex, France)) and Ruch2 (established
in house) were cultured in Dulbecco’s modified Eagle medium
containing 10% fetal calf serum (FCS).
Sphere cultures were derived from and enriched over several
passages by seeding the cell lines in a defined serum free medium
(SC medium) consisting of Neurobasal medium (Invitrogen)
supplemented with 10ng/ml EGF (R&D Systems), 20ng/ml b-
FGF (R&D Systems) and 26 B27 (10ml; Invitrogen) [31].
Adipogenesis was induced as described [32,33]. Briefly, after
preparing spheroids, cells were seeded into chamber slides and
treated with or without 0.1% DMSO for 3 days. After 8 days in
differentiation medium, containing 85nM insulin, 2nM triiodthyr-
onine (T3) and 10% FCS, cells were stained with OilRedO
(ThermoScientific) [34]. Neurogenesis and Myogenesis were
assayed as described [35]. Briefly, cells were seeded into 6 well
plates and treated with different concentrations of retinoic acid
(RA; 1nM, 10nM, 300nM). After 24 days in differentiation
medium containing RA and 0.5% FCS, cells were fixed in 4%
paraformaldehyde (PFA) and stained for differentiation markers.
Resistance to chemotherapeutics was tested by seeding 2000 cells
in a 6-well plate 48 hours before treatment. The cells were treated
twice a week with different concentrations of cisPlatin (Sigma;
10 mM and 50 mM) and Chlorambucil (Sigma; 6.45 mM). Twice a
week, colonies were counted and documented. For visualizing the
colonies, we stained them with crystal violet according to Franken,
et al. [36].
Immunofluorescence, immunohistochemistry and flow
cytometry/sorting
For immunofluorescence staining, cells were fixed in 4% PFA
and blocked in medium containing 10% FCS and 0.5% Tri-
ton. Cells were stained over night at 4uC for CD133 (1/100)
(polyclonal antibody, Abcam), GFAP (1/300) (monoclonal anti-
body, R&D Systems), myogenin (1/2) (F5D; monoclonal antibody,
Developmental Studies Hybridoma bank) and N-CAM (1/2)
(5.1H11; Developmental Studies Hybridoma bank)). Alexa Fluor
488 or 594 (1/200) (Invitrogen) antibodies were used as secondary
antibodies. All stainings were analyzed with an Axioskop2 mot
plus fluorescence microscope (Zeiss). Xenograft tumors were
embedded in paraffin, fixed and analyzed for H&E, Myogenin
(1/20) (Myf4, monoclonal antibody, Novocastra Laboratories Ltd)
and desmin (1/20) (monoclonal antibody; Dako) by immunohis-
tochemistry. As secondary antibody a horseradish peroxidase
(HRP) labeled rabbit anti-mouse antibody (Epitomics) was used.
Stainings were visualized with the Refine DAB-Kit (Leica).
For flow cytometry, cells were trypsinized, washed and stained
(1/10) with a fluorochrome labeled antibody (CD133/2-APC,
Miltenyi). All samples were measured with a BDFACSCanto II
flow cytometer (BD Bioscience) or MoFlo high speed cell sorter
(DakoCytomation) and analyzed with the software FlowJo.
Molecular methods
RNA was extracted using RNeasy Plus Mini Kits (Qiagen).
Reverse transcription was carried out using the high-capacity
cDNA reverse transcription kit (Applied Biosystems) according
to the manufacturer’s instructions. RNA and cDNA concentra-
tions were measured with a Nanodrop ND1000 spectrometer.
Quantitative Real-Time PCR was performed using vali-
dated TaqMan Gene Expression Assays (Applied Biosystems)
for POU5F1/OCT3-4 (Hs02397400_g1), NANOG (Hs023874-
00_g1), SOX2 (Hs01053049_s1), CMYC (Hs00153408_m1),
PAX3 (Hs00992437_m1), NMYC (Hs00232074_m1), PROM1/
CD133 (Hs01009261_m1) and GAPDH (Hs99999905_m1) as an
endogenous housekeeping gene for normalization. Reactions were
run using the standard conditions on an ABI 7900HT Fast Real-
Time PCR machine. Relative fold difference was calculated using
the 2DDCt method. Gene expression profiling of different RNA
samples from different sphere passages (early = passage 3; inter-
mediate = passage 5 to 7; late = passage 10) and their correspond-
ing adherent control was performed by an Affymetrix Exonmi-
croarray (HuEx-1_0-st-v2). The samples were analyzed with
the Genespring10 and Ingenuity IPA software and compared
with published data sets (hematopoietic (GSE2666), FM95
(GSE10435), embryonic skeletal myoblast (GSE3230), mesenchy-
mal stem cells (GSE2248), embryonic stem cells (GSE9440),
neuronal cells (GSE10691), glioblastoma cells and patient samples
(GSE7181), neurospheres (GSE8049) and prostate cancer samples
(GSE10832)). The correlation of the samples was analyzed with a
script programmed in R (Functional Genomic Center Zurich).
Xenograft experiments
Xenograft experiments were approved by the veterinary office
of the Canton of Zurich.
Different amounts of adherent cells and their corresponding
sphere cultures were injected intra muscularly into the right
leg of NOD.CB17-Prkdcscid/J (NOD/Scid) and NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory) and tumor
size was determined every 2 to 3 days by measuring two diameters
(d1 and d2) in right angles of both legs with a calliper. Tumor
volumes were calculated using the following formula V= [4/3 p
K(d1+d2)]right leg2[4/3 p K(d1+d2)]left leg.
Patient characteristics
76 eRMS patients, 43 male and 33 female patients, were
included from the CWS95 study. The age of the patients at
diagnosis varied from a few months to 22 years.
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Figure 1. Cancer stem-like cells are enriched in Rhabdospheres. A), B) Embryonal rhabdomyosarcoma (eRMS) cell lines (RD, Rh36 and Ruch2)
were cultured in stem cell medium (SC-medium) over several passages. A glioblastoma (U87MG) and a fibroblast (MRC5) cell line were used as
controls. A) Representative phase contrast pictures of cultured RD, Ruch2 and Rh36 sphere cultures (4006 magnification). B) Subpopulation
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19506
Statistical analysis
For in vitro experiments, Student’s t test was used on triplicates.
P values of less than 0.05 were considered significant.
Results
Rhabdospheres are enriched with cancer stem-like cells
To determine whether RMS cells might contain a subpopula-
tion of CSC cells, we attempted to grow embryonal rhabdomyo-
sarcoma (eRMS) cell lines (RD, Rh36 and Ruch2) as rhabdo-
myosarcoma spheres (short rhabdospheres) in stem cell medium
(SC-medium). A glioblastoma cell line (U87MG) and fibroblast
cells (MRC5) were used as positive and negative controls,
respectively. Three eRMS cell lines (RD, Rh36 and Ruch2)
formed rhabdospheres under these conditions over several
passages (Figure 1A). To test, whether sphere cells could be
serially enriched, we seeded 20000 sphere cells over several
passages into the SC-medium and determined the number of
spheres at each passage (Figure 1B). Compared to the positive
control U87MG sphere cultures which showed the highest
enrichment over 10 passages (up to 1750 spheres per 20000 cells),
1300 spheres were counted for RD cultures after 10 passages,
while Ruch2 and Rh36 sphere cultures could also be enriched
albeit to a lesser extent (600 counted spheres) indicating that a
subpopulation of cells with self renewal property can be enriched
from three different eRMS cell lines. To investigate whether this
self renewing subpopulation is more tumorigenic than the
adherent population, we injected different numbers of RD
cells and their corresponding sphere cultures (106, 105 and 104)
intramuscularly (i.m.) into the right leg of NOD/Scid mice (n = 6)
and measured tumor growth over several weeks (Figure 1C).
Xenograft tumors from sphere cultures started to grow around day
40 after injection, compared to adherent cells where we detected
the earliest tumor growth around day 80 post injection. Moreover,
tumor growth was observed when we injected 100 fold less sphere
cells (104), whereas no tumor growth was seen using the same
number of adherent cells. 125 days after injection, in two out of six
NOD/Scid mice injected with 105 adherent cells, a small tumor
was seen, while we detected tumors in every mouse injected
with 105 sphere cells already after 60 days. These results were
subsequently confirmed in a second mouse strain, namely NSG
mice, where tumor growth was observed with 105, 104 and 103
(one out of three mice) injected sphere cells, but only with 106
adherent cells (Figure 1D). Therefore, in both mouse models cells
from sphere cultures are more tumorigenic and fewer cells are
needed for tumor growth compared to adherent cells. To
demonstrate that all xenograft tumors were indeed RMS tumors,
we collected tumor samples and constructed a xenograft tissue
microarray (TMA) with adherent RD cells and corresponding
sphere cultures as controls. Stainings of the TMA with RMS
markers, myogenin and desmin, was positive in both adherent cells
and spheres (Figure 1E) which were negative for markers of other
small blue round cell tumors (CD45, CD99, cytokeratin (CK),
S100b, Synaptosin, smooth muscle actin (SMA) and WT1; data
not shown). Furthermore, all xenograft tumors displayed typical
RMS hallmarks such as multinucleated cells and positive stainings
for desmin and myogenin, irrespective of the mouse strain they
were grown in. These results confirmed that all xenograft tumors
represented RMS tumors with similar features. We conclude from
these experiments that a subpopulation of RMS cells can be
enriched in sphere cultures over several passages which is more
tumorigenic in vivo and therefore could represent a potential CSC
population.
Sphere cultures have stem cell characteristics
To further substantiate the notion that rhabdospheres are
enriched for CSC, we quantified the expression levels of several
known SC genes like oct4, nanog, c-myc, sox2 and pax3 with real-
time PCR in different passages of sphere cultures (passages 3, 7,
10) compared to adherent cells. While oct4 and pax3 showed the
highest upregulation in RD sphere cultures (P,0.0001), also c-
myc (P = 0.0016), sox2 (P = 0.0068) and nanog (P = 0.0028) were
significantly upregulated (Figure 2A). Similar results were
obtained with Rh36 cells with the exception of pax3 and c-myc
which did not change significantly (Figure 2B). This could be due
to already high endogenous expression levels in the adherent
Rh36 cell line when compared to RD adherent cells (data not
shown). Therefore, we selected RD cells for all subsequent
experiments.
It has been shown that cells with multilineage differentiation
potential can differentiate into neuronal cells, myocytes and
adipocytes after treatment with dimethylsulfoxid (DMSO) or
retinoic acid (RA) [32,35,37,38]. On that basis, we next assessed to
which extent RD cells can be differentiated towards these line-
ages. First, we treated adherent and sphere cultures with different
concentrations of RA (1nM, 10nM and 300nM). After 24 days,
cells were stained with myogenic (myogenin, N-CAM) and
neuronal markers (GFAP, N-CAM) (Figure 2C, D). Although
adherent cells expressed low levels of myogenin (3,6% and 11,5%)
after treatment (Figure 2C), sphere cultures showed much stronger
upregulation of myogenin positivity (,50%) (Figure 2D). The
highest expression of N-CAM (52%) was detectable after
treatment with 10nM RA. While both spheres and adherent
cells were negative for myogenin when treated with 300nM RA,
we observed positive stainings for N-CAM and GFAP (9,4%),
indicative of neuronal differentiation, only in sphere cultures
(Figure 2D) and not in adherent cells (Figure 2C). In contrast, no
GFAP positive cell was found after 1 and 10nM RA treatment
(data not shown). Untreated controls were negative for all markers
analyzed (data not shown).
To differentiate cells towards adipocytes, we treated spheroids
from both adherent and sphere cells for 3 days with DMSO. After
subsequent cultivation in appropriate differentiation medium for 8
days, around 5% of DMSO treated adherent cells were positive for
fatty vacuoles (Figure 2E). However, sphere cultures had positively
stained fatty vacuoles in up to 90% (mean 73.75%) of the cells
when treated with DMSO (Figure 2E).
In conclusion, sphere cultures had a significantly increased
expression level of stem cell genes and regained the capability
to differentiate towards neurogenic, myogenic and adipogenic
lineages with appropriate stimulants. These results indicate that
stem-like cells are enriched in rhabdospheres.
enrichment over several passages (x-axis) was estimated by counting the obtained spheres per cell (y-axis). C), D) Limited dilution (106, 105 and 104) of
adherent versus sphere cells in vivo. Cells were intramuscularly (i.m.) injected into NOD/Scid (n = 6) (C) and NSG mice (n = 3) (D) at the indicated
numbers and tumor growth (y-axis; tumor volume in mm3) was measured over time (x-axis). E) Immunohistochemical (IHC) stainings of xenograft
tumor sections on a xenograft tissue microarray (TMA). Adherent and sphere cells were used as controls on the TMA. The TMA was stained for H&E
and RMS markers (desmin and myogenin). Representative IHC stainings are shown (4006magnification). The small inserts represent magnifications
of positively stained cells.
doi:10.1371/journal.pone.0019506.g001
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CD133 is upregulated in sphere cultures
To characterize sphere cultures in further detail and to identify
marker proteins specifically up- or downregulated, a gene ex-
pression profiling was performed with a human exonmicroarray
(HuEx-1_0-st-v2) for both RD and Rh36 cells and three different
passages (early, intermediate and late) of their corresponding
spheres.
In Figure 3A, a heat map of all samples is shown which revealed
that RD and Rh36 cells cluster with their corresponding sphere
cells indicating that both cell lines are more different from each
other than their different passages. Nevertheless, in total 2217
genes (upregulated 1568 genes, downregulated 649 genes) are
differentially expressed in RD spheres compared to adherent cells
with a fold change of at least two. To restrict the number of genes
and to find potential markers characterizing the rhabdospheres, a
metaanalysis with different microarray samples publicly available
(hematopoietic, FM95, embryonic skeletal myoblast, mesenchymal
stem cells, embryonic stem cells, neuronal cells, glioblastoma cells
and patient samples, neurospheres and prostate cancer samples)
was implemented. All RMS samples, both adherent and rhabdo-
spheres (red (RD) and pink (Rh36)), clustered together with
neuronal and glioblastoma cells and their spheres, and patient
samples (depicted in green) (Figure 3B). Due to this observation,
we searched for genes commonly up- or downregulated in RD and
glioblastoma sphere cultures compared to their corresponding
adherent cells with a fold change of at least two (Table 1). 31 genes
were identified and further subgrouped according to their
subcellular localization; membrane (8 genes), secreted (1 gene),
endoplasmatic reticulum ER membrane (1 gene), golgi apparatus
(1 gene), cytoplasm (12 genes) and nucleus (8 genes). In addition,
12 genes are commonly downregulated (membrane (6), secreted
(2), cytoplasm (4)). To be able to identify and isolate a putative
CSC population, we were interested mainly in membrane proteins
of which we identified 14 genes. One obvious candidate gene in
this list was CD133 or Prominin1 which is a well described SC and
CSC marker. Therefore, we validated CD133 as a potential
marker of rhabdospheres at the expression level by performing
real-time PCR (Figure 3C). In sphere cultures of both RD and
Rh36, CD133 expression was indeed significantly upregulated. To
verify these results on protein level, RD cells and spheres were
stained for CD133 and analyzed by flow cytometry (Figure 3D),
fluorescence microscopy (Figure 3E) and western blotting
(Figure 3F). In all experiments, CD133 is upregulated in rhab-
dospheres compared to adherent cells also on protein level.
These experiments suggest that CD133+ cells , a known CSC
marker, are enriched in rhabdospheres and CD133 might be a
potential CSC marker in RMS.
CD133+ RMS cells are more chemoresistant and
tumorigenic
To verify whether a CD133+ subpopulation is more tumo-
rigenic and resistant to commonly used chemotherapeutics in
RMS, we sorted RD cells for CD133 positive and negative
(CD133+, CD1332) populations (Figure 4A) and performed li-
miting dilutions by orthotopical injections into NOD/Scid mice
using adherent RD cells and unsorted bulk RD cells as controls. In
contrast to the control where the highest number of cells injected
(106 cells) developed a tumor, mice injected with CD1332 cells
(105 – 102) did not develop any tumor after 140 days. In contrast,
we could detect at least one tumor in the CD133+ injected mice
in three out of four dilutions (Figure 4B). To demonstrate that
these tumors are indeed RMS tumors, we analyzed them by
immunohistochemistry using known RMS markers as described
before. All tumors were positive for desmin and myogenin and
histologically identical with RMS tumors (Figure 4C). To inves-
tigate potential resistance to commonly used chemotherapeutics,
we seeded sorted cells at low density 48 hours before starting
treatment with cisPlatin and Chlorambucil. Cells were treated
twice a week and colonies obtained were counted after staining
with crystal violet (Figure 4D). CD133+ sorted RD cells were more
resistant to treatment and formed viable colonies which developed
significantly less in the CD1332 population.
Therefore, rhabdospheres are enriched for a CD133+ popula-
tion being more tumorigenic and resistant to cisPlatin and
Chlorambucil.
High expression of CD133 correlates with poor overall
survival
Finally, we investigated whether a CD133+ subpopulation is
also present in human patient material. To this end, we stained a
human RMS TMA, first described by Wachtel [19], for CD133.
For quantification, we scored for two variables, namely intensity of
staining and number of positive cells. The added scores were used
to classify the tumors as having negative, low, middle or high
expression. ERMS patients showing no or low to intermediate
CD133 expression showed an overall survival around 75% which
is comparable with the survival rate of translocation negative RMS
patients [39]. In contrast, patients with high expression of CD133
had a clearly worse survival (less than 50%, p= 0.0272, Figure 5A).
Representative tumor sections of high, intermediate and low
CD133 stainings are shown in Figure 5B.
These results therefore indicate that CD133 is a potential CSC
marker in eRMS that might identify eRMS patients with a poor
outcome.
Discussion
Due to a better understanding of tumor organization, new
treatment approaches that target directly a CSC population now
seem possible [22]. It has been reported that not only leukemia [2]
and carcinomas [3] have a subpopulation of cells with self renewal
properties [27], but also some sarcomas such as Ewing’s sarcoma
might follow the cancer stem cell model [1]. For the most common
sarcoma in childhood, RMS, no clear subpopulation has been
identified until now [16,17]. Therefore, we used a functional
approach to investigate whether rhabdomyosarcoma tumors might
Figure 2. Sphere cultures have stem cell characteristics. A), B) Expression analysis of stem cell genes (oct4, nanog, sox2, c-myc and pax3) by
Real-time PCR. RD (A) and Rh36 (B) adherent cells and 3 different sphere culture passages (36, 76, 106) were compared. C), D) RD cells (C) and their
corresponding sphere cultures (D) were treated with retinoic acid (1nM, 10nM, 300nM) for 24 days and stained for differentiation markers (N-CAM,
myogenin and GFAP). Percentage of positivity was calculated by counting 3 different random microscopic fields with at least 30 cells. E) RD cells and
spheres were treated with 0.1% DMSO for 3 days. After additional 8 days, cells were stained for OilRedO. Percentage of cells with fatty vacuoles was
calculated by counting 4 independent slides. Representative pictures and magnifications (small box) of OilRedO stainings are shown. For A) wwww
P,0.0001; ww P= 0.0028; w P= 0.0016; www P= 0.0068. For B) wwww P= 0.0015; ww P= 0.0281; www P= 0.0275. For E) www P= 0.0004.
Abbreviations: ns, not significant; GFAP, glial fibrillary acidic protein; N-CAM, neural cell adhesion molecule; sph, spheres; adh, adherent; DMSO,
dimethylsulfoxid.
doi:10.1371/journal.pone.0019506.g002
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have a subpopulation enriched in CSCs and are hierarchically
organized.
We first adopted a sphere forming assay to enrich a sub-
population with stem cell properties in vitro. Testing different
conditions of growth factor concentrations and media, sphere
formation over several passages could be observed only in one
condition which was described previously as a neuronal stem cell
medium [31]. Several lines of evidence then indicate that these
rhabdospheres are enriched for stem-like cells. First, limiting
dilution in two different immunosuppressed mouse strains indicate
Table 1. List of genes up- or downregulated at least two fold in RD rhabdospheres.
upregulated downregulated
Localization Chosen Gene IDs Gene Symbol Chosen Gene IDs Gene Symbol
Membrane 2535 FZD2 2674 GFRA1
7976 FZD3 3778 KCNMA1
8842 PROM1 4907 NT5E
23554 TSPAN12 7010 TEK
51678 MPP6 7057 THBS1
55704 CCDC88A 23768 FLRT2
57633 LRRN1
84216 TMEM117
Secreted 255743 NPNT 4015 LOX
7424 VEGFC
Golgi apparatus 22836 RHOBTB3
ER membrane 80055 PGAP1
Cytoplasm 2037 EPB41L2 3433 IFIT2
3157 HMGCS1 3437 IFIT3
4133 MAP2 9060 PAPSS2
6860 SYT4 10231 RCAN2
9315 C5orf13
9456 HOMER1
9735 KNTC1
54874 FNBP1L
55792 PCID2
56992 KIF15
91057 CCDC34
113263 GLCCI1
Nucleus 7552 ZNF711
9735 KNTC1
10926 DBF4
55769 ZNF83
64105 CENPK
81931 ZNF93
84250 ANKRD32
90317 ZNF616
151648 SGOL1
doi:10.1371/journal.pone.0019506.t001
Figure 3. CD133 is upregulated in sphere cultures. Gene expression profiling (HuEx-1_0-st-v2) of two eRMS cells (RD and Rh36) and spheres
(early, middle and late). A) left side: Cluster plot of RD and Rh36 cells and spheres. Right side: Analysis of RD samples. Genes, being up- or
downregulated in RD spheres with a fold change of at least 2, are shown. B) Correlation plot of a metaanalysis performed with different publicly
available expression data (hematopoietic and mesenchymal stem cells biopsies, FM95 cells, embryonic skeletal myoblast cells, embryonic stem cells,
neuronal cells, glioblastoma spheres, cells and patient samples, neurospheres and prostate cancer samples) as indicated C) Expression of CD133
mRNA quantified by real-time PCR after correction with GAPDH levels as house-keeping gene. D) Flow cytometry analysis of CD133 (blue) expression.
As controls unstained adherent and sphere cells were used, respectively (grey). E) Immunofluorescence staining of CD133 (green) of adherent and
sphere cells. The nuclei were counterstained with DAPI (blue). Fields of two independent slides with at least 50 cells each were counted and the
percentage of positive stained cells calculated. F) Western blot analysis of CD133 protein expression in adherent and sphere cells. ß-Tubulin was used
as a loading control. A representative blot is shown. For C) w P= 0.0284; ww P= 0.0079. Abbreviations: ctrl, control; MSC, mesenchymal stem cells.
doi:10.1371/journal.pone.0019506.g003
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that the rhabdosphere population is at least 100 fold more
tumorigenic than adherent cells. In contrast, culturing cell lines
representing the alveolar subtype of RMS in the same stem cell
medium leads to formation of spheres which surprisingly were not
tumorigenic after injection into immunosuppressed mice (data not
shown). Hence, it seems unlikely that media conditions themselves
were responsible for induction of the observed phenotypes and
rather selection of a preexisting subpopulation was occurring
specifically in eRMS. Second, our data analyzing expression levels
of stem cell genes in rhabdospheres compared to adherent cells
demonstrate that the stem cell genes oct4, nanog, sox2, c-myc as well
as pax3, are significantly upregulated. While sox2, nanog, and oct4
are required for induction of the pluripotent stem cell pheno-
type, c-myc expression also correlates with tumor formation and
upregulation of this oncogene could trigger the higher tumor
initiating potential [40]. Pax3 is a known developmental marker
expressed during muscle and brain development, repressed in
adult tissue and connected to tumor formation and a poor overall
survival [41,42,43].
As an additional hallmark of cancer stem cells [1], we
investigated whether rhabdospheres have the potential to dif-
ferentiate into multiple lineages. Indeed, rhabdospheres treated
with DMSO and RA, respectively, differentiate towards adipo-
genic, myogenic and neurogenic lineages similar to what has been
observed in cells with multilineage differentiation potential such as
embryonal carcinoma cells [32,33,35]. These data support the
concept that rhabdospheres contain cells with stem-like features
and that RMS tumors are hierarchical organized [1].
Figure 5. High expression of CD133 correlates with a poor survival rate. Immunofluorescence staining of a human RMS TMA with CD133
(green). Nuclei were counterstained with DAPI (blue). Two values were chosen for scoring: Staining intensity (1 = low, 2 =middle and 3=bright) and
number of positive cells (0 = 0; 1 = 1–10; 2 = 11–20; 3$21). Both values were added up to the scorings negative (0 and 1), low (2 and 3), middle (4) and
high (5 and 6). A) Stainings of representative tumor sections are shown for high, middle and low scorings. B) Overall survival of eRMS patients as
shown by a Kaplan-Meier curve. For A) ww P= 0.0272.
doi:10.1371/journal.pone.0019506.g005
Figure 4. CD133+ RMS cells are more chemoresistant and tumorigenic. A) RD cells were stained for CD133 (blue) and sorted into CD133+
(green) and CD1332 (violet) populations with a MoFlo high speed cell sorter (DakoCytomation). Unstained RD cells were used as control (grey). After
sorting the different fractions were reanalyzed by flow cytometry. B) Limited dilutions in vivo of different subpopulations (106, 105, 104, 103and 102).
Bulk stained (106) and unstained cells without sorting (106) were used as controls. Cells were injected i.m. into NOD/Scid mice (n = 4) and tumor
growth measured. Numbers indicate mice with growing tumors. C) Immunohistochemical (IHC) analysis of all xenograft tumors (H&E, Myogenin and
Desmin). Representative stainings are shown. D) Clonogenic assay with sorted subpopulations (CD133+ and CD1332). Cells were treated with cisPlatin
(IC10 = 10 mM and IC60= 50 mM) and Chlorambucil (IC10= 6.45 mM). Colonies were visualized by crystal violet. cisPlatin: mean of 3 independent
sortings 6 SEM; Chlorambucil: mean of 2 independent sortings 6 SEM. For D) ww P= 0.0377; w P= 0.0241. Abbreviations: IC, inhibitory
concentration; ctrl, control.
doi:10.1371/journal.pone.0019506.g004
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Previous studies have suggested that mesenchymal stem cells
could be the origin of RMS [17,44,45]. In contrast, our me-
taanalysis of exon microarray data with published data sets
revealed that RMS samples had an expression profile more simi-
lar to neuronal cells and patients than mesenchymal stem cells.
Furthermore, expression profiles also detected a large number of
neuronal genes being expressed in RMS biopsies [19,46,47,48]
such as pax3 which is crucial for the development of both the
myogenic and neuronal lineage [42]. Interestingly, it has been
demonstrated earlier that a population of myogenic, myf-5 positive
cells can be derived from neural tube during mouse development
[49]. These myf-5 positive cells co-express both neuronal and
muscle markers, raising the intriguing possibility that the cell of
origin of our CSC population could also be a multipotential stem
cell derived from cells in the neuronal compartment. In support of
this, it has also been described that neuronal stem cells can
differentiate into malignant muscle cells after activation [18].
However, this issue needs to be addressed further in the future.
Previous studies have shown that CD133 marks hematopoietic
stem cells [20] and cancer stem cells [29], in particular neuronal
and mesenchymal CSCs [21]. Moreover, a CD133+ population
was identified as a CSC population in sarcomas such as Ewing’s
sarcoma [27] and osteosarcoma [50] which was more resistant to
chemotherapy and radiation [7,8,9,10,11]. It was therefore not
surprising that CD133 emerged as a marker for RMS CSC in our
study as well. Interestingly, also the fraction of CD133+ cells in
both Ewing’s sarcoma and RMS seem to be similar. It has been
reported that expression of FGFR3 might mark a tumorigenic
subpopulation in RMS. However, we did not find an increase in
mRNA expression of this receptor in rhabdospheres (Figure S1).
The same report also found that CD133 positive cells were not
more tumorigenic than the negative population. However, the
discrepancy with our study might be explained by the different
CD133 epitopes that were used in the two studies. Here, using
CD133 as a marker to sort cells which were then injected
orthotopically into mice without prior cultivation in stem cell
media, we readily detected tumor growth at lower cell numbers in
CD133 positive versus CD133 negative cells. Indeed, in the
CD133+ injected group one mouse at every dilution developed a
RMS tumor which was not observed in the CD1332 population.
The relatively low tumorigenicity detected in the sorted population
in general is likely due to impaired viability of the cells by the
sorting procedure. Interestingly, CD133+ sorted cells were also
more resistant to cisPlatin and Chlorambucil treatment suggesting
that anti-apoptotic or mismatch repair proteins are active. Indeed,
we observed upregulation of several transcripts encoding mis-
match repair proteins in rhabdospheres (data not shown).
Finally, we stained a human RMS tissue microarray (TMA) [19]
for CD133 to demonstrate that a CD133+ population is also
present in human tumor biopsies. Patients with high positivity for
CD133 were found to have the worst overall survival, which could
be explained by a higher recurrence. However, in a multivariate
analysis using a cox regression model, we were not able to
demonstrate that CD133 is an independent prognostic marker for
eRMS since the number of patients in this group was too low.
More patients will have to be included therefore in a future study.
Nevertheless, CD133 might represent the first candidate marker to
identify eRMS patients with poor survival and might be used to
stratify patients in the future.
Conclusion
Overall, our results demonstrate that cells with self renewal
property that can drive tumorigenicity and have the potential to
differentiate into multiple lineages are enriched in rhabdospheres.
With CD133, we identified an already known CSC marker in an
additional sarcoma [27,50] whose expression also correlated with
a poor prognosis in eRMS patients. Further characterization
of this CD133 positive CSC population might lead to a better
understanding of the development of RMS. It now seems possible
to screen directly for therapeutically active substances targeting the
CSC subpopulation in eRMS to further advance treatment of this
childhood sarcoma.
Supporting Information
Figure S1 Prominin and fibroblast growth factor recep-
tor (FGFR) expression in adherent and sphere cells. A)
Prominin1 and Prominin2 gene expression profiles in adherent
and sphere cells analyzed by Genespring10 software. Intensity
values were normalized to adherent cells. B) FGFR1, FGFR2,
FGFR3 and FGFR4 gene expression profiles in adherent and
sphere cells. Intensity values were normalized to adherent cells.
C) Quantitative Real-time PCR with primers for FGFR3
(Hs00997400_g1) and for GAPDH was done with cDNA of adhe-
rent cells and three different passages of sphere cells. Quan-
titative results are indicated in arbitrary units (AU). FGFR3 was
not differentially expressed in sphere cells compared to adherent
cells.
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Figure S1. Prominin and fibroblast growth factor receptor (FGFR) expression in adherent and sphere 
cells. A) Prominin1 and Prominin2 gene expression profiles in adherent and sphere cells analyzed by 
Genespring10 software. Intensity values were normalized to adherent cells. B) FGFR1, FGFR2, FGFR3 and 
FGFR4 gene expression profiles in adherent and sphere cells. Intensity values were normalized to adherent 
cells. C) Quantitative Real-time PCR with primers for FGFR3 (Hs00997400_g1) and for GAPDH was done 
with cDNA of adherent cells and three different passages of sphere cells. Quantitative results are indicated in 
arbitrary units (AU). FGFR3 was not differentially expressed in sphere cells compared to adherent cells. 
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 Abstract 
 
 
Current treatment regimens for Rhabdomyosarcoma (RMS), the most common pediatric soft tissue 
cancer, rely on conventional chemotherapy and although they show clinical benefit there is a 
significant risk of adverse side effects and secondary tumors later in life. Therefore, identifying and 
targeting sub-populations with higher tumorigenic potential and self-renewal capacity would offer 
improved patient management strategies. The self-renewing cellular compartments enriched from 
embryonal RMS (ERMS) cell lines using sphere assay showed upregulation of several components 
of the Hedgehog pathway. Genetic loss- and gain-of-function experiments and the use of clinically 
relevant small molecule modulators revealed that hedgehog signaling is important for determining 
self-renewal in vitro and tumor initiation in vivo. In addition, the hedgehog pathway altered the 
chemoresistance, motility and differentiation status of ERMS cells. Furthermore, NANOG was 
determined as an important downstream effector of active hedgehog signaling. Importantly, 
evaluating the presence of self-renewing cells identified by GLI1 and NANOG expression could 
predict patient survival. This work presents novel functional aspects of hedgehog signaling in 
ERMS, redefining the rationale for its targeting as means to control ERMS self-renewal and also 
underscores the importance of studying tumor heterogeneity in pediatric cancer in general. 
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 Introduction 
Rhabdomyosarcoma (RMS) comprises a heterogeneous set of neoplasms that possess features of 
halted skeletal muscle differentiation. It is the most common soft tissue cancer in the pediatric 
population with an incidence of 4.3 per million per year.  There are two major histological subtypes: 
embryonal (ERMS) and alveolar (ARMS). The two variants differ in their molecular cytogenetic 
profiles, clinical presentations and prognosis. In 80% of ARMS cases presence of the chromosomal 
translocation t(2;13)(q35;q14) or t(1;13)(p36;q14) has been observed which leads to the expression 
of a fusion transcription factor PAX3-FOXO1 or PAX7-FOXO1 respectively. The fusion-positive 
status has been shown to predict poor survival (Hawkins et al. 2014). ERMS accounts for about 
70% of all diagnosed RMS cases. These tumors are fusion-negative but possess a relatively more 
complex genomic landscape with a loss of heterozygosity at 11p15 locus and a frequent alteration 
of the RAS pathway (Shern et al. 2014). A multi-modal approach is routinely used in the clinics for 
RMS treatment which includes intensive multi-agent chemotherapy with conventional cytotoxic 
drugs, surgical resection and radiotherapy. After an initial improvement in overall survival the 
progress in clinical care has reached a plateau in recent years (Malempati and Hawkins 2012; 
Hawkins et al. 2013; Hawkins et al. 2014). Currently, pre-treatment histology and initial clinical 
presentation guide risk stratification for relapse which is used to determine therapy intensity 
(Hawkins et al. 2013). While a majority of ERMS patients have good prognosis with event-free 
survival of over 75%, the situation is dismal for high risk metastatic ERMS patients and patients 
with progressive or recurrent disease, with a five year survival estimate at 35% and 17%, 
respectively (Hawkins et al. 2014). Furthermore, current treatment regimens cause severe morbidity 
and lead to late sequelae (Stevens 2005). Therefore there is an urgent need to implement rationally 
selected targeted treatment options to reduce rate of relapse, therapy burden and improve clinical 
outcome (Schafer and Niggli 2010; Norris and Adamson 2012). 
To this end, it will be important to delineate the molecular mechanisms which initiate and 
maintain ERMS tumors. Recent data suggest that ERMS is a hierarchically organized tumor. We 
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 have previously shown that de-differentiated highly tumorigenic cells could be enriched by 
propagating human ERMS cancer cell lines as clonal spheres (Walter et al. 2011). Additionally, 
cells with activated satellite cell phenotype have been shown to possess long-term tumor 
propagating potential in the transgenic RAS-activated zebrafish model of ERMS (Langenau et al. 
2007; Ignatius et al. 2012). Therefore the tenets of the cancer stem cell model could be used to 
highlight pathways that are important for ERMS cancer initiating cells (CICs) and thereby provide 
novel therapeutic interventions. At present little is known about the pathways employed to maintain 
self-renewal and initiate tumor formation in ERMS. 
The master developmental pathways in ontogenesis such as Wnt, Notch, and Hedgehog 
signaling networks are prime candidates for cancer stem cell-based therapies since they have been 
recently shown to also play key roles in oncogenesis (Takebe et al. 2011). Amongst these, 
activation of the hedgehog pathway is the most commonly documented in ERMS. Canonical 
hedgehog pathway is a ligand-activated signaling system with three mammalian ligand variants – 
sonic (SHH), indian (IHH) and desert hedgehog (DHH) (Stecca and Ruiz 2010; Ruiz i Altaba 
2011). The secreted ligands bind to the extracellular domain of the patched (PTCH) receptor 
leading to the release of the receptor smoothened (SMO). SMO is then free to translocate to the 
primary cilium to activate the downstream signaling cascade which primarily involves relieving the 
inhibition of suppressor of fused (SUFU) upon the activity of the GLI transcription factors. There 
are three GLI transcription factors, of which GLI1 is the most potent transactivator. In general 
ERMS tumors have higher hedgehog pathway activity than ARMS (Zibat et al. 2010; Pressey et al. 
2011; Chen et al. 2013). In a recent study over 50% of ERMS cases showed increased hedgehog 
pathway activation (Paulson et al. 2011) and PTCH1 mRNA expression has been reported to predict 
poor prognosis in ERMS patients (Zibat et al. 2010). Additionally, patients with germline activation 
of hedgehog pathway (Gorlin syndrome) are predisposed to ERMS development. Interestingly, also 
all mouse models of activated hedgehog signaling develop ERMS with varying penetrance. 
Although there is evidence suggesting an important role for hedgehog signaling in ERMS, its role 
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 in maintaining ERMS CIC features has not been directly investigated. This distinction would be 
critical in determining many aspects of treatment strategy in the clinics. 
In the present study, using small molecules and various genetic approaches we show that 
hedgehog signaling modulates ERMS self-renewal and tumor initiation. We describe additional 
novel roles played by this pathway in determining ERMS chemoresistance, invasion and 
differentiation status. We also identify NANOG as the functionally important target gene 
downstream of the pathway, previously unknown in any soft tissue sarcoma. Importantly, for the 
first time, we show that functional intra-tumoral heterogeneity measured by the presence of 
hedgehog-active CIC markers in ERMS patients is clinically relevant. Therefore, targeting 
hedgehog signaling mediated self-renewal could be a viable therapeutic approach for ERMS 
management. 
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 Results 
Hedgehog signaling is necessary for ERMS self-renewal and efficient tumorigenesis 
First, we analyzed the expression of hedgehog pathway components in ERMS sphere cultures 
which have been previously shown to be enriched in de-differentiated, self-renewing and highly 
tumorigenic cells (Walter et al. 2011). Real-time gene expression analysis revealed that the mRNA 
level of the key hedgehog target gene and effector transcription factor GLI1 was increased in both 
RD (+2185%) and RH36 (+191%) spheres compared to their respective adherent counterparts (Fig. 
1A and Supplemental Fig. 1A). Similar changes were observed for other target genes such as GLI2, 
PTCH1 and HHIP. The increased expression levels of GLI1 and HHIP were also noted in ERMS 
xenografts (Fig. 1B). To evaluate whether hedgehog pathway might play a causative role in ERMS 
self-renewal the small molecule hedgehog agonist SAG1.3 was added to the sphere media during 
the formation of primary spheres, which were then plated at clonal density to form secondary 
spheres without drug. Primary sphere formation increased slightly but significantly for RD cells 
(+25%) and a larger relative increase in secondary sphere formation was observed for both cell lines 
(RD: +50% and RH36: +170%), indicating that SAG1.3 treatment increased the sphere initiating 
compartment (Fig. 1C). Next, we used siRNA to reduce the expression of SUFU in RD sphere cells 
to ensure the specificity for hedgehog pathway activation (Supplemental Fig. 1B) and indeed this 
led to a doubling in the RD sphere initiating ability (Fig. 1D). Additionally, to exclude any 
extraneous effects of the sphere media components on hedgehog pathway activation, ERMS 
adherent cells were treated with SAG1.3 prior to plating in normal sphere media. This treatment did 
not affect the cell cycle profile or viability of ERMS cells but led to increased sphere initiating 
capacity in a dose-dependent manner for both the cell lines studied (Fig. 1E and Supplemental Fig. 
1, C-E). Taken together the data indicates that ERMS cells enriched for higher self-renewal capacity 
and tumorigenicity possess higher hedgehog pathway activity. Furthermore, transient activation of 
hedgehog pathway leads to higher self-renewal. 
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 To study the role of hedgehog pathway activation in ERMS in more detail, we generated stable 
cell lines that either over-expressed GLI1 (pCMV-GLI1) or ‘empty’ control plasmid (pCMV-
Empty). GLI1 over-expression led to upregulation in HHIP mRNA expression by 180 fold in RD 
cells and 2 fold in RH36 cells (Fig. 1F and Supplemental Fig. 1, F and G). HHIP was consistently 
found to be a more responsive target gene than PTCH1 in vitro. The RD pCMV-GLI1 cells showed 
a 30% increase in primary sphere formation while the RH36 pCMV-GLI1 cells formed twice as 
many spheres as control cells (Fig. 1, G and H). When plated for secondary sphere formation the 
relative increase in sphere initiation capacity became more apparent in both the cell lines (RD: 
+87% and RH36: +230%). The RD pCMV-GLI1 cells also had 50% higher adherent colony 
forming ability (Supplemental Fig. 1H). To investigate the consequences of increasing hedgehog 
pathway activity on tumor initiation and growth in vivo we injected the stable cell lines 
orthotopically in NOD/SCID mice. Both RD and RH36 pCMV-GLI1 cells displayed significantly 
faster tumor growth rate (Fig. 1, I and J). In the case of RH36 the number of cells injected per 
mouse was found to be limiting since only 2 out of the 6 mice injected with pCMV-Empty cells 
formed tumors, whereas the RH36 pCMV-GLI1 cells showed greater tumor initiating capacity (4 
out of 6 mice). The xenografts retained GLI1 over-expression (Supplemental Fig. 1I) and were 
confirmed to be of ERMS histotype, as judged from the positive myogenin and desmin 
immunostaining (Supplemental Fig. 2). Overall, ERMS cells displaying an active hedgehog 
pathway possess higher self-renewal and increased tumor initiating capacity. 
Next, we inhibited the hedgehog pathway both pharmacologically and genetically to evaluate its 
necessity for ERMS pathogenesis. ERMS cells were treated first with SMO inhibitor GDC-0449 or 
GLI inhibitor GANT61 during the primary sphere formation stage. This led to a decrease in the 
number of spheres formed in RD cells by 33% and 70%, respectively (Fig. 2A). Similar results 
were obtained for RH36 cells (Supplemental Fig. 3A). The GDC-0449 treatment led to a decrease 
of 88% in the secondary sphere initiating capacity of RD cells and there were no spheres formed in 
the case of RH36 cells. GANT61 treatment was more potent since no viable cells were available for 
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 secondary sphere formation from either cell line. Using siRNA we specifically reduced GLI1 
expression in RD sphere cells to corroborate the results obtained with hedgehog inhibitors. 
Consequently, the sphere initiation decreased by about 30% (Fig. 2B). Next, ERMS cells were 
treated with GDC-0449, LDE-225 (also a SMO inhibitor) or GANT61 in adherent conditions and 
then plated for sphere formation. Dose-dependent decrease in sphere initiation was observed with 
all drugs (Fig. 2C and Supplemental Fig. 3B). The pre-treatment of RD cells with GANT61 in vitro 
led to slower tumor initiation in vivo (Fig. 2D). The treatments did not alter the cell cycle profile or 
viability status of the cells (Supplemental Fig. 3, C-F). All xenografts were collected for analysis 
once the control arm reached the maximum allowed volume of 1 cm
3
. The xenografts from the 
GANT61 treated cells weighed 50% lower than the control xenografts, corroborating the tumor 
volume difference observed from caliper measurements (Fig. 2E and Supplemental Fig. 3G). The 
GANT61 xenograft displayed lower desmin positivity and fewer strongly GLI1 positive cells 
(Supplemental Fig. 3H). Hence, the transient inhibition of hedgehog pathway with small-molecules 
seems to not only reduce self-renewal of ERMS cells in vitro but also tumor growth kinetics in vivo. 
To study the long-term effect of inhibiting the hedgehog pathway we generated stable cell lines. 
ERMS cells were transfected with SUFU over-expressing vector (pCMV-SUFU) to inhibit GLI 
activity directly. Ligand-based hedgehog signaling was inhibited by transducing ERMS cells with 
shRNA against SMO (shSMO) and the ‘empty’ backbone vector (pLKO.1) was used as control. 
Both cell lines showed a decrease in GLI1 and HHIP expression as expected (Fig. 2, F and G and 
Supplemental Fig. 4, A-D). The adherent colony forming ability of RD cells was decreased upon 
SUFU over-expression and SMO knockdown by 80% and 40% respectively (Supplemental Fig. 4, 
E and F). Sphere initiation was decreased by 50% upon SUFU over-expression and by 30-40% 
upon SMO knockdown in RD. Similar results were noted for RH36 cells (Fig. 2, H and I). There 
were no significant changes observed in cellular proliferation or cell cycle profiles (Supplemental 
Fig. 4, G-M and data not shown). When injected orthotopically in immunocompromised mice both 
pCMV-SUFU and shSMO cells showed decreased tumor growth kinetics (Fig. 2, J to M). 
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 Impressively, for RD cells there was no palpable tumor growth in the majority of hedgehog-
inhibited xenograft mice at the time when the control xenografts reached the maximum allowed 
tumor volume. While tumor initiation rate was 100% for control cells, only 3 out of the 5 mice and 
3 out of 7 mice injected with pCMV-SUFU and shSMO cells respectively, developed tumors. 
Taken together, the data supports the notion that active hedgehog signaling is necessary for ERMS 
self-renewal and efficient tumorigenicity. 
 
Autocrine ligand-based activation of hedgehog pathway in ERMS 
Pathway activation in ERMS seemed to be largely ligand-based since inhibition of either 
receptor-mediated or GLI-based hedgehog signaling led to similar effects on self-renewal and 
tumorigenesis. Since not much is known about ligand-based signaling mechanism in ERMS we 
analyzed the expression pattern of the hedgehog ligands - SHH, DHH and IHH, by quantitative 
PCR. We could not detect the expression of SHH in adherent cell lines, sphere cultures, xenografts 
or murine skeletal muscle. In contrast, DHH and IHH were expressed in all model systems. The 
expression of DHH was particularly higher for RD sphere cells and xenografts while both DHH and 
IHH expression was increased in RH36 sphere cultures and xenografts (Fig. 3, A-D). The 
expression levels of the ligands were also analyzed in ERMS patient samples using pooled human 
skeletal muscle RNA from three fetal and five adult donors as controls. Fetal skeletal muscle 
expressed all the ligands and at higher levels compared to adult skeletal muscle (Supplemental Fig. 
5, A-C). Also, the expression of SHH was not detected in adult skeletal muscle. The expression 
level of the ligands varied between patient samples, but in general the levels were intermediary to 
fetal and adult skeletal muscle with the average expression level of DHH being higher than that of 
IHH (Fig. 3E). While DHH and IHH were found be expressed in all nine ERMS patient samples, 
SHH was detected in only four patients.  
Also, to distinguish between autocrine and paracrine signalling mechanism in ERMS xenografts 
we used species specific PCR probes. The ligands expressed within ERMS xenografts were 
9 of 47
 determined to be primarily of human origin indicating an autocrine signalling mechanism (Fig. 3, F 
and G). We also noted a minor paracrine contribution, since the expression of murine Dhh was 
increased within xenografts when compared to murine muscle (Supplemental Fig. 5, D and E). 
Overall, hedgehog ligands are expressed in ERMS and importantly ligand-based signaling might be 
further increased under conditions of self-renewal and in vivo tumorigenesis. 
 
Hedgehog signaling alters chemoresistance of ERMS cells 
Therapy resistance is a clinically relevant property of CICs. Hence, we evaluated the self-
renewal ability of RD cells after treatment with high concentrations of Irinotecan. After 48 hours of 
treatment with the drug or vehicle, equal numbers of viable cells were plated for sphere formation at 
clonal density. Irinotecan treatment led to a G2/M cell cycle arrest (data not shown) leading to a 
reduction in the overall sphere forming ability of the cells. However the cells that had been treated 
with the highest concentration of Irinotecan (IC50) formed 74% more spheres than cells treated with 
the lowest concentration (IC50/4) indicating that sphere initiating cells were enriched in the former 
case (Fig. 4A). Importantly, when Irinotecan treatment was combined with hedgehog pathway 
inhibition using LDE-225, a relative reduction of 57% in sphere formation was observed, compared 
to treatment with Irinotecan only (Fig. 4B). 
Next, we investigated whether hedgehog pathway activity could impact upon the 
chemoresistance of ERMS cells. The previously described stable lines were treated with a serial 
dilution of Irinotecan or Doxorubicin. After 72 hours WST assay was performed and cell line-
specific IC50 concentrations were calculated (Fig. 4C). We noted that IC50 value for Irinotecan for 
RD pCMV-GLI1 cells was on average 73% higher than empty vector control cells. Similar results 
were obtained for RH36 cells. Also, IC50 for Doxorubicin were 54% and 81% higher in RD and 
RH36 pCMV-GLI1 cells, respectively. Overall, ERMS cells with increased hedgehog pathway 
activity show increased resistance to chemotherapy. As corollary, we expected that decreasing 
hedgehog pathway activity would increase sensitivity of ERMS cells. Indeed, we observed that the 
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 IC50 values for RD pCMV-SUFU cells were 32% and 25% lower for Irinotecan and Doxorubicin 
respectively. Similarly, SMO knockdown in RD cells led to a significant 50% reduction in 
Irinotecan IC50 with a minor reduction for Doxorubicin (10%). SMO knockdown in RH36 cells 
showed comparable reduction in IC50 values for both Irinotecan (57%) and Doxorubicin (53%). 
Overall hedgehog pathway activity levels could modulate chemoresistance of ERMS cells to 
cytotoxic drugs. 
 
Hedgehog signaling modulates cell motility and differentiation status of ERMS cells 
To evaluate the role of hedgehog pathway in cell motility we performed trans-well migration and 
invasion assays using ERMS stable lines. First, we observed that RD cells were more migratory and 
invasive than RH36 cells. Therefore, further experiments were performed with RD cell lines only. 
We noted that increasing the hedgehog pathway activity did not significantly impact cell motility 
since RD pCMV-GLI1 showed only a minor increase in migration and invasion (data not shown). 
Although inhibition of hedgehog activity significantly decreased migration by 53% in pCMV-
SUFU and 37% in shSMO RD cells (Fig. 4, D and E, and Supplemental Fig. 6A) it led to an 
increase in the ECM invasive potential. The RD pCMV-SUFU cells showed a 5 fold increase in 
invasiveness and for shSMO cells the increase was 1.8 fold (Fig. 4, F and G, and Supplemental Fig. 
6B). This effect was cell autonomous since coating the membrane filter with gelatin did not alter the 
results (Supplemental Fig. 6B).  
Next, we wanted to evaluate the effect of hedgehog signaling on ERMS differentiation since 
conceptually a CIC maintenance pathway would affect tumor cell differentiation status. ERMS 
tumors have been known to express key myogenic transcription factors such as Pax7, Myod and 
Myogenin which control the differentiation status of skeletal muscle. The expression of Pax7 is 
highest in the quiescent muscle stem cells while Myogenin is expressed by committed muscle 
progenitor cells. Therefore the expression of these proteins is mutually exclusive and provides a 
convenient readout to assess differentiation status. We immunostained the stable cell lines 
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 representing different hedgehog pathway activities for Pax7 and Myogenin. First, we noted that the 
expression of these transcription factors was mutually exclusive also in ERMS cells indicating that 
the differentiation programs present during normal myogenesis are also active in the pathological 
state (Fig. 5A and Supplemental Fig. 6D). Interestingly, RD pCMV-GLI1 cells increased PAX7
+
 
cells by 90% and RH36 pCMV-GLI1 cells by 154% (Fig. 5, A, B and D, and Supplemental Fig. 
6D). Concomitantly we observed fewer MYOGENIN
+
 cells (RD: -24.5% and RH36: -35%). 
Inhibition of the hedgehog pathway induced differentiation in RD cells as evidenced by a 65% and 
54% reduction in the percentage of PAX7
+
 cells in pCMV-SUFU cells and shSMO cells 
respectively (Fig. 5, A-C and Supplemental Fig. 6C). Correspondingly there was a gain in the 
percentage of MYOGENIN
+
 cells (pCMV-SUFU: +19% and shSMO: +56%). Similar results were 
obtained for RH36 cells (Fig. 5E and Supplemental Fig. 6E). Importantly, treatment with small 
molecule modulators of hedgehog signaling also induced similar alterations in the differentiation 
status (Supplemental Fig. 6, F-H). These data suggest that activation of hedgehog signaling confers 
a more stem-like state to ERMS cells and pathway inhibition induces differentiation. 
 
NANOG is a functionally important hedgehog pathway target gene for ERMS self-renewal 
To identify genes that could be regulated by the hedgehog pathway in ERMS cells, we used a 
stem cell-focused quantitative PCR based screening approach to survey the expression levels of 162 
individual genes previously associated with stem cell phenotype or components of important 
developmental pathways. Biologically duplicate sets of RNA from RD and RH36 cell lines with 
either activated (pCMV-GLI1) or inhibited hedgehog pathway (shSMO) and their respective 
controls were used. We found 147 genes to be reliably expressed (Ct value < 35), of which 142 
were common to both cell lines. The relative fold changes in expression of the common genes were 
used for non-supervised hierarchical clustering to identify genes either positively or negatively 
regulated by hedgehog signaling. The changes in expression levels of these genes were verified on 
an individual basis to include only those with least 1.5 fold difference in both RD and RH36 (Fig. 
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 5F). We found more genes to be negatively regulated by the hedgehog pathway than positively in 
both cell lines. A high representation of components of the TGF- and Wnt signaling was noted 
amongst the negatively regulated genes indicating that these pathways could be associated with the 
more differentiated phenotype of ERMS cells. Interestingly, expression of the stem cell 
transcription factor NANOG was found to be positively regulated by hedgehog signaling in both the 
cell lines. Due to its important role in the maintenance of the embryonic stem cell phenotype and 
the recent delineation of its function in cancer (Wang et al. 2013) we chose to further study its role 
in the hedgehog pathway-mediated stemness observed in ERMS. 
We first confirmed the alterations in NANOG mRNA expression in pCMV-GLI1 and shSMO 
ERMS cell lines using NANOG specific Taqman-based PCR probes and additional biological 
replicates (Supplemental Fig. 7, A and B). We also observed decrease in NANOG expression in 
pCMV-SUFU ERMS cells (Supplemental Fig. 7, C and D). Next, ERMS cell lines were co-
immunostained for GLI1 and NANOG. We noted that the expression of both the proteins was 
heterogeneous, co-localized and correlative, that is, GLI1
high
 cells were also NANOG
high
 (Fig. 6A 
and Supplemental Fig. 7E). Upon GLI1 over-expression the percentage of cells expressing NANOG 
increased significantly (Fig. 6B). Accordingly, when ERMS cells were treated with hedgehog 
pathway agonist SAG1.3 the NANOG expressing cellular compartment increased by almost 2 fold 
in both the cell lines (Fig. 6C and Supplemental Fig. 7, F-H). We also noted increased NANOG 
expression in ERMS sphere cultures and xenografts (Supplemental Fig. 7, I-K). We performed gene 
expression analysis by quantitative PCR on 9 ERMS patient samples for 17 genes which included 
components of canonical hedgehog pathway, myogenesis and stem cell-associated factors. Upon 
non-supervised hierarchical clustering we found that NANOG expression clustered with that of 
GLI1 and PTCH1 (Supplemental Fig. 7L). Statistical analysis revealed that the expression of 
NANOG and GLI1 correlated significantly (Fig. 6D). We observed the positive correlation even 
after including expression data from four additional patient samples (9+4; Fig. 6D). These data 
indicate that NANOG expression correlates with hedgehog pathway activity levels in ERMS cell 
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 lines and patient samples. Importantly, hedgehog pathway modulation can alter the expression of 
NANOG implying that it could be a target gene of the pathway in ERMS. 
To show that NANOG is necessary for ERMS self-renewal, stable RD cell lines were generated 
using a lentiviral vector containing shRNA against NANOG (shNANOG). The sphere forming 
ability of these cells in vitro was 21% lower than the control pLKO.1 cells (Fig. 6E). When 
NANOG was over-expressed transiently in pCMV RD cells the sphere formation increased by 40-
50% relative to control pCMV+pE1F cells (Fig. 6F). Importantly, NANOG expression in hedgehog 
inhibited cells rescued the lowered self-renewal ability of the cells (Fig. 6, F and G). We noted that 
the alteration in NANOG expression led to a concordant change in the expression of GLI1 (Fig. 6E 
and Supplemental Fig. 8A). To estimate the role of NANOG on self-renewal and tumor growth 
independently of this effect we generated stable rescue lines where NANOG expression was 
decreased in GLI1 over-expressing cells (GLI1+shNANOG). As controls we used stable lines with 
dual empty vector (pCMV+pLKO.1) or GLI1 over-expression and empty lentiviral backbone 
(GLI1+pLKO.1) (Supplemental Fig. 8, B and C). When both RD and RH36 rescue systems were 
allowed to form spheres, secondary sphere formation was increased significantly in the 
GLI1+pLKO.1 cells for both cell lines (RD: +108% and RH36: +59%) and impressively, NANOG 
knockdown rescued it back to almost control levels (Fig. 6, H and I). To study the effect on tumor 
growth in vivo RH36 pCMV+pLKO.1 and GLI1+shNANOG cell lines were injected in 
immunocompromised mice. The tumor growth rate of GLI1+shNANOG cells was significantly 
lower than control cells (Fig. 6J). Furthermore, GLI1+shNANOG xenografts displayed increased 
myogenin and desmin staining compared to control xenografts indicating that the tumor was in 
general more differentiated (Supplemental Fig. 8D). Taken together, NANOG seems to be a 
functionally important component of the hedgehog signaling in ERMS. 
 
GLI1 and NANOG expression has prognostic value for ERMS patients 
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 Next, we evaluated if the expression of GLI1 and NANOG is clinically relevant. To this end we 
performed a double-blind analysis of GLI1 and NANOG expression separately in a previously 
described set of tissue microarrays (TMA) with multiple tumor cores from 116 ERMS patient 
samples using immunohistochemistry (Wachtel et al. 2006). Reliable protein expression status was 
obtained for 91 ERMS patients. The distrubution of patient and tumor related parameters were 
similar among patient subgroups. Chi-square tests revealed no significant differences between the 
groups (data not shown). Most patients were negative for both proteins. However patients positive 
for one were in 80% of the cases also positive for the other. We found that only tumor cells 
expressed GLI1 and NANOG and importantly the expression was heterogeneous (Fig. 7A and 
Supplemental Fig. 8E). The clinical data analysis revealed that the expression of GLI1 alone could 
predict statistically significant worse overall survival and a similar trend was observed for NANOG 
expression status (Fig. 7, B and C). These patients also tended to have worse event-free survival, 
although the data did not reach statistical significance (Supplemental Fig. 8, F and G). However, 
statistically significant worse event-free and overall survival was estimated for patients who 
possessed GLI1
+
 and NANOG
+
 cellular sub-populations within their tumors (Fig. 7, D and E). Our 
analysis reveals that ERMS intra-tumoral heterogeneity represented by expression of both GLI1 and 
NANOG has significant impact on clinical outcome. 
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 Discussion 
Our study provides novel mechanistic insights into hedgehog signaling in ERMS and establishes 
a role specifically in the self-renewal of ERMS CIC compartment. Additionally we show that 
hedgehog pathway plays an important role in ERMS cell motility, differentiation, and 
chemoresistance. We identify NANOG as a key downstream effector and importantly, the 
evaluation of GLI1 and NANOG expression status within ERMS patient samples shows significant 
prognostic value. 
Hedgehog signaling has been previously shown to modulate self-renewal of CICs in various 
adult malignancies such as chronic myelogenous leukaemia (CML), multiple myeloma, melanoma, 
glioblastoma and cancers of the pancreas, prostate and breast (Peacock et al. 2007; Stecca et al. 
2007; Merchant and Matsui 2010; Zbinden et al. 2010). The role of hedgehog signaling in pediatric 
CICs has been largely investigated in medulloblastoma (Read et al. 2009; Po et al. 2010; Wang et 
al. 2012a). Although genetic evidence suggests a general role for hedgehog signaling in ERMS 
tumor initiation, its contribution to the functional tumor heterogeneity seen in ERMS had not been 
explored. Here we describe an important role of this pathway in maintaining CIC properties in 
ERMS by using three model systems: sphere cultures, adherent monolayer cultures and in vivo 
mouse xenografts. We have previously reported that sphere cultures could be used to enrich for 
ERMS CICs (Walter et al. 2011). We now show that ERMS CIC cultures and xenografts have 
increased hedgehog pathway activity. Importantly, modulating the pathway using either small 
molecules or genetic means had a significant impact on sphere initiation, adherent colony 
formation, sphere renewal capacity and tumor growth in vivo. Therefore hedgehog pathway activity 
is an important determinant of ERMS self-renewal and tumor initiating capacity.  
It is critical to understand the mechanisms of hedgehog pathway activation in ERMS for 
translational applicability. Our data shows the canonical SMO-based signaling to be important for 
maintaining ERMS CICs since inhibiting the pathway at the level of SMO and GLI activity 
provided equivalent outcomes. Additionally ligand/SMO-based hedgehog signaling seems to be 
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 occurring in sporadic ERMS primarily by autocrine secretion of IHH and DHH. Pressey et al 
already ruled out SHH autocrine signaling mechanism in ERMS patients, however expression of the 
other ligands was not evaluated (Pressey et al. 2011). Similar to previous reports we find that 
hedgehog pathway activity is reduced in vitro (Gerber et al. 2007) which could be partly explained 
by the reduction in ligand expression upon culturing ERMS cells as adherent monolayers. It is 
likely that components of the growth serum present in regular cell culture media are inhibitory to 
hedgehog activity since ERMS sphere cultures maintained in serum-deprived conditions show 
increased pathway activity. Therefore the in vitro culturing of ERMS cells in serum-supplemented 
media may obscure tumor hierarchy and associated developmental pathways which are relevant in 
vivo as described previously in medulloblastoma and glioblastoma (Lee et al. 2006; Ward et al. 
2009). 
CICs are also known to be responsible for tumor recurrence by being more resistant to 
chemotherapeutic strategies (Vidal et al. 2013). Accordingly, we show that increasing CIC 
properties by activating hedgehog signaling could render ERMS cells more resistant to anti-
proliferative drugs, such as Irinotecan (Topoisomerase-I inhibitor) and Doxorubicin (DNA 
intercalating agent), which are currently used in the clinics for ERMS management. Importantly the 
use of high-dose Irinotecan led to enrichment in self-renewing cells which could be rescued upon 
combination treatment with SMO inhibitor LDE225. This is similar to previous reports on imatinib-
resistant CML where SMO inhibition reduced CICs and improved survival (Zhao et al. 2009; 
Katagiri et al. 2013). 
Previous study evaluating in vivo tumor heterogeneity in a zebrafish model of ERMS reported 
that the myogenin-expressing (differentiated) ERMS tumor cell compartment had higher 
invasiveness but lacked tumor-initiating capacity (Ignatius et al. 2012). Concordantly we observed 
that the hedgehog-inhibited ERMS cells with lowered tumorigenicity were more differentiated 
(Pax7
low
Myogenin
high
) and possessed increased ECM invasion capacity. Surprisingly in the absence 
of a basement membrane matrix the differentiated cells had much lower migratory ability indicating 
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 that matrix adhesion probably plays an important role in determining cell motility in ERMS. 
Hedgehog pathway activation induced ERMS cell de-differentiation (Pax7
high
Myogenin
low
). 
However we could not find significant co-localization of PAX7 and GLI1 expression within ERMS 
cell lines indicating that PAX7 may not be a direct target of hedgehog pathway (data not shown). 
Therefore the hedgehog pathway probably inhibits differentiation further down the myogenic 
lineage (Gerber et al. 2007; Voronova et al. 2013). Interestingly, our qRT-PCR analyses revealed 
that hedgehog signaling modulation could impact key muscle differentiation nodes such as TGF, 
Wnt and Notch (Kuang et al. 2008). Previously, inhibition of TGF and Notch pathways has been 
shown to differentiate ERMS cells (Wang et al. 2010; Rossi et al. 2011; Raimondi et al. 2012). In 
contrast, we observed increased expression of pathway components in the more differentiated, 
hedgehog inhibited cells (Notch: data not shown). Activation of canonical Wnt signaling promotes 
muscle differentiation (Kuang et al. 2008) and hedgehog signaling has been reported to be 
antagonistic to the Wnt pathway (Roma et al. 2012). Accordingly, we observed increased 
expression of Wnt pathway components in hedgehog-inhibited ERMS cells. ERMS pro-
differentiation therapies are being actively investigated for clinical benefit (Saab et al. 2011). Our 
data indicates the presence of novel negative feedback mechanisms between key developmental 
pathways that could control ERMS differentiation and consequently invasiveness. 
A stem cell-focused qRT-PCR screen to identify downstream mediators of the hedgehog 
pathway led to identification of NANOG. NANOG is a homeodomain-containing transcription 
factor essential for derivation of ES cells, formation of primordial germ cells, establishing 
pluripotency (Theunissen and Silva 2011) and its increased expression has been noted in many 
cancer entities (Wang et al. 2013). NANOG has been characterized as a GLI target gene using 
chromatin immunoprecipitation assays and loss-of-function promoter reporter analyses in neural 
stem cells and medulloblastoma neurospheres (Po et al. 2010). Our data shows that NANOG 
behaves as a GLI1 target gene also in ERMS. We observed increased expression of NANOG in 
ERMS hedgehog activated model systems (sphere cultures and xenografts). Additionally we 
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 detected significant positive correlation in mRNA expression of NANOG and GLI1 in ERMS 
patient samples, similar to previous observations in medulloblastoma (Po et al. 2010). Crucially, 
expression of GLI1 and NANOG proteins was observed only in a subpopulation of ERMS cells, 
highlighting the heterogeneous nature of hedgehog pathway activity in ERMS. 
The role of NANOG in self-renewal and tumor initiation has been largely elucidated in adult 
solid tumors such as glioblastoma, prostate and colorectal cancer (Wang et al. 2013). The present 
study is the first to confirm that NANOG is functionally important in mediating “stemness” in a 
sarcoma. Alterations in NANOG expression led to changes in ERMS sphere initiation and 
importantly NANOG over-expression could completely rescue the decreased sphere forming ability 
observed in hedgehog-inhibited cells, indicating that it can also be epistatic to hedgehog pathway. 
Interestingly, although it was possible to generate stable NANOG-knockdown cells with partial 
protein reduction, stable over-expression was not tolerated by adherent ERMS cells. This indicates 
that NANOG expression is tightly controlled and maintained at a certain threshold. We noted that 
NANOG could provide positive feedback into the hedgehog pathway by modulating GLI1 
expression as previously reported in glioblastoma-initiating cells (Zbinden et al. 2010). To evaluate 
the function of NANOG independent of hedgehog pathway activity we generated phenotypic rescue 
lines where NANOG expression was downregulated in the presence of GLI1 over-expression. We 
observed a complete rescue of sphere renewal capacity in vitro and a significant reduction in tumor 
growth rate in vivo implying that NANOG is a key mediator of hedgehog-driven CIC properties in 
ERMS. Furthermore it has been reported that NANOG is capable of inhibiting skeletal muscle 
differentiation by reducing MyoD transcriptional activity (Lang et al. 2009) and therefore its 
expression could have an impact also on ERMS differentiation status. 
We also investigated the impact of hedgehog pathway modulation on other previously reported 
ERMS CIC markers, such as CD133, FGFR3 and MYF5 (Hirotsu et al. 2009; Walter et al. 2011; 
Ignatius et al. 2012). Although CD133 expressing cells are enriched in ERMS sphere cultures 
(Walter et al. 2011) we could not find evidence for positive regulation of CD133 expression by the 
19 of 47
 hedgehog pathway (data not shown). On the contrary, the expression of CD133 was highest in the 
SMO inhibited ERMS cells (data not shown). Also it has been reported that CD133 expression in 
ERMS cells increased upon in vitro culturing (Sana et al. 2011), unlike the effect observed on 
hedgehog pathway activity status ex vivo (this study and (Gerber et al. 2007)). FGFR3
+
 cells from 
ERMS cell lines were shown to have increased tumorigenic potential (Hirotsu et al. 2009). In this 
study we noted FGFR3 expression to be positively regulated by hedgehog pathway in RD cells and 
negatively regulated in RH36 cells (data not shown). Therefore FGFR3 could mark active hedgehog 
phenotype depending on ERMS cell context. MYF5 has been identified as a component of the 
ERMS signature from transgenic mouse models and also marks the CIC compartment in the RAS-
activated zebrafish model of ERMS (Langenau et al. 2007; Rubin et al. 2011; Ignatius et al. 2012). 
It has been shown to be a hedgehog target gene during myogenesis (Anderson et al. 2012). 
Although MYF5 mRNA expression level was reported to be higher in ERMS patient samples with 
high GLI1 mRNA expression (Pressey et al. 2011), we did not find a correlation in our cohort of 
patients which could be due to the small sample size. Importantly however, we could not detect 
MYF5 expression in ERMS cells lines used in this study implying that it may not be the factor 
responsible for hedgehog-mediated stemness in our human ERMS cancer models. Therefore, at 
present, the expression of GLI1 and NANOG alone could be used as a reliable indicator of 
hedgehog-driven CIC phenotype. 
Additionally the GLI1-NANOG
high
 phenotype is, as of yet, the most developmentally primitive 
to be described in ERMS. The expressions of transcription factors important for the development of 
neural crest-derived mesenchymal and neural tissues, namely PAX6, PITX2 and LMX1B (Hsieh et 
al. 2002; Gage et al. 2005; Liu and Johnson 2010), were positively regulated by the hedgehog 
pathway in both ERMS cell lines studied; while pathways that maintain a more myogenic (early or 
late) phenotype were downregulated. Therefore GLI1-NANOG
high
 ERMS cells could possess a pre-
myogenic multipotent phenotype which could be reminiscent of neural crest or non-myogenic 
origin for ERMS. This is concordant with recent observations in hedgehog-activated mouse models 
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 wherein ERMS ‘cell of origin’ was determined to be from either pre-somitic or non-muscle 
mesenchyme (Nitzki et al. 2011; Hatley et al. 2012; Rajurkar et al. 2013). The phenotype of ERMS 
cells expressing the other CIC markers is possibly restricted to the skeletal muscle lineage. FGFR3
+
 
ERMS cells were reported to show increased expression of quiescent muscle stem cell markers 
CD34 and PAX3 (Hirotsu et al. 2009). MYF5 is a marker for activated muscle stem cells and 
MYF
high
 ERMS CIC compartment consequently showed increased expression of some muscle stem 
cell genes (Ignatius et al. 2012). CD133 could be a marker for pro-myogenic precursors since 
CD133
+
 cells have been used to regenerate muscle in dystrophic muscle mouse models (Kuang et 
al. 2008), CD133
+
 ERMS cells are reported to be myogenically primitive (Pressey et al. 2013) and 
CD133 expression was found to be highest in ERMS cells with a more myogenic rather than neural 
crest background (this study; data not shown). It is possible that different ERMS CIC phenotypes 
with varying differentiation potentials are concomitantly present within tumors. The hierarchical 
relationship between these compartments and their relative importance in ERMS tumorigenicity is 
yet to be determined and warrants further research. 
In the present study we provide evidence that the functionally important GLI1-NANOG axis is 
also a clinically relevant ERMS CIC phenotype. Previously PTCH1 mRNA expression in ERMS 
patients was shown to predict poor outcome (Zibat et al. 2010), which could not be substantiated by 
an independent study (Pressey et al. 2011). Although PTCH1 mRNA expression correlates 
significantly with that of GLI1 mRNA (this study and (Zibat et al. 2010; Pressey et al. 2011)), 
mechanistically PTCH1 provides negative feedback cues into the hedgehog pathway obscuring the 
final outcome on cellular self-renewal. Hence PTCH1 expression status may not be a reliable 
predictor of prognosis. Therefore we propose evaluating expression of NANOG protein, a 
functionally important downstream target, along with GLI1 to refine the identification of hedgehog-
active self renewing compartments within ERMS tumors. A previous study could not find 
prognostic significance for GLI1 mRNA expression in ERMS patients (Pressey et al. 2011). This 
discrepancy could be due to the lack of concordance between mRNA and protein expression. 
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 Additionally the quantitative estimation of mRNA levels in bulk tumor samples precludes 
evaluation of tumor heterogeneity and also leads to patient stratification based on arbitrary gradient 
expression levels that are prone to sampling bias. In this study patients were distinguished based on 
presence or absence of protein expressing tumor cells irrespective of expression levels and analysis 
performed in a blinded manner to avoid any form of subjective bias. It is however important to note 
that we could not confirm the co-localization of the proteins in patient samples since serial sections 
were not available from the TMA. Interestingly we observed heterogeneous expression of GLI1 and 
NANOG also within ARMS patient tumors but it did not have prognostic significance (data not 
shown). Therefore the GLI1-NANOG axis could be important specifically for ERMS patient 
stratification and further highlights the biological disparity between the two RMS variants. 
Previously we reported that ERMS patients with CD133
high
 expression have poor overall survival 
(Walter et al. 2011), but the regulation and functional role of CD133 protein is unclear: hence 
hindering its use as a biomarker. At present the impact of FGFR3 or MYF5 expression on ERMS 
patient prognosis is unknown. To our knowledge this is the first report in sarcoma showing that 
evaluation of intra-tumoral heterogeneity defined by a CIC pathway could help identify high-risk 
patients.  
Although strategies to evaluate and target self renewing compartments are being actively 
explored in many adult tumor entities (Takebe et al. 2011; Kreso et al. 2014), research on the 
signaling mechanisms that modulate CICs in pediatric cancers is still in its early stages. Using 
various ERMS cancer models, our study is the first to evaluate the addiction to a ‘targetable’ 
developmental pathway - the hedgehog pathway - in the maintenance of the CIC compartment in a 
major pediatric sarcoma. It is possible that the hedgehog-active CIC phenotype may be a common 
feature in ERMS cancer since the oncogenic signaling pathways and mutational backgrounds 
documented in ERMS have been shown to have a positive influence on hedgehog signaling. For 
example key ERMS therapeutic targets, growth factor receptor tyrosine kinase signaling and PI3K-
AKT;mTOR-S6K signaling positively interact with the hedgehog pathway (Stecca and Ruiz 2010; 
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 Wang et al. 2012b; Sokolowski et al. 2013). RAS signaling, which is the most commonly mutated 
pathway in ERMS (Chen et al. 2013; Shern et al. 2014), is known to increase GLI activity (Stecca 
et al. 2007). Disruption of the p53 pathway has been documented in sporadic ERMS tumors (Chen 
et al. 2013; Shern et al. 2014) and in one study cohort 59% of ERMS patients had a mutant p53 
signature (Rubin et al. 2011). Interestingly, active p53 has been known to repress NANOG 
expression and specifically loss of p53 has been shown to increase GLI-NANOG axis signaling 
strength in stem cells and CICs of neural origin (Po et al. 2010; Zbinden et al. 2010; Wang et al. 
2013). The cell lines used in this study for functional analyses also contain the aforementioned 
common genetic backgrounds (RD: NRAS
Q61H
; p53
R248V
 and RH36: HRAS
Q61K
). Therefore 
hedgehog pathway targeting could be of broad interest in sporadic ERMS. 
Our data presents hedgehog inhibition specifically as an anti-CIC strategy. CIC-targeting 
requires updating the current clinical trial management protocols since the biomarkers and end 
points used to estimate treatment efficacy would be conceptually altered (Vermeulen et al. 2012; 
Schott et al. 2013; Satheesha and Schäfer 2014). Accordingly we noted that the effect of hedgehog 
pathway modulation on ERMS pathology was not due to changes in cell cycle, cell viability or 
proliferation implying that tumor regression may be an inappropriate end point to estimate 
treatment efficacy. Although our data suggests SMO as a viable targeting option the downstream 
inhibition of the pathway could avoid emergence of cross talks converging on the GLI-code and 
resistance mechanisms (Takebe et al. 2011; Amakye et al. 2013). A combinatorial approach using 
hedgehog-targeted therapy along with bulk-reducing or other pro-terminal differentiation strategies 
may be more promising in reducing relapse and metastatic progression since the non-CIC 
compartments that make up the heterogeneous ERMS cellular milieu probably also have important 
roles to play in tumor progression (this study and (Ignatius et al. 2012)). Our report is particularly 
relevant since a SMO inhibitor is already in clinical trial for progressive RMS however as a single 
agent (clinicaltrials.gov; NCT01125800). Severe toxicities are noticed with current generic 
treatment modalities for ERMS and reducing therapy burden leads to increase in relapse rates 
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 (Stevens 2005; Jenney et al. 2014). Our data shows that combination therapy could allow use of 
lowered drug doses since inhibiting the hedgehog pathway in ERMS can increase sensitivity to 
generic drugs; therefore possibly maintaining treatment efficacy but with reduced morbidity.  
Patients with progressive, recurrent or metastatic ERMS have very low survival rate. Therefore 
there is a clear need to select treatment strategies that are specifically based on principles of ERMS 
etiology. To this end it is important to consider the hierarchical ERMS tumor organization along 
with the mutational background since evaluating hedgehog-driven CIC markers had a significant 
impact on ERMS patient risk stratification, which has not yet been possible with mutational status 
or signature (Rubin et al. 2011; Chen et al. 2013). Our study highlights that phenotypic and 
functional tumor heterogeneity could have significance for clinical management of ERMS patients 
and suggests hedgehog inhibition as a treatment strategy aimed at reducing the rate of relapse for a 
long term cure. 
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 Materials and Methods 
Cell culture and treatments 
Human ERMS cell lines RD (purchased from ATCC) and RH36 (kindly provided by Peter 
Houghton, St. Jude’s Children’s Hospital, USA) were maintained at  37°C in a humid atmosphere 
with 5% CO2 and routinely cultured in DMEM media supplemented with 10% fetal bovine serum 
(FBS), 2mM L-glutamine and 100U/ml penicillin-streptomycin. Sphere cultures were maintained as 
previously described (Walter et al. 2011). Sphere dissociation was carried out using Accutase 
(Sigma-Aldrich). Trypan-Blue staining (0.4%; Sigma-Aldrich) was used to estimate live cell 
numbers in all experiments. For sphere initiation and renewal studies, equal numbers of cells were 
plated at clonal density in Ultra-Low attachment plates (Corning) or in non-treated polystyrene petri 
plates (BD Biosciences). SMO inhibitors GDC-0449 and LDE-225 (both purchased from Selleck 
Chemicals), GLI inhibitor GANT61 (Tocris Biosciences), and GLI activator SAG1.3 (Calbiochem) 
were used at indicated concentrations to modulate the hedgehog pathway. For IC50 measurements of 
generic chemotherapeutic drugs Irinotecan (SN-38; Sigma-Aldrich) and Doxorubicin (Sandoz), 
cells were plated in quadruplicate in standard 96-well plates and treated with five-step serial 
dilutions of the drugs for 72 hours in 10% FBS media. In all experiments DMSO (Sigma-Aldrich) 
was used as vehicle control except SAG1.3 which was diluted in water. 
 
Transfection, Transduction and generation of stable cell lines 
Sphere cells were transfected with Silencer® select siRNAs (Ambion, Life technologies) against 
GLI1 (s5816), SUFU (s28520) or scrambled control (Silencer® Negative Control# 2) using 
Lipofectamine® RNAiMAX (Invitrogen) following manufacturer’s instructions at a final 
concentration of 10nM. Cells were used for sphere initiation 24 hours post transfection. The 
plasmids pCMV6-Entry (C-terminal Myc and DDK Tagged) referred to as pCMV-Empty, GLI1-
transcript variant 1- Myc-DDK (referred to as pCMV-GLI1), SUFU-Myc-DDK tagged (referred to 
as pCMV-SUFU) were purchased from Origene. The plasmids pEGIP (26777; referred to as pE1F), 
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 and pSin-EF-Nanog-Pur (16578; over-expressing NANOG) were purchased from Addgene. All 
plasmid transfections were carried out using Lipofectamine® 2000 (Invitrogen) on 80-90% 
confluent culture following manufacturer’s instructions. Transduction of MISSION® TRC1.5 
shRNA lentiviral particles (Sigma-Aldrich) - control (pLKO.1; SHC001V), TRCN0000014364 
(shSMO) and TRCN0000004885 (shNANOG) -  was carried out at a ‘multiplicity of infection’ of 
1.5 on 70% confluent culture in 1µg/ml Polybrene (Sigma-Aldrich) supplemented media. For stable 
cell line generation, plasmid transfected cells were continuously cultured in media supplemented 
500 µg/ml G-418 antibiotic for 3-4 weeks and thereafter 100 µg/ml antibiotic media was routinely 
used; viral transduced cells were continuously cultured in media supplemented with 1µg/ml 
Puromycin (Invivogen) for 10 days and thereafter 0.3 µg/ml antibiotic media was routinely used. 
Stable pCMV-Empty and pCMV-GLI1 cells were transduced with pLKO.1 and shNANOG viral 
particles and selected with Puromycin as described above to generate stable phenotype rescue 
system. 
 
Trans-well migration and invasion assays 
Migration assays were carried out using BD Falcon™ cell culture inserts (BD Biosciences; 8µm 
pore size) for 24-well format. For invasion assays, BioCoat™ matrigel-coated inserts (BD 
Biosciences) or the inserts coated manually with gelatin were used. Cells were maintained in 1% 
FBS media for 4 hours prior to plating. The cells were allowed to migrate over 24 hours or invade 
over 48 hours towards 10% FBS medium. Membrane with migrated or invaded cells was fixed with 
4% paraformaldehyde (PFA; Carl Roth) and stained with 0.05% Crystal Violet. Cells were 
visualized using Olympus CX41microscope and images were captured from 5 viewing fields across 
the membrane using INFINITY software (version 6, Lumenera). Cells were counted manually using 
ImageJ software (version 1.47).  
 
Orthotopic xenograft generation 
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 RD (3x10
5
cells/mouse) or RH36 (2.5x10
5
cells/mouse) were injected into the femoral muscles of 
one leg of NOD.CB17-Prkdc
scid
 mice (NOD/SCID; The Jackson Laboratory). Once tumor was 
palpable size was determined every 4 days by measuring two diameters (d1 and d2) in right angles 
of both legs with a Vernier caliper .Tumor volumes were calculated using the following formula: 
V=[4/3 x π x 1/2(d1+d2)]injected leg -[4/3 x π x 1/2(d1+d2)]control leg 
Freshly isolated xenografts were stored in RNAlater solution (Ambion) for RNA extraction, snap 
frozen in liquid N2 for protein extraction or fixed in 4% PFA for imunohistochemistry. The 
experiments were performed following institutional guidelines and were approved by the veterinary 
office of the Canton Zurich. 
 
Quantitative Real-Time PCR 
Normal human skeletal muscle pooled RNA lysate, referred to as AdSkM_P, from five adults 
(R1234171_P) and individual RNA lysates from three fetal donors (R1244171; Lot # A503105, 
B505186, A508111) were purchased from Amsbio. The expression data from the fetal samples was 
pooled for analysis (referred to as FeSkM_P). Total RNA was extracted using RNeasy Mini Kit 
(Qiagen) following manufacturer’s recommendations. Normal murine muscle RNA was extracted 
from femoral muscle of NOD/SCID mice.  
Genomic DNA contamination was removed using RNase-free DNase (Qiagen). RNA concentration 
and purity was evaluated using NanoDrop ND-1000. cDNA synthesis was carried out using High-
Capacity cDNA Reverse Transcription kit (Life Technologies) according to the manufacturer’s 
instructions. Quantitative Real-Time PCR (qRT-PCR) was performed using commercially available 
mastermix and TaqMan® Gene Expression Assays (Life Technologies; assay IDs are listed in the 
Supplemental Table 1) at standard conditions on an ABI 7900 HT Real-Time PCR machine and the 
data was analyzed with SDS software (Version 2.2; Applied Biosystems, Life Technologies). 
Absolute and relative expression levels of the target genes were calculated using the t method. 
Ct values were normalized to mean expression of housekeeping genes: HMBS (unless otherwise 
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specified) and Gapdh for murine gene expression. For screening, RT
2
 Profiler PCR Arrays [Stem
Cell Signaling (PAHS-047ZE) and Stem Cell Transcription Factors (PAHS-501ZE)], all associated 
reagents for cDNA synthesis and qRT-PCR reactions were purchased from Qiagen. The reactions 
were set up according to manufacturer’s instruction. Each plate contained biological duplicates of 
cDNA samples from hedgehog-modulated and the respective control cells to avoid cross plate 
analysis. Data analysis was performed using the RT
2 
Profiler PCR Array Analysis web-based
software (version 3.5; http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).  
Absolute RNA expression (2
-ΔCt
; patient samples) and relative fold change (PCR array) were used
for non-supervised hierarchical clustering; analyzed by dChip (Build: 2010; 
http://www.hsph.harvard.edu/cli/complab/dchip/) 
Western Blotting, Immunofluorescence and Immunohistochemistry 
Total protein was extracted using RIPA buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1% Triton 
X-100, 0.1% SDS) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche). Protein 
concentration was measured with Pierce® BCA protein Assay Kit (Thermo Scientific). Proteins 
were separated using NuPAGE gradient SDS-PAGE pre-cast gels (Life Technologies) and 
transferred for Western Blotting (XCell II™ Blot Module; Life Technologies). Specific proteins 
were labelled and identified by chemiluminescence using Amersham ECL Detection reagent (GE 
Healthcare) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). For 
immunofluorescence, cells were grown in BD Falcon™ culture slides, fixed with 4% PFA and 
incubated over night at 4°C with primary antibodies. Coverslips were positioned using 
VECTASHIELD® mounting media containing DAPI (Vector Labs). Cells were visualized using 
Leica 6000 DM epifluorescence microscope and images were captured using OpenLab software 
(version 3, Improvision). Cells stained only with conjugated-secondary antibodies were used as 
controls. Cell count estimation and image analysis was performed using ImageJ. 
Immunohistochemistry was performed on 3 µm thick sections from blocks of formalin-fixed, 
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 paraffin-embedded tissue at the Department of Pathology (University of Zurich) as previously 
described (Wachtel et al. 2006). The procedure for detecting GLI1 and NANOG expression was 
optimized by Sophistolab AG (Eglisau, Switzerland) using an array containing a series of normal 
tissue and cancer tissues as controls. In brief, immunohistochemistry was performed according to 
manufacturer’s guidelines on Leica BondMax instruments using Refine HRP-Kits (Leica DS9800) 
and buffer-solutions from Leica Microsystems Newcastle, Ltd. Slides were visualized using Zeiss 
Axioskop microscope. Images were captured and analyzed using Cell
B
 software (version 3.4; 
Olympus Soft Imaging Solutions GmbH). All the antibodies for the abovementioned procedures are 
listed in Supplemental Table 2. 
 
Patient tissue samples 
All patient tissue specimens used for RNA extraction in the study were obtained from the Swiss 
Pediatric Oncology Group (SPOG) Tumor Bank except ZH_ERMS which was obtained from 
Department of Pathology (University Hospital Zurich). The use of SPOG Tumor Bank tissue 
samples for cancer research purposes was approved by the Ethical Review Board of Zurich (Ref. 
No. StV-18/02). Written informed consent was obtained from each patient by the hospital that 
provided the tissue samples. The Tissue Microarray (TMA) used in this study included multiple 
tumor cores from 149 RMS patients (116 ERMS and 33 ARMS) enrolled in the German soft-tissue 
sarcoma group (CWS) studies -81, -86, -91 and -96 has been previously described (Wachtel et al. 
2006). 
 
TMA scoring and data analysis 
TMA was evaluated in collaboration with a senior pathologist (P.B.). A minimum of two desmin 
positive intact cores were required for the patient to be included in the analysis. At least three 
stained cells were required to label a patient as positive. Tumors from 91 ERMS and 23 ARMS 
patients provided reliable GLI1 and NANOG expression status. Clinical data was maintained and 
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 analysed independently by CWS study member (S.F.). Statistical analysis was performed using 
SPSS software (version 21, IBM) based on all data available up to the cut-off date, 05.04.2013.The 
Kaplan-Meier method was used for the estimation of overall survival (OS) and event-free survival 
(EFS). OS was defined as the time between date of diagnosis and death from any cause. EFS was 
defined as the time from diagnosis to first event (disease recurrence, progression or death). 
Differences in survival rates were analyzed using the log-rank test. 
 
Statistical analysis 
Data was analyzed using GraphPad Prism (version 4.03). Significance was calculated using 
Student’s t-test (unpaired, two-tailed). P<0.05 was considered significant. 
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Figure legends 
 
Figure 1. Activation of hedgehog signaling increases self renewal and tumorigenicity of ERMS 
cells. (A) Left panel: Expression levels of hedgehog signaling components in RD spheres compared 
to adherent monolayer cultures by quantitative PCR (Log2 scale; N=2-3). Right panel: Western Blot 
anaysis showing GLI1 protein expression in RD sphere and adherent cells. (B) Western Blot 
analysis of GLI1 and HHIP protein expression in ERMS xenografts. (C) Sphere initiation capacity 
of ERMS cells treated with hedgehog agonist SAG1.3 (500nM) every 48h (3 rounds) during 
primary sphere formation and thereafter plated for secondary sphere formation in normal sphere 
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 media (N=2-3). (D) Sphere formation after siRNA mediated knockdown of SUFU (10nM) in RD 
sphere cells compared to scrambled control siRNA (N=2). (E) Sphere formation following 48 hours 
treatment of ERMS adherent cultures with SAG1.3 (N=4-5). (F) Western Blot analysis of indicated 
proteins in ERMS stable cell lines. Primary (1°) and secondary (2°) sphere formation measured in 
ERMS stable lines (G: RD; N=3 and H: RH36; N=2-3). (I) Tumor growth rate followed by caliper 
measurements of RD-based stable lines pCMV-Empty (N=6) and pCMV-GLI1 (N=5) injected 
orthotopically in NOD/SCID mice. (J) Tumor growth rate followed by caliper measurements of 
RH36-based stable lines pCMV-Empty (N=6) and pCMV-GLI1 (N=6) injected orthotopically in 
NOD/SCID mice. *P<0.05; **P<0.01; ***P<0.001. Data represent mean ± S.D. Each data point in 
the Scatter plots represents a technical replicate with the line drawn at the mean.  
 
Figure 2. Inhibition of hedgehog signaling decreases self renewal and tumorigenicity of ERMS 
cells. (A) Sphere initiation capacity of RD cells treated with small-molecule inhibitors GDC-0449 
or GANT61 every 48h (3 rounds) during primary sphere formation and further plated for secondary 
sphere formation in normal sphere media (N=2-3). § No viable cells were recovered for secondary 
sphere formation (B) Sphere formation measured following siRNA (10nM) mediated GLI1 
knockdown in RD sphere cells (N=2). (C) Sphere formation ability of RD adherent cells after 48 
hour treatment with hedgehog inhibitors (N=2-6). Tumor growth rate (D) and tumor weight (E) of 
RD cells pre-treated in vitro with GANT61 (3µM) (N=5 per condition). Western Blot analysis of 
indicated proteins in stable ERMS lines over-expressing tagged SUFU (F; Myc-DDK) and 
knockdown of SMO (G). Primary (1°) and secondary (2°) sphere formation measured in ERMS 
stable lines (H: N=2 per cell line; I: N=2-4 per cell line). Tumor growth kinetics of hedgehog 
inhibited pCMV-SUFU (J: RD; N=5 and K: RH36; N=6) and  control pCMV-Empty (J: RD;N=5 
and K: RH36; N=6) cells  in NOD/SCID mice. Tumor growth kinetics of hedgehog inhibited 
shSMO (L: RD; N=3/7 and M: RH36; N=6/7) and control pLKO.1 (L: RD; N=7/7 and M: RH36; 
N=7/7) cells in NOD/SCID mice. *P<0.05; **P<0.01; ***P<0.001. Data represent mean ± S.D.  
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 Figure 3. Cell autonomous ligand-based hedgehog pathway activation in ERMS. Relative RNA 
expression level of hedgehog ligands in ERMS sphere cells compared to adherent cells (A: RD, 
N=2; B: RH36, N=3). Absolute RNA expression level of hedgehog ligands in ERMS xenografts (C: 
RD; D: RH36; N=4 per cell line) and their respective in vitro cultured cells (N=3 per cell line) 
normalized to housekeeping gene HMBS. (E) Absolute RNA expression of hedgehog ligands 
normalized to geometric mean of HMBS and GAPDH in ERMS patients samples (N=8). Each data 
point represents a single patient and the line represents median expression level in the cohort. 
Species specific ligand RNA expression estimated in ERMS xenografts (F: RD; G: RH36; N=4-
16). h - human; m - mouse. Data represent mean ± S.D.  
 
Figure 4. Hedgehog signaling alters ERMS chemoresistance and cell motility. (A) Sphere initiation 
ability of RD cells treated for 48 hours with Irinotecan (N=3). (B) Sphere initiation ability of RD 
cells treated for 48 hours with Irinotecan alone or in combination with SMO inhibitor LDE-225 
(N=2). (C) IC50 values of indicated conventional cytotoxic drugs estimated from WST-based cell 
viability assays for ERMS cells treated with 5-step drug dilutions (N=4-5 per cell line per drug). (D 
and E) Relative migration of RD cells across porous membrane filter towards a growth serum 
gradient over 48 hours (N=3; 5 fields counted per experiment). (F and G) Total number of RD cells 
that could invade through matrigel-coated porous membrane filter towards a growth serum gradient 
over 48 hours (N=3). *P<0.05, **P<0.01, ***P<0.001. Data represent mean ± S.D. 
 
Figure 5. Hedgehog signaling alters the differentiation status of ERMS cells. (A) Representative 
images of RD cells stained for PAX7 and MYOGENIN expression. All images were taken at 400x 
magnification. Scale bar represents 20µm (B and C) Quantification of percentage of PAX7 or 
MYOGENIN positive RD cells normalized to DAPI stained nuclei counted per viewing field, using 
ImageJ (N=4). (D and E) Quantification of PAX7 or MYOGENIN positive RH36 cells (N=5). (F) 
39 of 47
 Non-supervised hierarchical clustering of common positively and negatively regulated genes by 
hedgehog pathway in ERMS cells. *P<0.05, **P<0.01, ***P<0.001. Data represent mean ± S.D.  
 
Figure 6. Nanog is a functionally important target gene of hedgehog pathway in ERMS. (A) 
Representative images of RD cells co-stained for GLI1 and NANOG expression. All images were 
taken at 400x magnification. Scale bar represents 20µm. Quantification, using ImageJ, of NANOG 
expressing cellular compartments normalized to DAPI stained nuclei per viewing field in ERMS 
stable lines (B; N=6-9) and RD cells treated with SAG1.3 (500nM) for 48 hours (C; N=5-7). (D) 
Correlation analysis of normalized mRNA expression levels of indicated genes in ERMS patient 
tumor samples. The geometric mean of GAPDH and HMBS was used for normalization. (E) Left 
panel: Sphere formation in RD cells with stable knockdown of NANOG (shNANOG; N=3). Right 
panel: Western blot analysis of RD stable lines. (F and G) Primary sphere formation upon transient 
over-expression of NANOG in RD cells (N=2). Secondary sphere formation in RD (H) and RH36 
(I) rescue systems (N=3). (J) Tumor growth rate of RH36 cells in NOD/SCID mice (N=6 per cell 
line). *P<0.05, **P<0.01, ***P<0.001. ns – not significant. Data represent mean ± S.D. 
 
Figure 7. Presence of GLI1
+
 and NANOG
+
 compartment predicts adverse patient survival. (A) 
Representative images of immunohistochemical staining for GLI1 and NANOG within an ERMS 
patient tumor core. All images were taken at 400x magnification. Scale bar represents 20µm. 
Kaplan-Meier curve representing overall survival of 91 ERMS patients determined to be either 
negative (black line) or positive (grey line) for GLI1 (B) or NANOG (C) alone. Kaplan-Meier curve 
representing event-free survival (D) and overall survival (E) of 91 ERMS patients determined to be 
either negative (black line) or positive (grey line) for GLI1-NANOG co-expression. The P-value 
was generated using log rank test. 
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Additional Materials and Methods 
Cell viability, proliferation and clonogenic assays 
To assess cell viability and proliferation, cells were plated in quadruplicate per condition in 96-well 
plates. After the indicated treatment viability was measured using Cell Proliferation Reagent WST-
1 (Roche) following manufacturer’s instruction. Cell proliferation was measure 24 hours post 
plating using Cell Proliferation ELISA, BrdU (chemiluminescent) assay (Roche) following 
manufacturer’s instruction.  Clonogenic assay was performed as described in (Franken et al. 2006). 
In brief, cells were plated at clonal density in 6-well plates in triplicates in normal media. Media 
was changed every 3 days until colonies (>50 cells) were visible. Colonies were fixed and stained 
using with Crystal Violet staining solution (0.5% Crystal Violet and 6% gluteraldehye in water. 
Colonies were quantified using ImageJ software (version 1.47).  
 
Flow Cytometry 
For cell cycle analysis, cells were fixed with ice-cold 70% ethanol, stored overnight at -20° and re-
suspended in propidium iodide solution (PBS, 1% Triton X-100, 100mg/ml RNaseA, 1mg/ml 
Propidium Iodide solution) just before analysis. Cells were analyzed in the 488nm channel. For 
intra-cellular staining cells were fixed with cold 4% PFA and permeabilized with 0.2% Triton X-
100. Cells were indirectly stained using indicated antibodies (Supplementary table 2). Unstained 
cells were used to set the gate for data collection. Cells stained only with conjugated secondary 
were used to set the positivity gate in the 488nm channel. Flow cytometry analysis was performed 
on a BD FACS Canto II instrument (BD Biosciences) using BD FACSDiva software. Data was 
analyzed with FlowJo software (version 7.6.1, TreeStar Inc.). 
 
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. 2006. Clonogenic assay of cells in 
vitro. Nat Protoc 1: 2315-2319. 
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Supplemental Table 1. List of TaqMan®-probe based gene expression assays used in the study. 
Gene Species 
TaqMan® Gene 
Expression Assay ID 
HMBS Human Hs00609297_m1 
GAPDH Human Hs02758991_g1 
GLI1 Human Hs01110766_m1 
GLI2 Human Hs01119974_m1 
GLI3 Human Hs00609233_m1 
PTCH1 Human Hs00181117_m1 
HHIP Human Hs01011008_m1 
SMO Human Hs01090242_m1 
SUFU Human Hs00171981_m1 
SHH Human Hs00179843_m1 
IHH Human Hs00745531_s1 
DHH Human Hs00368306_m1 
NANOG Human Hs02387400_g1 
PAX7 Human Hs00242962_m1 
MYF5 Human Hs00929416_g1 
MYOD1 Human Hs02330075_g1 
MYOG Human Hs01072232_m1 
PROM1 Human Hs01009261_m1 
Shh Mouse Mm00436528_m1 
Dhh Mouse Mm01310203_m1 
Ihh Mouse Mm00439613_m1 
Gapdh Mouse Mm99999915_g1 
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Supplemental Table 2. Details of antibodies used in the study 
A 
Abbreviations: WB – Western Blotting, IF – Immunofluorescence, IC-FC – Intra-cellular Flow 
Cytometry, IHC – Immunohistochemistry, HRP – Horseradish peroxidise 
B 
HRP-conjugated secondary antibodies for IHC were purchased pre-diluted in the reagents 
associated with the automated systems used for processing (see text). 
Primary antibodies (Anti-human)
A 
Detected 
protien 
(clone) 
Catalogue # Company Species Clonality Application Dilution 
GLI1 (V812) 
2534 
Cell Signaling 
Technology 
Rabbit poly WB 1/1000 
HHIP (R-20) sc-9408 Santa Cruz Goat poly WB 1/100 
SUFU 
(C81H7) 
2522 
Cell Signaling 
Technology 
Rabbit mono WB 1/1000 
SMO (N-19) sc-6366 Santa Cruz Goat poly WB 1/500 
NANOG ab21624 Abcam Rabbit poly WB 1/500 
NANOG 
(D73G4)
4903 
Cell Signaling 
Technology 
Rabbit mono WB 1/1000 
GAPDH 
(D16H11) 
5174 
Cell Signaling 
Technology 
Rabbit mono WB 1/10000 
-TUBULIN 
(DM1A) 
T9026 Sigma-Aldrich Mouse mono WB 1/40000 
PAX7 PAX7 
Developemtal 
Studies Hybridoma 
Bank 
Mouse mono 
IF and IC-
FC 
1/50 
MYOGENIN 
(M-225) 
sc-576 Santa Cruz Rabbit poly 
IF and IC-
FC 
1/1000 
GLI1 (H-300) sc-20687 Santa Cruz Rabbit poly IF 1/100 
NANOG 
(hNanog.2) 
14-5768-82 eBioscience Mouse mono IF 1/50 
MYOGENIN 
(L026) 
PA0226 Novocastra, Leica Mouse mono IHC 1/20 
DESMIN (D33) M076029 Dako Mouse mono IHC 1/20 
MIB-1 (30-9) - Ventana, Roche Rabbit mono IHC 
Prediluted (Ventana, 
Roche) 
GLI1 (H-300) sc-20687 Santa Cruz Rabbit poly IHC 1/75 
NANOG 
(NNG-811) 
ab62734 Abcam Mouse mono IHC 1/2000 
Secondary Antibodies
B
Detected 
species 
Catalogue 
no. 
Company Species Conjugation Application Dilution 
Anti-Mouse 
IgG 
7076 
Cell Signaling 
Technology 
Horse HRP WB 1/2000 
Anti-Rabbit IgG 7074 
Cell Signaling 
Technology 
Goat HRP WB 1/2000 
Anti-Goat IgG A50-201P Bethyl Donkey HRP WB 1/2000 
Anti-Mouse 
IgG 
A21202 Life technologies Donkey 
Alexa Fluor-
488 
IF and IC-
FC 
1/500 
Anti-Rabbit IgG A21206 Life technologies Donkey 
Alexa Fluor-
488 
IF and IC-
FC 
1/500 
Anti-Mouse 
IgG 
A21203 Life technologies Donkey 
Alexa Fluor-
594 
IF 1/500 
Anti-Rabbit IgG A21207 Life technologies Donkey 
Alexa Fluor-
594 
IF 1/500 
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Supplemental Figure Legends 
Supplemental Figure 1. Analysis of RH36 spheres and effect of GLI1 over-expression on ERMS 
cells. (A) Left panel: Increased expression of multiple hedgehog signaling components was seen in 
RH36 spheres compared to adherent monolayer cultures by quantitative PCR (Log2 scale; N=2-3). 
(B) SUFU protein expression is decreased upon siRNA mediated knockdown in RD sphere cells, 
which led to an increase in GLI1 expression. Flow cytometry-based cell cycle profile estimation 
from Propidium Iodide staining of RD (C)  and RH36 (D) cells treated with SAG1.3 for 48 hours 
(N=2 per cell line per condition). (E) Viability of ERMS cells, evaluated by WST assay, was not 
greatly affected by the 48 hours treatment with SAG1.3 (N=3-4). Upon stable over-expression of 
GLI1 in RD (F; N=5) and RH36 (G; N=4) cells the expression of target genes of hedgehog pathway 
was increased. (H) Right panel: Colony forming ability of RD cells stably over-expressing GLI1 
was higher than empty vector transfected cells (N=4). Left panel: Representative images of the 
colonies stained with Crystal Violet in one well of a standard 6-well plate. (I) GLI1 over-expression 
is maintained in the xenografts from the stable cell lines. ***P<0.001. Data represent mean ± S.D.   
Supplemental Figure 2. Immunohistochemical analysis of ERMS xenografts. Representative 
images of immunohistochemistry performed on formalin-fixed paraffin-embedded (FFPE) sections 
of ERMS xenografts grown in NOD/SCID mice. The images for H&E (Hematoxylin and Eosin), 
Myogenin and Desmin were taken at 200x magnification. Scale bar represents 50µm. The images 
for GLI1 staining were taken at 400x magnification. Scale bar represents 20µm. GLI1 staining was 
found to be heterogeneous within xenografts and the over-expression was more readily detected in 
case of RD. The RH36 pCMV-GLI1 xenograft contained more number of strongly positive GLI1 
cells and in general the tumor appeared to be composed of more primitive looking cells.  
Supplemental Figure 3. Effect of hedgehog inhibition by synthetic small molecules on ERMS 
cells. (A) RH36 cells plated in sphere media and treated with small-molecule inhibitors GDC-0449 
or GANT61 every 48h (3 rounds) showed decreased primary sphere formation and a further 
decrease in secondary sphere formation in recovery conditions (N=2). # No spheres formed. § No 
viable cells were recovered for secondary sphere formation. (B) RH36 adherent cells treated with 
hedgehog inhibitors for 48 hours had decreased sphere initiation capacity (N=2-3). Cell cycle 
profiles generated by flow cytometry-based measurement of Propidium Iodide staining of RD (C)  
and RH36 (D) cells treated with hedgehog inhibitors for 48 hours were not different from vehicle 
treated cells (N=2 per cell line per condition). Viability evaluated by WST assay, of RD (E) and 
RH36 (F) cells was not greatly affected by the 48 hours treatment with hedgehog inhibitor (N=2-4). 
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(G) Representative whole mounts of xenograft tumors formed by injecting RD cells either pre-
treated with vehicle or GANT61 (3µM) for 48 hours in vitro. (H) Representative images of 
immunohistochemistry performed on FFPE sections of xenograft tumors formed by injecting RD 
cells either pre-treated with vehicle or GANT61 (3µM). The images for H&E, Myogenin, Desmin 
and Ki-67 were taken at 200x magnification. Scale bar represents 50µm. The images for GLI1 
staining were taken at 400x magnification. Scale bar represents 20µm. *P<0.05, **P<0.01. Data 
represent mean ± S.D. 
Supplemental Figure 4. Effect of stable genetic hedgehog inhibition on ERMS cells.Upon stable 
over-expression of SUFU in RD (A; N=2) and RH36 (B; N=1) cells the expression of target genes 
of hedgehog pathway were decreased. Stable knockdown of SMO in RD (C; N=3) and RH36 (D; 
N=3) cells led to decrease in expression of target genes of hedgehog pathway. (E) Right panel: 
Colony forming ability of pCMV-SUFU RD cells was lower than pCMV-Empty cells (N=2). Left 
panel: Representative images of the Crystal Violet stained colonies in one well of a standard 6-well 
plate. (F) Right panel: Colony forming ability of shSMO RD cells was lower than empty vector 
transfected cells (N=2). Left panel: Representative images of the Crystal Violet stained colonies 
formed in one well of a standard 6-well plate. (G and H) Cell proliferation measured by BrdU 
incorporation in RD cells (N=2). (I) Histogram plots of cell cycle profiles generated from 
Propidium Iodide (PI) staining of RD stable lines by flow cytometry. (J and K) Quantification of 
cell cycle stage distributions observed in RD cell lines with different hedgehog pathway status. (L 
and M) Quantification of cell cycle stage distributions observed in RH36 cell lines with different 
hedgehog pathway status. ***P<0.001. Data represent mean ± S.D. 
Supplemental Figure 5. Real-time gene expression analysis of hedgehog ligands in ERMS patient 
samples and xenografts.(A, B and C) Quantitative PCR for hedgehog ligands performed on nine 
ERMS patient tumor samples. Data normalized to geometric mean of HMBS and GAPDH. 
Expression of Dhh is particularly higher within ERMS tumors (D: RD; E: RH36; N=4-10) 
compared to normal murine skeletal muscle (N=2). Expression levels are normalized to Gapdh. 
FeSkM_P - Pool of Fetal Skeletal Muscle RNA (N=3); AdSkM_P - Pool of Adult Skeletal Muscle 
RNA (N=5); m - mouse. Data represent mean ± S.D. 
Supplemental Figure 6. Effect of hedgehog pathway modulation on ERMS cell motility and 
differentiation. Representative images of RD cells stained with Crystal Violet post-migration (A) 
and post-invasion (B) in trans-well assay. All images were taken at 200x magnification. Scale bar 
represent 50µm. (C) Representative images of RD cells stained for PAX7 and MYOGENIN 
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expression. (D and E) Representative images of RH36 cells stained for PAX7 and MYOGENIN 
expression. All images were taken at 400x magnification. Scale bar represents 20µm. Intra-cellular 
flow cytomtery performed on RH36 cells treated with hedgehog inhibitors GDC-0449 (F) and 
GANT61 (G) for 48 hours showed relative decrease in PAX7 positivity and increase in 
MYOGENIN positive cellular compartment indicating differentiation of cells, while treatment with 
hedgehog agonist SAG1.3 (H) for 48 hours induced de-differentiation of cells since PAX7 
positivity increased and MYOGENIN positivity decreased (N=2). Data represent mean ± S.D. 
Supplemental Figure 7. Modulation of Nanog expression by hedgehog signaling. (A) GLI1 over-
expression increases NANOG RNA expression (N=4-5) while the expression decreases in shSMO 
(B; N=3) and pCMV-SUFU (C; N=1-2) ERMS cells. (D) NANOG protein expression (arrow) 
decreases upon inhibition of hedgehog pathway activity in ERMS cells. (E) Representative images 
of RH36 stable cells co-immunostained for GLI1 and NANOG expression. All images were taken 
at 400x magnification. Scale bar represents 20µm. (F) RH36 NANOG expressing cells increased 
upon 48 hours treatment with SAG1.3 (N=3). Representative images for RD (G) and RH36 (H) 
cells treated with SAG1.3 and stained for NANOG. All images were taken at 400x magnification. 
Scale bar represents 20µm. NANOG RNA expression, normalized to HMBS, is higher in RD (I) and 
RH36 (J) xenografts (N=2 per condition). (K) NANOG protein expression level (arrow) is higher in 
ERMS sphere and xenografts compared to adherent cultures. (L) Non-supervised hierarchical 
clustering of normalized expression levels of indicated genes in nine ERMS patient samples and 
pooled samples of normal human muscle (FeSkM_P and AdSkM_P). **P<0.01. Data represent 
mean ± S.D. 
Supplemental Figure 8. Characterization of phenotype rescue cell lines and additional clinical data 
analysis. (A) Western Blot analysis of RD stable lines indicates that expression of GLI1 increases 
upon NANOG over-expression. Expression analysis to verify the stable cell lines generated from 
RD (B) and RH36 (C) cells with knockdown of NANOG in the presence of GLI1 over-expression. 
Error bars represent S.D. (D) Representative images of immunohistochemistry performed on FFPE 
sections of RH36 stable line xenografts grown in NOD/SCID mice. The images were taken at 200x 
magnification. Scale bar represents 50µm. (E) Representative images of immunohistochemistry 
staining for GLI1 and NANOG within an ERMS patient tumor core. All images were taken at 400x 
magnification. Scale bar represents 20µm. Kaplan-Meier curve for event-free survival of 91 ERMS 
patients determined to be either negative (black line) or positive (grey line) for expression of GLI1 
(F) or NANOG (G) alone. The P-values were generated using log rank test.  
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Abstract 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Most alveolar 
(aRMS) cases bear the chimeric transcription factor PAX3/7-FOXO1 and have a poor prognosis 
compared to the more common embryonal (eRMS) subtype. Previous studies have characterized 
eRMS as being a hierarchically organized tumor with rare cancer-initiating populations but there have 
been no reports on the cellular organization in aRMS. This knowledge would be important to guide 
future treatment strategies. In this study we show that no cancer stem cells (CSC) subpopulation could 
be detected in aRMS by a range of common methods whereas 100 aRMS cells were sufficient to 
generate tumors in NOD/SCID mice. The stem cell factors Nanog, Oct4, and Sox2 were 
homogeneously expressed in aRMS cell lines and their genetic loss- or gain-of-function did not 
change cellular physiology unlike silencing of PAX3-FOXO1, which caused cell cycle arrest and 
apoptosis. Importantly, the addition of PAX3-FOXO1 to standard human fibroblast reprogramming 
protocol led to significant increase in generation of induced pluripotent stem cells (iPSC). Strikingly, 
PAX3-FOXO1 iPSC showed reduced ability to differentiate in vitro into all three germ layers and 
initiated undifferentiated tumors in vivo unlike control iPSC that could generate bona fide teratomas. In 
conclusion, PAX3-FOXO1 is a general inhibitor of differentiation in iPSC and it could act as ‘stemness’ 
mediator in aRMS. Moreover, contrary to eRMS, fusion-positive aRMS tumors are comprised of a 
majority of cancer-initiating cells which are dependent on PAX3-FOXO1 activity, and therefore could 
follow the stochastic clonal evolution model. 
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Introduction 
For the development of more effective cancer therapies, it is of fundamental importance to determine 
which cancer cells have the potential to contribute to disease progression. Since tumors consist of 
populations with heterogeneous proliferation and differentiation capacities, in the past years at least 
two models of tumor propagation have been postulated: the clonal evolution model and the cancer 
stem cell (CSC) model. The clonal evolution model postulates that tumor cells are under selective 
pressure. This process leads to the generation of genetically heterogeneous and highly aggressive 
clones with equipotent tumorigenic potential. On the other side numerous studies, first in leukemia and 
later in solid tumors, have demonstrated that often only a subset of cancer cells has the capability to 
extensively proliferate and generate new tumors 
1, 4, 32
. These CSCs after transplantation give rise to
new CSCs as wells as a heterogeneous, more differentiated population of non-tumorigenic cells. The 
origin of CSCs is not yet clear; nevertheless they share many features with embryonic (ESC) and adult 
stem cells. Two common characteristics define normal and CSCs: their ability to undergo indefinite 
mitotic self-renewal and to differentiate into a range of specialized cell types. Based on phenotypic 
traits such as cell surface markers and on functional properties such as quiescence and drug 
resistance, CSC can nowadays be isolated from a number of primary tumors or cell lines and, after 
establishing the optimal conditions, can be maintained and enriched in vitro. 
Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children (reviewed in 
12
). RMS
share features with skeletal muscle and based on histologic criteria they are divided into two groups: 
embryonal RMS (eRMS) and alveolar RMS (aRMS). eRMS have higher incidence, are less 
aggressive, and mainly affect children in the age of 0-5 years 
34
. On the other hand aRMS occur in
adolescents and young adults, and are more aggressive tumors with poor response to therapy and in 
general worse prognosis than eRMS 
7, 36, 37
. The pathogenic marker of aRMS is the result of specific
chromosomal translocations 
33, 43
. The most common translocations are t(2;13)(q35;q14) or 
t(1;13)(p36;q14), which generate the chimeric transcription factor PAX3-FOXO1 (also known as 
PAX3-FKHR) or PAX7-FOXO1 respectively. The resulting fusion protein contains the DNA-binding 
domain of PAX3 or PAX7 and the transactivation domain of FOXO1 
11
. Several studies have proven
the oncogenic role of the fusion protein and have demonstrated its fundamental importance in 
maintaining aRMS cells 
2, 3, 14, 25, 40
. Importantly, it was demonstrated that PAX3-FOXO1 actively 
contributes to the undifferentiated myogenic phenotype typical of RMS cells, in which it suppresses 
the transcriptional activity of MyoD-target genes 
8
. Moreover, recently JARID2, a protein involved in
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recruiting various complexes with histone-methylating activity, was identified as a novel PAX3-FOXO1 
target gene 
51
. Thus, the chimeric protein controls cellular differentiation programs and interacts with
epigenetic regulators, maintaining aRMS cells in a pre-differentiated state. Similar features are 
possessed by transcription factors, which regulated stemness in ESC and induced pluripotent stem 
cells (iPSC). Recently, it was demonstrated that the core stem cell factors NANOG, OCT4, and SOX2 
together with KLF4, c-MYC, and LIN28 are sufficient for de-differentiate or reprogram terminally 
differentiated cells into iPSC 
45, 46, 54
. Not surprisingly, most of these reprogramming factors are found
expressed and upregulated in cancer (stem) cells where they are involved in maintaining the 
tumorigenic state and sustaining cell self-renewal 
17, 22, 28
.
Although CSC have been already identified in many sarcomas 
16, 29, 44
 and among them recently also
in eRMS 
50
, it is still unclear as to whether the most aggressive aRMS subtype possesses a 
subpopulation of CSC. In this study we present evidence that aRMS contrary to eRMS does not 
possess an exclusive subpopulation of cells with tumor potential but rather more each aRMS cell 
exhibits similar tumorigenic potential. Survival and maintenance of aRMS cells is strictly PAX3-FOXO1 
dependent. Here we demonstrate that the chimeric protein confers also stemness properties and is 
able to enhance the efficiency of reprogramming human fibroblasts. Importantly, we prove for the first 
time that PAX3-FOXO1 inhibits not only mesodermal, and specifically skeletal muscle differentiation, 
but also ectodermal and endodermal differentiation. In sum, this iPSC system offers new possibilities 
for understanding the biology of PAX3(or 7)-FOXO1, which is an essential step for developing novel 
therapies for aRMS.  
Materials and Methods 
Cell lines  
Alveolar Rhabdomyosarcoma (aRMS) cell lines RH4, RH41 (both kindly provided by Peter Houghton, 
The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA), RH3, RH5 (kindly 
provided by Susan Ragsdale, St.Jude Children`s Research Hospital, Memphis TN, USA), CW9019 
(kindly provided by Soledad Gallego, Hospital Universitari Vall d'Hebron, Barcelona, Spain), RMS13 
(kindly provided by Roland Kappler, Ludwig-Maximilians-Universität München, Munich, Germany), 
RH30 (purchased from the American Type Cell Culture Collection, LGC Promochem, Molsheim 
Cedex, France), the human testicular embryonal carcinoma cell line NTERA-2 clone D1 (purchased 
from Biological Bank and Cell factory, IRCCS university hospital San Martino, Genoa, Italy), 293-GPG 
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cells, neonatal human foreskin fibroblast (PC501A-HFF-SBI, purchased from System Biosciences, 
CA, US) were routinely maintained in complete medium: DMEM supplemented with 10% fetal bovine 
serum (FBS), 2mM L-glutamine, and 100 U/ml penicillin/streptomycin.  
Sphere assay, transgenic aRMS cell lines, and siRNA 
For sphere assay, cells were seeded at clonal dilution in petri dishes and cultured in sphere medium 
consisting of DMEM/HAM’s F12, 20% knockout Serum Replacement (GIBCO), 2mM L-glutamine, 100 
U/ml penicillin/streptomycin either supplemented with 10ng/ml bFGF or with 10ng/ml bFGF, 10ng/ml 
EGF, and 10ng/ml PDGF (all from R&D Systems). At each passage spheres were quantified and 
passaged at clonal density. All experiments were performed in triplicates. Transgenic cell lines stably 
overexpressing NANOG, OCT4, and SOX2 were generated using jetPRIME Transfection Reagent 
(Polyplus) according to manufacturer’s instructions. The following plasmids have been used: control 
EGFP pEGIP (Addgene no. 26777, 
56
), pSin-EF-Sox2-Pur, pSin-EF-Nanog-Pur, pSin-EF-Oct4-Pur (all
from Addgene no. 16577-16579, 
54
). Overexpression of the genes was proven at RNA and protein
levels. For knockdown experiments cells were transfected using INTERFERin
TM
 siRNA Transfection
Reagent (Polyplus) as described in the manufacturer’s instructions. Silencer® Select siRNAs (Ambion, 
Life technologies) against SOX2 (1-siSOX2: Silencer® Select ID s13296, 2-siSOX2: s13295, 3-
siSOX2: s13294), against PAX3-FOXO1 (siP2F 
26
), and scrambled control (Silencer® Negative 
Control No. 2 siRNA) were used at a final concentration of 5nM. Cells were harvested after 48h and 
72h for further functional assays. Gene silencing was controlled on RNA and protein levels.  
Cancer stem cell markers, Aldefluor assay, and separation of ALDH1 high cells 
For CSC marker analysis, single cell suspensions were incubated at room temperature for 30 min with 
1:10 diluted fluorochrome labeled antibody for: CD133/2-APC, CD133/1-APC (both Miltenyi), CD44-
FITC, CXCR4-APC (both BD Bioscience). Flow cytometry analysis was performed on a BD FACS 
Canto II instrument (BD Biosciences). Data were collected with DIVA software (BD Biosciences) and 
analyzed with FlowJo software (TreeStar Inc., Ashland, OR, USA). To monitor ALDH1 enzymatic 
activity Aldefluor® assay system (Stem Cell Technologies) was used according to manufacturer’s 
instructions. In brief, 10
6
 cells/ml were incubated with activated ALDH1 substrate for 40 min at 37°C.
Using identical conditions as a negative control for each experiment a set of cells was stained with 
ALDH1 inhibitor DEAB. ALDH1 high cells were detected with FACS as described before. For ALDH1 
activity after drug selection, aRMS cells were incubated for 72h with the chemotherapeutics Vincristine 
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(5nM and 5µM, Teva Pharma AG, Switzerland), Actinomycin D (5nM and 5µM, Sigma Aldrich, 
Switzerland), and Mafosfamide (5µM and 30µM, Santa Cruz, CA, USA). Thereafter, cells were stained 
with Aldefluor® assay and processed for flow cytometry analysis. Only viable, 7AAD (BD Bioscience) 
negative cells were investigated for ALDH1 activity as described above. Aldefluor® labeled RH30 
aRMS cells were sorted with FACS Aria III and fractioned into ALDH1 high, ALDH1 low, and a mixed 
population. The three populations were cultured either in monolayer conditions and analysed for 
ALDH1 activity after 3, 6, and 10 days or sphere assay was performed as previously described. 
 
Clonogenic, Proliferation, viability, and cell cycle analysis 
For clonogenic assay 2000 cells were seeded on 6 well plates in triplicates. Cells were cultured with 
complete medium and allowed to grow till clones were visible. Cells were stained with crystal violet 
and clones were quantified. For proliferation assay Cell Proliferation ELISA, BrdU assay (Roche 
Applied Science) was used following manufacturer’s instruction. For knockdown experiments the data 
were normalized with the scrambled control, whereas for transgenic overexpressing cell lines the data 
were normalized with EGFP control line. For cell viability assay Cell Proliferation Reagent WST-1 
(Roche Applied Science) was used following manufacturer’s instruction. All experiments were 
performed in triplicates. For cell cycle analysis siRNA treated cells were harvested after 24h, 48h, and 
72h and they were fixed in ice-cold 70% ethanol. Cells were resuspended in propidium iodide solution 
(PBS, 1% Triton X-100, 100mg/ml RNaseA, 1mg/ml PI), and processed for FACS analysis as 
previously described.  
 
Real-time PCR 
Total RNA was extracted using RNeasy Mini Kits (Qiagen) and reverse transcription was carried out 
using high-capacity cDNA reverse transcription kit (Life Technologies) according to the manufacturer’s 
instructions. Quantitative Real-Time PCR (qRT-PCR) was performed using commercially available 
mastermix and TaqMan Gene Expression Assays (Life Technologies, Supplemental Table 1). 
Reactions were run using standard conditions on an ABI 7900 HT Real-Time PCR machine and the 
data were analyzed with SDS2.2 software. CT values were normalized to GAPDH or HMBS 
housekeeping genes. Relative expression levels of the genes were calculated using the CT 
method. All experiments were performed in triplicate and repeated at least three times. Data analysis 
was done with the GraphPad prism software and statistical analysis using the Student’s t-test. Heat 
map for aRMS clone analysis was generated with dChip software. 
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Western blotting, immunofluorescence, and immunohistochemical analysis 
For western blot, total protein extracts were obtained from cells lysed with RIPA buffer (50 mM Tris-Cl, 
pH 6.8, 100 mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with Complete Mini Protease 
Inhibitor Cocktail (Roche Applied Sciences). Protein concentration was measured with Pierce® BCA 
protein Assay Kit (Thermo Scientific). Proteins were identified by SDS-PAGE and western blotting 
using antibodies reported in Supplemental Table 2. Signal was detected by chemiluminescence using 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). For immunofluorescence 
analysis, aRMS cells were grown on chamber slides whereas iPSC were cultured on 3.5 cm cell 
culture dishes, fixed with 4% paraformaldehyde (Carl Roth, Arlesheim), and incubated over night at 
4°C with primary antibodies. aRMS staining were analyzed with an Axioskop2 mot plus fluorescence 
microscope (Zeiss, Jena, Germany). iPSC staining were analyzed with Axiovert 40 CFL (Zeiss, Jena, 
Germany) and AxioVision Rel. 4.6 software. For immunohistochemical analysis of xenografts and 
teratomas, three-micron thick sections of blocks of formalin-fixed, paraffin-embedded tissue were 
mounted on glass slides (SuperFrost Plus), deparaffinized, rehydrated and stained with hematoxylin 
and eosin (H&E) using standard histological techniques. Immunohistochemical staining were 
performed with Ventana Benchmark automated staining system (Ventana Medical Systems) using 
Ventana UltraView DAB reagents. All primary antibodies were diluted in Ventana diluent. Slides were 
counterstained with hematoxylin, dehydrated and mounted. 
Generation of human induced pluripotent stem cells (iPSC) 
iPSC were generated as described in 
56
. In brief, 293-GPG cells were cultured with complete medium
and were transfected using jetPRIME Transfection Reagent (Polyplus) with the following retroviral 
plasmids: pMXs-hOCT3/4, pMXs-hSOX2, pMXs-hKLF4, pMXs-hc-MYC (all from Addgene no. 17217-
17220 
46
). PAX3-FOXO1 full sequence was cloned into pMSCV-pBabeMCS-IRES-GFP (Addgene no.
33336) and the same plasmid without PAX3-FOXO1 was used as a control. 72h post-transfection the 
virus-containing medium was collected. A solution containing equal amount of the four reprogramming 
factors plus either PAX3-FOXO1 or the control plasmid was prepared and immediately used for 
fibroblast transduction. Equal amount of human fibroblasts were plated onto gelatinized 6 well plates 
and the cells were incubated over night with virus-containing medium. Thereafter, viruses were 
removed and the cells were cultured for additionally 5 days with complete medium. At day 5 same 
amounts of infected fibroblasts were transferred on plates coated with mitotically inactivated mouse 
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embryonic fibroblasts (MEFs). From day 6 on cells were cultured with iPSC medium consisting of 
DMEM/HAM’s F12, 20% knockout Serum Replacement (GIBCO), 10ng/ml of bFGF (R&D Systems), 
100M nonessential amino acids (Life Technologies), 100M 2-mercaptoethanol (Sigma), 1mM L-
glutamine, 50 U/ml penicillin/streptomycin. Two weeks later single iPSC colonies were picked and 
expanded as clones on MEF coated plates. Total DNA (DNeasy Blood & Tissue Kit, Qiagen) form 
iPSC clones was isolated and PAX3-FOXO1 was detected with PCR (fwd: 
GCACTGTACACCAAAGCACG, rev: AACTGTGATCCAGGGCTGTC). qRT-PCR analyses of the 
iPSC clones were performed as described above. 
In vitro differentiation of iPSC clones 
iPSC were separated from MEF and cultured in suspension for 7 days in iPSC-medium without bFGF 
to form embryoid bodies (EB), which were then analyzed for gene expression as described above or 
were plated onto 0.1% gelatin-coated dishes for further differentiation. For mesodermal (muscle) 
differentiation, attached EB were culture in high-glucose DMEM, 10% FBS , 5% horse serum (Sigma), 
100µM nonessential amino acids, 100µM 2-mercaptoethanol, 1mM L-glutamine, 50 U/ml 
penicillin/streptomycin. After 14 days the amount of serum was reduced to 1% and cells were 
additionally cultured for 3 weeks. For ectodermal (neural) differentiation, attached EB were cultured for 
10 days in DMEM/HAM’s F12, 50x B27 Supplement (GIBCO), 100x N2 Supplement (GIBCO), 2% 
FBS, 10ng/ml bFGF, 1mM L-glutamine, 50 U/ml penicillin/streptomycin. For endodermal (pancreatic) 
differentiation, iPSC were separated from MEF and plated on gelatin-coated dishes in medium 
consisting of RPMI 1640, 1% FBS, 50x B27 Supplement, 1mM L-glutamine, 50 U/ml 
penicillin/streptomycin supplemented with Activin A (100ng/ml, GIBCO). Cells were cultured for 6 days 
under these conditions, and thereafter the medium was changed into: DMEM/HAM’s F12, 50x B27 
Supplement, 100x N2 Supplement, 1% FBS, 100M nonessential amino acids, 100µM 2-
mercaptoethanol, 1mM L-glutamine, 50 U/ml penicillin/streptomycin. Cells were additionally cultured 
for 8 days. All differentiated cells were then either fixed for immunofluorescence or lysed for total RNA 
extraction.  
Generation of xenografts and teratomas 
The veterinary office of the Canton Zurich approved all xenograft and teratoma experiments. For the 
generation of xenograft, different amount of aRMS cells were injected intra muscularly (i.m) into the 
left leg of NOD/Scid mice. Tumor size was determined every 4 days by measuring two diameters (d1 
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and d2) in right angles of both legs with a caliper. Tumor volumes were calculated using the following 
formula:  
V=[4/3x π/2(d1+d2)]left leg - [4/3x π/2(d1+d2)]right leg  
For secondary tumor formation, primary xenografts were isolated and tumor dissociation was 
performed as described in 
35
 for 30 min at 37°C in a rotator oven. An aliquot of each cell suspension
was analyzed by flow cytometry for determining the percentage of viable (7-AAD negative), EGFP 
positive cells. Based on these data cell dilutions with 10
4
 cells were prepared and injected as
described before into NOD/Scid mice. Approximately 1cm
3
 tumors were dissected and analyzed. For
teratoma generation, 1-3x10
6
 undifferentiated, MEF free iPSC were injected either subcutaneously
into one dorsal flank or i.m into the left leg of NOD/Scid mice. Tumors were measured once a week 
and allowed to grow till 1cm
3
. Subcutaneous tumor volumes were calculated using the following
formula:  
V= ½(length x width
2
).
Results 
Identification of putative cancer stem cell subpopulation in aRMS cell lines 
Recently, we demonstrated that CSCs can be enriched in eRMS by using the sphere assay 
50
. In
order to understand whether also the more aggressive aRMS possess a subpopulation of CSC we 
performed sphere assays with aRMS cells. Sphere medium was either supplemented with bFGF 
(referred as FGF-medium) or with bFGF, EGF, and PDGF (ALL-medium). Seven human aRMS cell 
lines were tested for their ability to generate spherical clones and to self-renew in anchorage-
independent, serum-starved culture, using either FGF- or ALL-medium. While all aRMS cell lines were 
able to grow and to form spheres in both media (data not shown), only three cell lines (RH4, RMS13, 
and RH30) showed enhanced self-renewal at clonal density and could be passaged for more than 5 
weeks (Fig. 1A and Supplemental Fig. 1A-B). Although the increase of cells forming spheres was very 
moderate over the passages, no upregulation of the core stem cell genes NANOG and OCT4 was 
observed in RH4 and RH30 spheres when compared to the same cells cultivated under standard, 
adherent conditions. Only a slight increase was monitored in RMS13 spheres for NANOG and in 
RH30 spheres for SOX2 (Fig. 1A and Supplemental Fig. 1A-B). Thus, in contrast to eRMS cells with 
the sphere assay no clear enrichment of CSC was observed in aRMS spheres.  
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We further analyzed the expression of three cell surface markers known to characterize different CSC 
types. The glycoprotein CD133 (PROMININ 1) is upregulated in CSC of different tumors 
15, 31, 39
 and
importantly also in eRMS 
50
. Most of the aRMS cell lines were negative for CD133 expression, with the
exception of RMS13, which was composed of an almost 100% positive population and RH3, which 
had a subpopulation of about 30% positive cells (Fig. 1B). CD44 is a major hyaluronan receptor used 
as a marker for mesenchymal stem cells and CSC 
38, 49
. CD44 was shown to play a crucial role in the
activation of tumor-promoting signaling pathways 
5, 6
. Four out of seven aRMS cell lines possessed a
population of CD44 positive cells, which was varying from 15% in RH3 to almost 100% in RH30 and 
CW9019 lines (Fig. 1C). In contrast, RH4, RMS13, and RH5 were negative for CD44. The expression 
of the chemokine receptor CXCR4 has been associated with metastasis, poor prognosis in primary 
tumors, and CSC 
10, 13
. No subpopulation was identified in the analyzed aRMS cell lines but almost all
the lines showed high expression of CXCR4 (Fig. 1D). CXCR4 gene was identified as target of PAX3-
FOXO1 
30, 47
 hence explaining the high expression observed in almost all aRMS cell lines with the
exception of RH4 and RH41 (Fig. 1D). Thus, none of the analyzed markers characterize a small 
subpopulation in all seven aRMS cell lines, which could be further studied for stemness properties. 
aRMS cell lines possess a dynamic subpopulation of ALDH1 high cells which do not have stem 
cell properties 
The cytosolic enzyme aldehyde dehydrogenases (ALDHs) are involved in oxidizing intracellular 
aldehydes into carboxylic acids. Recently, ALDH1 was identified as a marker for CSC in many 
different tumors such as breast 
18
, ovary 
27
, lung 
23
, and sarcomas 
21
. Based on these data, we 
analyzed seven aRMS cell lines for their ALDH1 activity using Aldefluor® assay system and flow 
cytometry 
24
. All aRMS cell lines possessed a subpopulation of ALDH1 high cells, which varied from
3% in RH41 to about 40% in RH3 (Fig. 1E). RH30 was selected for further investigation and ALDH1 
high and ALDH1 low fractions were separated. As a control a mixed population of positive and 
negative cells was used for all the experiments (Supplemental Fig. 2A). We next assessed the 
capability of the three cell populations to maintain or modulate ALDH1 activity over the time. Sorted 
and control cells were cultivated and ALDH1 activity was measured after 3, 6, and 10 days (Fig. 1F). 
The ALDH1 high fraction generated ALDH1 positive and negative cells, as it would be expected from 
stem cells. Nevertheless, ALDH1 low fraction already after 3 days of culture showed a small 
population of ALDH1 positive cells, which increased after 10 days (Fig. 1F). Thus, ALDH1 high cells 
are not a fixed population but rather more a dynamic population. Gene expression analysis of the 
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sorted populations showed no upregulation of the core stem cell genes in the ALDH1 high fraction 
(Fig. 1G). Interestingly, NANOG expression was strongly reduced in the ALDH1 high cells and no 
differential expression of aRMS specific genes was observed (Fig. 1G). The three fractions were 
analyzed also under sphere conditions: ALDH1 high cells generated slightly more primary spheres; 
nevertheless the difference was not significant (Fig. 1H). Over the passages no enhanced self-renewal 
was observed in any of the fractions (Fig. 1I). These data confirm the fact that ALDH1 positive cells 
are dynamic and can therefore not be maintained in culture as exclusively negative or positive 
population. All these results were confirmed with the aRMS cell line RH4 (data not shown). 
The ALDH enzymes are an important component of cellular defenses against toxic aldehydes 
42
 and
are therefore supposed to be involved in CSC drug resistance. Therefore we investigated whether 
drug selection could enrich for ALDH1 high cells in aRMS cells cultivated as a monolayer under 
standard culture conditions. Since aRMS tumors are usually treated with the VAC-protocol 
(Vincristine, Actinomycin D, and Cyclophosphamide), RH30 cells were incubated for 72 hours with 
either high or low concentrations of the chemotherapeutics Vincristine, Actinomycin D, or the 
metabolic active form of Cyclophosphamide, called Mafosfamide. Thereafter, viable cells were 
analyzed for ALDH1 activity by flow cytometry. Treatment with Vincristine and Actinomycin D reduced 
the population of ALDH1 high cells with both drug concentrations (Fig. 1J). ALDH1 population was not 
affected when the cells were treated with the lower concentration of the alkylating agent Mafosfamide 
but decreased with the highest concentration (Fig. 1J). Thus, treatment with the VAC-protocol is 
sufficient for eliminating ALDH1 high cells in aRMS cell lines.  
In sum, aRMS cell lines possess a subpopulation of cells with high ALDH1 activity; nevertheless these 
cells do not have stem cell properties and are sensitive to chemotherapeutics treatment.  
Silencing of PAX3-FOXO1 but not of the stem cell regulators NANOG, OCT4, and SOX2 affects 
aRMS cellular physiology 
The transcription factors NANOG, OCT4, and SOX2 are key regulators of pluripotency in mammalian 
ESC and iPSC but they also play crucial roles in the maintenance of CSC in many different tumors 
9, 
17, 19, 29
. Expression analysis of the core stem cell genes in seven aRMS cell lines revealed that all cells 
expressed NANOG, OCT4, and SOX2 although at very low levels (Fig. 2A and Supplemental Fig. 3A-
C). To understand the function of the stem cell regulators in aRMS, siRNA mediated silencing of the 
three factors was performed in RH4 and RH3 and thereafter gene expression, cell cycle distribution, 
cell proliferation and viability was investigated. Surprisingly, knockdown of the pluripotency factors 
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never affected aRMS cells on molecular or functional levels. For instance, silencing of SOX2 using 
three specific siRNA sequences did not induce upregulation of differentiation markers like MYL1 or 
alter gene expression of PAX3-FOXO1 and its target genes AP2β and OLIG2 (Fig. 2B). Similar results 
were obtained after silencing of NANOG and OCT4 with several specific siRNA sequences (data not 
shown). Contrary to the stem cell factors, silencing of PAX3-FOXO1 induced downregulation of its 
target genes and strong upregulation of muscle differentiation factors (Fig. 2C). Cell viability was 
significantly altered upon downregulation of the oncogene but not upon reduction of NANOG, OCT4, 
and SOX2 expression (Fig. 2D). Moreover, reduction in cell proliferation (Fig. 2E) and cell cycle arrest 
at G1 phase (Fig. 2F) occurred only upon silencing of PAX3-FOXO1 whereas no detectable changes 
could be observed upon downregulation of the stem cell genes. Taken together our data confirm that 
PAX3-FOXO1 expression is essential for aRMS cell maintenance whereas in contrast to other types of 
cancer, the expression of the core stem cell genes in aRMS is dispensable.  
 
Forced expression of NANOG, OCT4, and SOX2 negatively correlates with stemness properties 
in aRMS cell lines 
All analyzed aRMS cell lines expressed NANOG, OCT4, and SOX2, although not at levels comparable 
to pluripotent stem cells. For better understanding of their role in aRMS, we generated RH30 and RH4 
cells transgenic lines (Supplemental Fig. 4A) overexpressing NANOG, OCT4 or SOX2, or the three 
genes simultaneously (referred as ‘NOS’). These cell lines were tested for enhanced stemness 
properties. Gene expression analysis of the transgenic lines displayed different behaviors between 
RH4 and RH30 cells. Brieflly, all RH4 transgenic lines never showed differential expression of PAX3-
FOXO1 or its target gene AP2β (Fig. 2G). Nevertheless, the muscle specific differentiation marker 
MYL1 was reduced in the cell lines overexpressing SOX2 and NOS (Fig. 2G) highlighting a less 
differentiated state compared to the control cells. In RH30 cell system, OCT4 overexpression induced 
a slight upregulation of PAX3-FOXO1 and a strong increase of AP2β (Supplemental Fig. 4B). Similarly 
AP2β was upregulated in the SOX2 and NOS transgenic cells. Nevertheless, no downregulation of 
MYL1 was observed in any of these transgenic cells (Supplemental Fig. 4B). Analysis of cell 
proliferation demonstrated that RH4 transgenic cells proliferated faster (Fig. 2H) whereas RH30 cells 
proliferated slower than the control cells (Supplemental Fig. 4C). Interestingly, also the ability of 
generating clones was affected by the overexpression of the stem cell genes: in RH4 cells NANOG, 
OCT4, and SOX2 forced expression reduced the number of clones, whereas no difference was 
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observed upon overexpression of NOS (Fig. 2I). Also RH30 transgenic cells formed fewer clones after 
forced expression of OCT4, SOX2, and NOS (Supplemental Fig. 4D). Since in the adherent culture 
system none of the transgenic cell lines gained stemness properties, we performed sphere assay. 
Both RH4 and RH30 cells overexpressing NANOG, OCT4, and SOX2 showed reduced ability to form 
primary spheres (Fig. 2J and Supplemental Fig. 4E) and reduced self-renew over a period of 5 weeks 
(Fig. 2K and Supplemental Fig. 4F).  
In sum, overexpression of the core pluripotency stem cell genes in aRMS cells does not increase stem 
cell properties, confirming a minor role of these genes in aRMS.  
High frequency of tumor initiating cells in aRMS 
Since our data did not support the presence of CSC subpopulations in aRMS we hypothesized that 
aRMS does not follow the CSC model but rather the clonal evolution model, which postulates that 
each cell is equally able to propagate the tumor. We therefore performed in vivo limiting dilutions with 
RH30 cell line. Three dilutions of cells (10
5
, 10
4
, and 100 cells) were injected i.m. into the left leg of
NOD/Scid mice. All mice injected with 10
5
 (n = 3) and 10
4
 (n = 4) cells developed tumors (Fig. 3A) and
after about 80 days post-injections also 3 out of 5 mice injected with only 100 cells formed tumors (Fig. 
3A). Immunohistochemical analysis of the xenografts confirmed aRMS diagnosis, with the typical 
small blue round cell morphology and the expression if the skeletal muscle markers MYOGENIN and 
DESMIN (Supplemental Fig. 5A). In order to clarify whether each aRMS cell possesses tumorigenic 
potential we performed clonal analysis. RH30 cells expressing EGFP were plated with a dilution of 0.5 
cells/100µl into several 96 well plates and the following day each well was analyzed for the presence 
of one single cell expressing EGFP. Sixteen clones were expanded and analyzed for their 
heterogeneous gene expression by qRT-PCR. PAX3-FOXO1 and several target genes as well as the 
stem cell factors and differentiation markers were differentially expressed between the clones (Fig. 
3B), confirming their heterogeneous clonal origins. Based on these data we selected 8 clones for 
testing their tumorigenic potential in immunocompromised mice, which were also highly divergent in 
their gene expression profiles. 5x10
4
 cells for each clone were injected i.m. into the left leg of
NOD/Scid mice (n = 4). After a period of time varying between 40 and 140 days post-injection all mice 
developed tumors (Fig. 3C and Supplemental Fig. 5B). To prove that each clone had the capability to 
self-renew and to propagate the tumors, we selected six primary tumors for generating secondary 
xenografts. Dilutions with 1x10
4
 primary xenograft cells were prepared and injected i.m. in NOD/Scid
mice. Once more after a period varying between 50 and 100 days post-injection all clones generated 
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secondary tumors (Fig. 3C and Supplemental Fig. 5C). Immunohistochemical analysis of primary and 
secondary xenografts confirmed aRMS histology (Fig. 3D). Interestingly, xenografts originating from 
different clones showed variable expression of the aRMS markers MYOGENIN and DESMIN (Fig. 
3D), highlighting dissimilar levels of differentiation and confirming their heterogeneous origin.  
In conclusion, we demonstrated that 100 cells are sufficient for generating aRMS tumors in 
immunocompromised mice. Moreover, all clones had equal tumor potential, implying that aRMS arise 
from stochastic rather than hierarchical differentiation processes.  
In the presence of c-MYC PAX3-FOXO1 enhances reprogramming efficiency of human 
fibroblasts 
The fact that each aRMS cells possess equal tumorigenic potential together with the observations that 
PAX3-FOXO1 is the key regulator of aRMS cell maintenance, we hypothesized that PAX3-FOXO1 
itself might confer stem cell properties to all aRMS cells. We therefore investigated whether PAX3-
FOXO1 can contribute to reprogramming differentiated cells into iPSC. For this purpose human fetal 
fibroblast (HFF) were transduced with retroviruses separately encoding human OCT4, KLF4, SOX2, 
and c-MYC along with either EGFP (control iPSC) or PAX3-FOXO1 (PAX3-FOXO1 iPSC). Gene 
expression analysis five days post-infection revealed upregulation of the pluripotency factors NANOG, 
REXO1, and DNMT3β  as well as of PAX3-FOXO1 and its target gene AP2β (Supplemental Fig. 6A). 
Around 14 days post-transduction iPSC colonies began to arise in the control cells as well as in the 
PAX3-FOXO1 cells and the total number of iPSC-like colonies was quantified. Interestingly, PAX3-
FOXO1 transduced cells generated about 45% more iPSC colonies than the control cells (Fig. 4A), 
indicating that the fusion protein increases the reprogramming efficiency. Morphology of the iPSC 
colonies was similar in both cell types and showed the classical round and compact shape of 
undifferentiated embryonic stem-like cells (Fig. 4B). Both control and PAX3-FOXO1 iPSC were 
positive for the pluripotency markers NANOG, OCT4, SSEA4, and TRA60, confirming that both cell 
types were true iPSC (Fig. 4C and Supplemental Fig. 6B).  
We next assessed whether PAX3-FOXO1 could replace one or more reprogramming factors. A known 
target gene of PAX3-FOXO1 is the proto-oncogene n-MYC. This gene shares cellular functions with 
the family member c-MYC. Since reprogramming with three factors in the absence of c-MYC is 
sufficient for generating iPSC, although with lower efficiency, we hypothesized that replacing c-MYC 
with PAX3-FOXO1 might re-establish the original efficiency obtained in the presence of c-MYC. Five 
days post-transduction PAX3-FOXO1 and AP2β were strongly upregulated in the transduced cells, 
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confirming transcriptional activity of PAX3-FOXO1 (Supplemental Fig. 7A). On the contrary no strong 
upregulation of the stem cell genes was observed (Supplemental Fig. 7A). Moreover, iPSC colonies 
appeared only 30 days post-transduction. Although the overall efficiency in the absence of c-MYC was 
much lower than the cells reprogrammed with c-MYC; the control cells generated slightly more 
colonies compared to the cells transduced with the chimeric oncogene (Supplemental Fig. 7B). Thus, 
we hypothesized that the simultaneous expression of PAX3-FOXO1 and c-MYC might have 
synergistic effects during reprogramming and that PAX3-FOXO1 alone cannot replace c-MYC.  
Reprogramming with PAX3-FOXO1 and the combination of only two reprogramming factors (OCT4-
SOX2, OCT4-KLF4, KLF4-SOX2) never generated iPSC-like colonies (data not shown), indicating that 
PAX3-FOXO1 cannot substitute OCT4, SOX2, KLF4, or c-MYC but it increases the efficiency of 
reprogramming in the presence of all four factors.  
PAX3-FOXO1 prevents differentiation of iPSC 
Single iPSC colonies obtained from the transduction with the four reprogramming factors plus PAX3-
FOXO1 were clonally expanded. Clone number 1 showed genomic integration of PAX3-FOXO1 
transgene and a strong expression of the oncogene as well as of AP2β (Fig. 4D), confirming 
transcriptional activity. Three other clones (clone 5, 6, and 25) showed neither genomic integration nor 
expression of PAX3-FOXO1 (Fig. 4D) and were therefore selected as control (wild type) iPSC. The 
expression of AP2β was varying between the wild type clones but was much lower than in clone 1 
(Fig. 4D). The pluripotency markers NANOG, DNMT3β, OCT4, and SSEA4 were expressed in wild 
type and PAX3-FOXO1 clones at very high levels (Fig. 4E-F and Supplemental Fig. 8). Additionally, 
PAX3-FOXO1 cells co-expressed together with the pluripotency markers also the target gene AP2β 
(Fig. 4F). Thus, having confirmed the undifferentiated state of the iPSC clones we investigated their 
pluripotent potential in vitro as well as in vivo. PAX3-FOXO1 clone 1 and the wild type clone 6 (control) 
were selected for in vitro differentiation into the three germ layers. Embryoid bodies (EB) were 
generated with control and PAX3-FOXO1 iPSC (Fig. 5A) and were analyzed for their differentiation 
level. The endodermal markers GATA4 and AFP were strongly upregulated in control EB whereas 
their expression was undetectable in PAX3-FOXO1 EB (Fig. 5B). Similar results were obtained for the 
mesodermal markers PAX7 and MSX1, which were strongly upregulated in the control EB and barely 
expressed in PAX3-FOXO1 EB (Fig. 5B). Control EB also showed higher expression of the 
ectodermal markers PAX6, SOX1, and DCX (Fig. 5B). Nevertheless, the pluripotency markers 
NANOG and DNMT3β were in both control and PAX3-FOXO1 EB downregulated, whereas the 
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oncogene and its target gene AP2β were still highly expressed exclusively in the PAX3-FOXO1 EB 
(Supplemental Fig. 9A). These data indicate that PAX3-FOXO1 expression interferes with the ability of 
iPSC cells to differentiate towards the three germ layers.  
In order to prove whether the oncogene can also block terminal differentiation, control and PAX3-
FOXO1 iPSC were differentiated into muscle cells (mesoderm), pancreatic cells (endoderm), and 
neurons (ectoderm). Differentiation levels were thereafter assessed by qRT-PCR and by 
immunofluorescence. When iPSC were differentiated into muscle cells, wild type cells migrated out 
from the attached EB and formed single layers as well as myofiber-like clusters (Supplemental Fig. 
9B). On the contrary, much less PAX3-FOXO1 cells migrated out and no myofiber-like clusters were 
visible after 14 days of differentiation (Supplemental Fig. 9B). Expression of the fusion protein as well 
as of AP2β was still high (Supplemental Fig. 9C). After 3 additional weeks of culture with reduced 
serum multinucleated myofibers were visible exclusively in the control cells (Fig. 5C). Analysis of 
mesodermal and muscle differentiation markers confirmed strong upregulation in the control cells but 
not in the PAX3-FOXO1 cells (Fig. 5D), whereas the oncogene and its target gene were exclusively 
expressed in PAX3-FOXO1 cells (Supplemental Fig. 9D). Thus, similarly like in aRMS tumor cells 
PAX3-FOXO1 impairs mesodermal differentiation and blocks terminal muscle differentiation in iPSC.  
For endodermal differentiation, control cells showed cytosolic expression of AMYLASE (Fig. 5E) and 
strong upregulation of GATA4 and AFP (Fig. 5F). Interestingly, PAX3-FOXO1 differentiated cells had 
different morphology compared to the control cells being much smaller and round shaped (Fig. 5E). 
The expression of the endoderm markers GATA4 and AFP was reduced compared to the 
differentiated control cells but AMYLASE was similarly expressed in both clones (Fig. 5F). PAX3-
FOXO1 cells still expressed high levels of the transgene and of AP2β (Supplemental Fig. 9E). Thus, 
these data show for the first time that PAX3-FOXO1 can block endodermal differentiation in iPSC.  
During neural differentiation, wild type cells migrated out from the attached EB and generated many 
mature neurons and glia cells (Fig. 5G). On the contrary, much less PAX3-FOXO1 cells migrated out 
and formed neurons (Fig. 5G). Expression analysis of neural differentiation markers like PAX6, SOX1, 
and DCX confirmed higher expression in the control cells and reduced expression in the PAX3-
FOXO1 cells (Fig. 5H and Supplemental Fig. 9F). These data indicate that PAX3-FOXO1 interferes 
also with ectodermal differentiation and blocks neural differentiation of iPSC.  
In conclusion, despite the expression of all the pluripotency markers, PAX3-FOXO1 iPSC are 
surprisingly not able to differentiate into derivatives of all the three germ layers. In order to further 
prove that, undifferentiated iPSC were injected into immunocompromised mice for generating 
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teratomas. iPSC of the wild type clones 6, 5, and 25 and PAX3-FOXO1 positive clone 1 were injected 
either subcutaneously or i.m. in NOD/Scid mice. After a period of about 10 weeks post-injections 
teratomas were isolated and analyzed for their differentiation levels. Independent from the site of 
injection, teratomas generated from the three control clones presented derivatives of the three germ 
layers (Fig. 6A), confirming the pluripotent potential of the iPSC. For instance we observed in the 
control teratomas glands with intestinal type mucosa and colon crypt (both endodermal origin), 
squamous epithelium (ectoderm), and bones, cartilage, and smooth muscle (all mesodermal tissues) 
(Fig. 6A). On the contrary, PAX3-FOXO1 expressing cells generated homogeneous tumors with plump 
to spindle like cells and frequent mitotic figures, indicating an undifferentiated tumor type (Fig. 6B). 
qRT-PCR confirmed the expression of PAX3-FOXO1 in the tumor as well as the expression of 
AP2β (Fig. 6C). Independently from the location of the tumor (subcutaneous or intra muscular), all 
PAX3-FOXO1 tumors showed homogeneous high expression of AP2β whereas all controls showed 
only sporadic expression of the gene (Fig. 6D and Supplemental Fig 10A). Moreover, in line with a 
less differentiated state all PAX3-FOXO1 tumors were highly proliferative and were homogeneously 
positive for the proliferation marker MIB1, whereas all control tumors showed less proliferative state 
(Fig. 6E and Supplemental Fig 10B).  
Discussion 
Our study demonstrates that aRMS develop and progress via stochastic rather than hierarchical 
differentiation processes. It was already reported that the fusion oncogene PAX3-FOXO1 ensures 
aRMS cells survival 
2, 3, 14
 and hence its expression and transcriptional activity is crucial. Here we
report for the first time that the fusion protein not only controls survival processes, but can also confers 
stem cell-like properties since it could contribute to reprogramming human fibroblasts. Moreover, we 
demonstrate that the differentiation inhibitory effect of PAX3-FOXO1 on the iPSC system is not 
restricted to the mesoderm lineage like in aRMS, but also to the endodermal and ectodermal lineages.  
Rhabdomyosarcoma is the most common soft tissue cancer in childhood. Especially for the 
translocation positive aRMS the survival rates are low, and in cases of recurrence the disease is 
almost always fatal. Therefore, establishment of novel therapies is necessary for improving clinical 
outcome of aRMS patients. To this end, a fundamental and complex question in cancer research is to 
understand whether tumor heterogeneity arises from clonal evolution or from hierarchical evolution. 
We previously demonstrated that the fusion negative eRMS possess a small subpopulation of cells 
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with stem cell-like potential 
50
. These cells were positive for the CSC marker CD133 and generated
spheres, which were enriched for CSC as proved by the expression of the core stem cell factors and 
by the in vivo enhanced tumorigenic potential 
50
. Three out of four CSC markers analyzed in this study
were either highly abundant in the entire population or not expressed at all. Only ALDH1 distinguished 
a small subpopulation in all investigated cell lines. However, a conventional requirement for CSC is to 
be able to self-renew and generate identical and tumorigenic progeny but also to asymmetrically 
divide and give rise to non-tumorigenic cells. The ALDH1 high aRMS cells did not fulfill this 
prerequisite, thus indicating their non-CSC state. Another approach often used for identifying CSC is 
the sphere assay, which was employed in several cancers and among them also in eRMS 
50
. We
examined four different compositions of sphere media and among them also the one employed for 
eRMS spheres (data not shown) but only in the medium used in this study all aRMS cells formed 
spheres, which were able to self-renew for a prolonged period of time. Nevertheless, no enrichment of 
CSC and therefore no upregulation of the core stem cell genes was observed in the spheres when 
compared to cells cultured under standard conditions. In sum, aRMS cells highly express some CSC 
marker and are able to propagate under stem cell-like conditions. These observations lead to the 
hypothesis that aRMS possess high percentage of cells with tumor initiating potential. Limiting dilution 
and clonal analysis experiments performed in immunocompromised mice confirmed that 100 aRMS 
cells are sufficient for generating tumors and moreover all analyzed clones possess tumorigenic 
potential despite their heterogeneous origin. Thus, the in vitro and in vivo experiments reinforced the 
notion that aRMS in contrary to eRMS follow the clonal evolution model in which not only an exclusive 
subpopulation of cells but rather the entire population can propagate the tumor.  
The core stem cell factors NANOG, OCT4, and SOX2 were reported in several tumors to be involved 
in promoting tumorigenesis, mainly acting on the regulation of the CSC population 
22, 29
. In numerous
malignancies high expression of these stem cell factors is associated with poor outcome 
20, 41, 48
. On
the other side, their ablation correlates with a decrease in the CSC population and a consequent 
reduction in the tumorigenic potential 
9, 17, 55
. Interestingly, aRMS cells homogeneously express the
core stem cell genes, although at very low level if compared to ESC and iPSC. Nevertheless, contrary 
to all other cancer types, silencing of the pluripotency factors in aRMS cells never influenced biological 
processes nor altered the expression of the chimeric protein or its target genes. Surprisingly, 
overexpression of NANOG, OCT4, and SOX2 did not induce de-differentiation of the cells like it was 
observed for instance for melanoma cells 
28
 but on the contrary it reduced the ability of aRMS cells to
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form clones and spheres. Hence, forced expression of the stem cell genes did not confer enhanced 
stemness properties, but rather it reduced them, highlighting a gene dosage effect. In contrast to the 
pluripotency genes, as already reported 
14, 26
, downregulation of PAX3-FOXO1 immediately resulted in
a strong upregulation of muscle differentiation factors, cell cycle arrest, and later apoptosis. Thus, 
PAX3-FOXO1 and not the stem cell factors is the key regulator in aRMS.  
Due to the fact that silencing of the chimeric protein in aRMS cells results in cell death, a more 
permissive cell system is needed for better studying the function of PAX3-FOXO1. Ectopic expression 
of the chimeric protein is highly cell context-dependent. It was reported that high levels of PAX3-
FOXO1 in immortalized mouse fibroblasts causes cell death 
52
 whereas high expression induces 
transformation in immortalized human myoblasts but only in combination with N-MYC 
53
. Thus, finding
the right context in which PAX3-FOXO1 can be studied is an urgent but challenging goal. Pluripotent 
iPSC possess a differentiation spectrum, which extends to all type of cells of the body, without 
restrictions. We therefore reasoned that the iPSC system could be used for better understanding the 
role of PAX3-FOXO1. Interestingly, we proved that not only is it possible to generate iPSC in the 
presence of the chimeric protein without inducing cell death, but its presence in collaboration with the 
four reprogramming factors enhances the efficiency of generating iPSC. Also, PAX3-FOXO1 could not 
replace one or more reprogramming factors, but showed an effect only in the presence of all four 
factors. These data highlight once more the context dependent influence of the chimeric protein. 
Further analyses during reprogramming processes are needed for determining which mechanisms 
and which PAX3-FOXO1 target genes contribute to the increased reprogramming efficiency. 
Nevertheless, these data confirm the stemness potential of PAX3-FOXO1. Additionally this system 
offers the opportunity to study processes which are very close to the early events of cancer 
progression and therefore it could facilitate the identification of early biomarkers or novel therapeutic 
pathways active in the initial stages of the disease.  
Also confirming that iPSC represent a good model for studying the chimeric protein is the fact that 
PAX3-FOXO1 iPSC showed another typical aRMS feature: impaired differentiation potential. The 
fusion protein inhibited mesodermal differentiation and specifically skeletal muscle differentiation as 
already known for aRMS cells 
8, 51
. We could further demonstrate for the first time that PAX3-FOXO1
can block also ectodermal and endodermal differentiation. Therefore it is possible that PAX3-FOXO1 
guides processes involving complex networks of transcription factors and chromatin remodeling 
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proteins which finally lead to the activation or repression of tissue specific genes that are not only 
restricted to the mesodermal lineage. Corroborating this observation is also the fact that in vivo, once 
injected into immunocompromised mice, PAX3-FOXO1 iPSC generated highly undifferentiated and 
proliferating tumors. Nevertheless, these tumors were not aRMS tumors. Although, they still highly 
expressed the chimeric protein and its target gene AP2β, other aRMS specific markers like DESMIN 
and MYOGENIN were not detected. Genome wide analyses of these tumors are needed to elucidate 
their similarity to primary aRMS tumors and xenografts.  
In conclusion, expanding the knowledge about PAX3-FOXO1 biology is an essential step for 
developing effective therapies for aRMS. Here for the first time we demonstrate that the iPSC system 
represents, in the absence of the aRMS cell of origin, an optimal strategy for studying tumor 
development and maintenance, which could be extended to other fusion-positive tumors.  
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Figure legends 
Figure 1:  
No subpopulations of cancer stem cells in aRMS cell lines 
(A) Sphere assay with RH4 line cultivated in sphere medium supplemented with bFGF or with bFGF, 
EGF, and PDGF (ALL) over several passages. Percentage of cells forming spheres was calculated at 
each passage (left panel). Expression of NANOG, OCT4, and SOX2 in spheres at passage 3, 4, and 5 
compared to RH4 cells cultured as a monolayer (right panel). (B-C-D) Flow cytometry analysis of the 
CSC markers CD133 (antibody for epitope 1 and for epitope 2), CD44, and CXCR4 in aRMS cell lines. 
(E) Aldefluor assay and flow cytometry analysis for ALDH1 high cells in aRMS cell lines. (F) ALDH1 
distribution of sorted ALDH1 high, low, and mixed population (control) from RH30 cell line after 10 
days of culture. At day 3, 6, and 10 the percentage of ALDH1 positive cells was analyzed with 
Aldefluor assay and flow cytometry. (G) Expression analysis of sorted ALDH1 high cells compared to 
sorted ALDH1 low cells for the indicated genes. (H-I) Sphere assay with RH30 sorted ALDH1 high, 
low, and control fractions. Cells were cultured at clonal density in ALL-sphere medium and primary 
sphere formation (H) as well as self-renewal ability over 4 passages (I) was quantified. (J) ALDH1 
analysis in RH30 cells after 72h of drug selection with Vincristine, Actinomycin D, and Mafosfamide. 
Viable cells were analyzed for ALDH1 activity by flow cytometry.  
Figure 2:  
aRMS cells express the core stem cell factors but only differential expression of PAX3-FOXO1 
affects aRMS cellular physiology.  
(A) Immunofluorescence for NANOG, OCT4, and SOX2 in RH3 cell line. (B) RNA expression analysis 
for the indicated genes upon 72h of SOX2 silencing with three specific siRNAs in RH3 and RH4 cell 
lines. Fold changes are calculated compared to cells treated with scrambled siRNA. Knockdown with 
siRNA 3-siSOX2 was confirmed at protein level (siSc = siScrambled; siS = 3-siSOX2). (C) RNA 
expression analysis for the indicated genes upon 72h of silencing of PAX3-FOXO1 in RH3 and RH4 
cell lines. Fold changes are calculated compared to cells treated with scrambled siRNA. (D) Cell 
viability measurements (WST-1 assay) upon 48h and 72h of knockdown of PAX3-FOXO1 (siP3F), 
NANOG, OCT4, and SOX2 in RH4 cells. Percentage of viable cells was calculated compared to 
scrambled cells (siScr). (E) Cell proliferation assay (BrdU incorporation) after 48h and 72h of PAX3-
FOXO1, NANOG, OCT4, and SOX2 knockdown in RH4 cells. (F) Flow cytometric analysis of RH4 cell 
cycle distributions using propidium iodide (PI) upon silencing of PAX3-FOXO1 (siP3F), NANOG, 
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OCT4, and SOX2 for the indicated time. (G) RNA expression analysis for the indicated genes in RH4 
cell lines stably overexpressing EGFP (control), NANOG, OCT4, SOX2, or the three stem cell genes 
simultaneously (NOS). Fold changes are calculated compared to EGFP control line. (H) Proliferation 
assay (BrdU incorporation) in RH4 transgenic lines overexpressing the stem cell genes. Percentages 
are calculated relative to EGFP control line. (I) Clonogenic assay with RH4 transgenic cell lines 
overexpressing the stem cell genes. Clones were stained with crystal violet and quantified. (J) Primary 
sphere formation with transgenic RH4 cell lines overexpressing the stem cell genes. (K) Sphere assay 
with RH4 lines overexpressing the stem cell genes. (unpaired t-test, *** p<0.0005; ** p<0.005, 
*p<0.05) 
 
Figure 3:  
High frequency of tumor initiating cells in aRMS cell lines 
(A) In vivo limiting dilution with RH30 cell line. 10
5
 (n=3), 10
4
 (n=4), and 100 cells (n=5) were injected 
intramuscularly (i.m.) into the left leg of NOD/Scid mice. Tumor growth was monitored over a period of 
180 days. (B) Heat map of qRT-PCR of total RNA relative to GAPDH from RH30 clones generated 
from one cell. Sixteen clones were analyzed for the expression of the indicated genes. Scale bar ln(2
-
∆Ct). (C) Generation of primary and secondary xenografts with 8 selected RH30 clones. For primary 
xenograft generation 5x10
4
 cells were injected i.m into the left leg of NOD/Scid mice (n=4). Single cell 
suspensions (10
4
 cells) of primary tumors were injected i.m into mice (n=2) for secondary tumor 
formation. (D) Immunohistochemical staining of primary (I) and secondary (II) xenograft sections of 
four clones. Tumors were stained with H&E and the aRMS markers MYOGENIN and DESMIN.  
 
Figure 4:  
PAX3-FOXO1 enhances generation of induced pluripotent stem cells  
(A) Quantification of colonies of iPSC generated from human fibroblast (HFF) transduced with the four 
Yamanaka’s factors plus either PAX3-FOXO1 or EGFP (control). (B) Representative image of control 
and PAX3-FOXO1 iPSC colony. (C) Immunofluorescence of control and PAX3-FOXO1 iPSC for the 
pluripotency markers OCT4, SSEA4 (upper panel) and NANOG, TRA60 (lower panel). Nuclei were 
counterstained with Hoechst (blue). Total amount of single or double positive colonies was quantified 
(right panel). (D) RNA expression of PAX3-FOXO1 and AP2β in iPSC clone 1, clone 5, 6, and 25 
(upper panel) compared to HFF prior transduction. Genomic PCR (lower panel) for PAX3-FOXO1 in 
the same clones (+ = positive control, - = negative control). (E) Expression analysis compared to HFF 
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for pluripotency factors NANOG and DNMT3in PAX3-FOXO1 clone 1 and in the wild type clones 5, 
6, and 25. (F) Immunofluorescence of the pluripotency marker SSEA4 and for PAX3-FOXO1 target 
gene AP2β in wild type clone 6 and in PAX3-FOXO1 clone 1. Nuclei were counterstained with 
Hoechst. (unpaired t-test, * p< 0.05) 
Figure 5:  
PAX3-FOXO1 blocks in vitro differentiation of iPSC 
(A) Representative image of embryoid bodies (EB) generated from wild type clone 6 iPSC (control) 
and from PAX3-FOXO1 expressing clone 1 (5x magnification). (B) Expression analysis of the 
indicated differentiation markers for endoderm, mesoderm, and ectoderm in EB. Fold changes are 
calculated compared to undifferentiated iPSC from wild type clone 6. (C-D) Muscle differentiation: 
representative picture of muscle differentiating cells (C). Arrows indicate multinucleated myoblasts. 
Cells are counterstained with Hoechst and PHALLOIDIN. qRT-PCR analysis for mesoderm and 
muscle differentiation markers (F) after 14 days of culture with 15% serum (+ FBS) and after 
additionally 21 days of culture with 1% serum (-FBS). (E-F) Endoderm differentiation: 
immunofluorescence staining for the pancreatic marker AMYLASE (E). Cells are counterstained with 
Hoechst and PHALLOIDIN. qRT-PCR analysis for endoderm markers (F) for control and PAX3-
FOXO1 differentiated cells compared to undifferentiated iPSC clone 6. G-H Neural differentiation: 
immunofluorescence staining for GFAP and 3βTUBULIN for differentiated control and PAX3-FOXO1 
cells (G). qRT-PCR analysis for ectodermal and neural differentiation markers (H) for control and 
PAX3-FOXO1 differentiated cells compared to undifferentiated iPSC clone 6. 
Figure 6:  
PAX3-FOXO1 iPSC generate undifferentiated and highly proliferative teratomas 
(A) Histological analysis of teratomas generated after subcutaneously (s.c) injections of 1x10
6
 iPSC
from control clones 6, 5, and 25. Sections were stained with H&E. Represented are derivatives of the 
three germ layers. ( endoderm, * mesoderm, ° ectoderm). (B) Histological analysis of teratoma 
generated from s.c. injections of 1x10
6
 iPSC from PAX3-FOXO1 clone 1. Sections were stained with
H&E. Represented are three magnifications of the tumor. (C) qRT-PCR of total RNA relative to 
undifferentiated clone 6 iPSC for PAX3-FOXO1 and its target gene in control and PAX3-FOXO1 
teratomas. (D) Immunohistochemical staining for AP2in control and PAX3-FOXO1 teratomas. (E) 
Immunohistochemical analysis of proliferation marker MIB1 in control and PAX3-FOXO1 teratoma. (F) 
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Tumor growth analysis of control clone 6 iPSC and PAX3-FOXO1 iPSC. 3x10
6
 cells were injected s.c. 
and tumor growth was weekly monitored. 
 
SUPPLEMENTAL FIGURES 
Supplemental figure 1: 
No CSC enrichment in spheres generated from RH30 and RMS13 aRMS cell lines 
(A-B) Sphere assay with RH30 (A) and RMS13 (B) cell lines cultivated at clonal dilution in sphere 
medium supplemented with bFGF or with bFGF, EGF, and PDGF (ALL) over several passages. 
Percentage of cells forming spheres was calculated at each passage (left panel). Expression of 
NANOG, OCT4, and SOX2 was analyzed by qRT-PCR from total RNA of spheres at passage 3, 4, 
and 5 and compared with the same cell lines cultured as a monolayer (right panel).  
 
Supplemental figure 2: 
Sorting of ALDH1 high and ALDH1 low fraction  
(A) RH30 cells were stained with Aldefluor kit and ALDH1 high, low, and mixed population (control) 
were sorted by FACS. In black are depicted cells treated with DEAB, which were used for set up the 
gating.  
 
Supplemental figure 3: 
Expression of ESC genes in aRMS cell lines 
(A-B-C) Immunofluorescence for the stem cell genes NANOG (A), OCT4 (B), and SOX2 (C) in 7 
aRMS cell lines (upper panel). Basal level RNA expression relative to GAPDH for the stem cell genes 
in the indicated aRMS cell lines (lower panel).  
 
Supplemental figure 4: 
Characterization of aRMS cell lines overexpressing ESC genes 
(A) Western blot analysis for RH4 and RH30 cell lines stably overexpressing NANOG, OCT4, SOX2, 
or the three genes simultaneously (NOS). The embryonic carcinoma line NTERA-2 was used as a 
positive control. (GFP = EGFP cell line, N = NANOG overexpressing cell line, O = OCT4 
overexpressing cell line, S = SOX2 overexpressing cell line, NT2 = NTERA-2). (B) RNA expression 
analysis for the indicated genes in RH30 cell lines stably overexpressing EGFP (control), NANOG, 
OCT4, SOX2, or NOS. Fold changes are calculated compared to the EGFP control line. (C) 
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Proliferation assay (BrdU incorporation) for RH30 transgenic lines overexpressing the stem cell genes. 
Percentages are calculated compared to EGFP control line. (D) Clonogenic assay with RH30 
transgenic cell lines overexpressing the stem cell genes. Clones were stained with crystal violet and 
quantified. (E) Primary sphere formation with transgenic RH30 cell lines overexpressing the stem cell 
genes. (F) Sphere assay with RH30 transgenic lines overexpressing the stem cell genes. At each 
passage the number of spheres was quantified. (unpaired t-test, * p<0.01, ** p<0.05, ***p<0.0005) 
Supplemental figure 5: 
Alveolar Rhabdomyosarcoma follows the clonal evolution model 
A Immunohistochemical analysis of xenografts generated from RH30 cell lines after injection of 10
5
,
10
4
, and 100 cells. Tumors were stained with H&E and the aRMS markers MYOGENIN and DESMIN.
B-C Tumor growth of clones generated from one RH30 cell. For primary xenograft generation (B) 
NOD/Scid mice (n=4) were injected with 5x10
4 
cells. For secondary xenograft generation (C)
NOD/Scid mice (n=2) were injected with 1x10
4 
cells.
Supplemental figure 6: 
PAX3-FOXO1 increases reprogramming efficiency of human fibroblast 
(A) Gene expression analysis for the indicated genes 5 days post-transduction of human fibroblast 
(HFF) with OCT4, SOX2, KLF4, c-MYC, and either PAX3-FOXO1 or EGFP (control). Fold changes 
are calculated compared to HFF before transduction. (B) Immunofluorescence staining and 
quantification for the pluripotency factors NANOG, SSEA4 (upper panel) and OCT4, TRA60 (lower 
panel) in control and PAX3-FOXO1 iPSC. Nuclei were counterstained with Hoechst.  
Supplemental figure 7: 
PAX3-FOXO1 increases reprogramming efficiency of human fibroblast only in the presence of 
c-MYC 
(A) Gene expression analysis for the indicated genes 5 days post-transduction of human fibroblast 
(HFF) with OCT4, SOX2, KLF4, and either PAX3-FOXO1 or EGFP (control). Fold changes are 
calculated compared to HFF before transduction. (B) Quantification of induced pluripotent stem cell 
(iPSC) colonies in fibroblast transduced with OCT4, SOX2, KLF4, and either EGFP (control) or PAX3-
FOXO1. (unpaired t-test, * p<0.05) 
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Supplemental figure 8: 
Wild type and PAX3-FOXO1 clones express NANOG and OCT4 
(A-B) Immunofluorescence analysis for OCT4 (A) and NANOG (B) in wild type iPSC (clone 5, 6 and 
25) and in PAX3-FOXO1 expressing clone 1. Nuclei were counterstained with Hoechst.
Supplemental figure 9: 
PAX3-FOXO1 transgene is expressed in differentiating iPSC 
(A) qRT-PCR for pluripotency markers, PAX3-FOXO1 and AP2β in embryoid bodies (EB). Fold 
changes are calculated compared to undifferentiated iPSC from wild type clone 6. (B) Representative 
image of attached EB cultured for 14 days in muscle differentiation medium supplemented with FBS. 
(C-D) qRT-PCR for PAX3-FOXO1 and AP2 in cells cultured either for 14 days under muscle 
differentiation conditions in the presence of serum (C) or for additional 21 days in the absence of 
serum (D). Fold changes are calculated compared to undifferentiated iPSC from wild type clone 6. (E) 
qRT-PCR for PAX3-FOXO1 and its target gene in cells differentiated towards endoderm lineages. 
Fold changes are calculated compared to undifferentiated iPSC from wild type clone 6. (F) qRT-PCR 
for PAX3-FOXO1 and its target gene AP2β after neural differentiation.  
Supplemental figure 10: 
PAX3-FOXO1 tumors express AP2β and are highly proliferating 
(A) Immunohistochemical analysis for AP2β expression in wild type teratomas (clone 5 and 6) and 
PAX3-FOXO1 clone 1 tumors injected either subcutaneously (s.c.) or intramuscularly (i.m.). For PAX3-
FOXO1 clone 1 i.m. two tumors are showed isolated from two mice marked as left (L) and right (R). 
(B) Immunohistochemical staining fro the proliferation marker MIB1 in control teratomas and PAX3-
FOXO1 clone 1 tumors. 
AFIGURE 1
B
E
I
J
ns
%
of
ce
lls
fo
rm
in
g
sp
he
re
s
RH4 cell line
passages
RH4 sphere NANOG
Fo
ld
in
cr
ea
se
passages
RH4 sphere OCT4
Fo
ld
in
cr
ea
se
passages
RH4 sphere SOX2
Fo
ld
in
cr
ea
se
passages
%
of
C
D
13
3
+
ce
lls
%
of
C
X
C
R
4
+
ce
lls
C D
%
of
C
D
44
+
ce
lls
%
of
A
LD
H
1
hi
gh
ce
lls
F ALDH1 control
%
of
A
LD
H
1
hi
gh
ce
lls
ALDH1 high fraction
%
of
A
LD
H
1
hi
gh
ce
lls
ALDH1 low fraction
%
of
A
LD
H
1
hi
gh
ce
lls
G H
Fo
ld
ch
an
ge
(h
ig
h
vs
lo
w
fra
ct
io
n)
%
of
ce
lls
fo
rm
in
g
sp
he
re
s
%
of
ce
lls
fo
rm
in
g
sp
he
re
s
FIGURE 2
A
mergedSox2 DAPI
Nanog mergedDAPI
Oct4 DAPI merged
RH3
100µm
100µm
100µm
RH3 cell line
Fo
ld
ch
an
ge
B
RH4 cell line
siScrambled 72h
1-siSOX2 72h
3-siSOX2 72h
2-siSOX2 72h
Fo
ld
ch
an
ge
siSsiScsiSsiSc
RH4 RH3
So
x2
Tu
b
C
RH3 cell line RH4 cell line
siScrambled 72h siPax3-Foxo1 72h
Fo
ld
ch
an
ge
Fo
ld
ch
an
ge
D
PI staining
ce
llc
ou
nt
siP3F (24h) siP3F (72h)siP3F (48h)scrambled
RH
4
ce
lll
in
e
scrambled (72h) siSox2 (72h)siOct4 (72h)siNanog (72h)
RH
4
ce
lll
in
e
F
%
of
pr
ol
ife
ra
tin
g
ce
lls
%
of
vi
ab
le
ce
lls
E
RH4 cell line
RH4 cell line
48h 72h
48h 72h
G
KJ
Fo
ld
ch
an
ge
RH4 cell line
%
of
pr
ol
ife
ra
tin
g
ce
lls
H RH4 cell line RH4 cell line
N
um
be
ro
fc
lo
ne
s
I
EGFP Nanog Sox2Oct4 NOS
N
um
be
ro
fs
ph
er
es
N
um
be
ro
fs
ph
er
es
RH4 cell line RH4 cell line
***
**
*
***
****
**
*****
II
clone
16
desminmyogeninH&E
I
clone
1
50 µm
II
I
II
I
clone
9
II
I
clone
8
A
days postinjection
Tu
m
or
vo
lu
m
e
(m
m
3 )
3/3 4/4
3/5
10
5
10
4
100
D
B
0 2-2
ln (2-∆Ct)
C
FIGURE 3
NANOG
OCT4phase SSEA4 merged
100 µm
OCT4phase SSEA4 merged
100 µm
co
nt
ro
l
P
ax
3-
Fo
xo
1
100 µm
NANOG TRA60 mergedphase
100 µm
NANOG TRA60 mergedphase
co
nt
ro
l
P
ax
3-
Fo
xo
1
BA
C
control Pax3-Foxo1
200 µm
D
+ 1 5 6 25 + -P3F
408bp
Fo
ld
ch
an
ge
(r
el
to
H
FF
)
PAX3-FOXO1 AP2β
Fo
ld
ch
an
ge
(r
el
to
H
FF
)
Fo
ld
ch
an
ge
(r
el
to
H
FF
)
Fo
ld
ch
an
ge
(r
el
to
H
FF
)
DNMT3βE
co
nt
ro
l
C
LO
N
E
6
P
ax
3-
Fo
xo
1
C
LO
N
E
1
AP2βphase SSEA4 Hoechst merged
AP2βphase SSEA4 Hoechst merged
100 µm
100 µm
F
1 100 µm
FIGURE 4
clones clones clonesclones
actin
GFAP merged / hoechst3βTUB
GFAP merged / hoechst3βTUB
200 µm
200 µm
co
nt
ro
l
C
LO
N
E
6
P
ax
3-
Fo
xo
1
C
LO
N
E
1
neural diff Pax3-Foxo1 clone 1
neural diff control clone 6
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
G H
amylase hoechst / amylase merged / phalloidin
50 µm
co
nt
ro
l
C
LO
N
E
6
P
ax
3-
Fo
xo
1
C
LO
N
E
1
iPSC control clone 6
endoderm diff Pax3-Foxo1 clone 1
endoderm diff control clone 6
amylase hoechst / amylase merged / phalloidin
50 µm
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
FE
5x
5x
A
co
nt
ro
l
C
LO
N
E
6
P
ax
3-
Fo
xo
1
C
LO
N
E
1
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
ENDODERM MESODERM ECTODERM
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6) iPSC control clone 6
EB Pax3-Foxo1 clone 1
EB control clone 6
co
nt
ro
l
C
LO
N
E
6
P
ax
3-
Fo
xo
1
C
LO
N
E
1
phase phase / hoechst merged / phalloidin
phase phase / hoechst merged / phalloidin
C
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
+ FBS
100 µm
100 µm
D
muscle diff Pax3-Foxo1 clone 1
muscle diff control clone 6
FIGURE 5
B
- FBS
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
teratoma P3F clone 1 s.c.
teratoma P3F clone 1 i.m.
teratoma control clone 6 s.c.
teratoma control clone 6 i.m.
FIGURE 6
A
200µm
*
°
control clone 6
200µm
*
**
°
control clone 5
200µm
*
°
control clone 25
200µm
PAX3-FOXO1 clone 1
100µm 50µm
B
C
200µm
PA
X3
-F
O
XO
1
cl
on
e
1
co
nt
ro
l
cl
on
e
6
AP2β
E
PA
X3
-F
O
XO
1
cl
on
e
1
co
nt
ro
l
cl
on
e
6
MIB1
50µm200µm
D
50µm200µm
50µm
50µm200µm
SUPPL FIG 1
A
B
%
of
ce
lls
fo
rm
in
g
sp
he
re
s
RH30 cell line
passages
%
of
ce
lls
fo
rm
in
g
sp
he
re
s
RMS13 cell line
passages
RH30 sphere NANOG
Fo
ld
in
cr
ea
se
passages
RH30 sphere OCT4
Fo
ld
in
cr
ea
se
passages
RH30 sphere SOX2
Fo
ld
in
cr
ea
se
passages
RMS13 sphere NANOG
Fo
ld
in
cr
ea
se
passages
RMS13 sphere OCT4
Fo
ld
in
cr
ea
se
passages
RMS13 sphere SOX2
Fo
ld
in
cr
ea
se
passages
A
DEAB treated cells DEAB treated cellsDEAB treated cells
control fraction ALDH1 low fraction ALDH1 high fraction
SUPPL FIG 2
NANOG DAPI merged
R
H
4
R
H
5
R
M
S1
3
R
H
30
R
H
41
C
W
90
19
A
100µm
100µm
100µm
100µm
100µm
100µm
1/
(∆
C
tN
an
og
-G
A
P
D
H
)
NANOG basal level expression
SUPPL FIG 3A
OCT4 DAPI merged
R
H
4
R
H
5
R
M
S1
3
R
H
30
R
H
41
C
W
90
19
100µm
100µm
100µm
100µm
100µm
100µm
B
1/
(∆
C
tO
ct
4-
G
A
P
D
H
)
OCT4 basal level expression
SUPPL FIG 3B
DAPI merged
R
H
4
SOX2
R
H
5
R
M
S1
3
R
H
30
R
H
41
C
W
90
19
SUPPL FIG 3C
C
100µm
100µm
100µm
100µm
100µm
100µm
1/
(∆
C
tS
O
X
2-
G
A
P
D
H
) SOX2 basal level expression
SUPPL FIG 4
NT2NOSNGFP
RH4
N
an
og
Tu
bu
lin
NT2 NOSOGFP
RH4
O
ct
4
NT2 NOSSGFP
RH4
S
ox
2
NT2NOSNGFP
RH30
N
an
og
NT2NOSOGFP
RH30
O
ct
4
NT2NOSSGFP
RH30
S
ox
2
A B
C D
E F
Fo
ld
ch
an
ge
RH30 cell line
EGFP Nanog Sox2Oct4 NOS
%
of
pr
ol
ife
ra
tin
g
ce
lls
RH30 cell line
Tu
bu
lin
Tu
bu
lin
Tu
bu
lin
Tu
bu
lin
Tu
bu
lin
nu
m
be
ro
fc
lo
ne
s
N
um
be
ro
fs
ph
er
es
RH30 cell line
RH30 cell line
N
um
be
ro
fs
ph
er
es
RH30 cell line
**
* ******
***
*
****
desminmyogeninH&E
10
5
ce
lls
10
4
ce
lls
10
0
ce
lls
50 µm
50 µm
SUPPL FIG 5
A
B PRIMARY TUMOR (5x104 cells)
C SECONDARY TUMOR (1x104 cells)
50 µm
SUPPL FIG 6
A
Fo
ld
ch
an
ge
Fo
ld
ch
an
ge
HFF fibroblast Pax3-Foxo1 iPSC control iPSC
B
NANOG SSEA4 mergedphase
100 µm
NANOG SSEA4 mergedphase
100 µm
co
nt
ro
l
P
ax
3-
Fo
xo
1
100 µm
OCT4 TRA60 mergedphase
100 µm
OCT4 TRA60 mergedphase
co
nt
ro
l
P
ax
3-
Fo
xo
1
SUPPL FIG 7
B
Fo
ld
ch
an
ge
Fo
ld
ch
an
ge
HFF fibroblast Pax3-Foxo1 iPSC control iPSC
A
SUPPL FIG 8
P
ax
3-
Fo
xo
1
cl
on
e
1
w
ild
ty
pe
cl
on
e
5
w
ild
ty
pe
cl
on
e
6
w
ild
ty
pe
cl
on
e
25
phase
phase
phase
phase
oct4
oct4
oct4
oct4
hoechst
hoechst
hoechst
hoechst
merged
merged
merged
merged
100 µm
100 µm
100 µm
100 µm
A
P
ax
3-
Fo
xo
1
cl
on
e
1
w
ild
ty
pe
cl
on
e
5
w
ild
ty
pe
cl
on
e
6
w
ild
ty
pe
cl
on
e
25
phase
phase
phase
phase
100 µm
100 µm
100 µm
100 µm
Nanog hoechst merged
Nanog hoechst
Nanog hoechst merged
Nanog hoechst merged
merged
B
AFo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
iPSC control clone 6
EB Pax3-Foxo1 clone 1
EB control clone 6
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
E
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
B
neural diff control clone 6
neural diff Pax3-Foxo1 clone 1
F
SUPPL FIG 9
control clone 6
EB
100 µm
EB
Pax3-Foxo1 clone 1
100 µm
+FBS +FBS
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6) +FBS muscle diff Pax3-Foxo1 clone 1
+FBS muscle diff control clone 6C
- FBS muscle diff Pax3-Foxo1 clone 1
- FBS muscle diff control clone 6
Fo
ld
ch
an
ge
(r
el
to
iP
S
C
cl
on
e
6)
iPSC control clone 6
endoderm diff Pax3-Foxo1 clone 1
endoderm diff control clone 6
D
cl
on
e
5
i.m
AP2β
cl
on
e
5
s.
c.
cl
on
e
6
i.m
.
A
200µm 50µm
200µm 50µm
200µm 50µm
B
cl
on
e
1
i.m
.L
cl
on
e
1
i.m
.R
200µm 50µm
200µm 50µm
cl
on
e
5
i.m
SUPPL FIG 10
cl
on
e
5
s.
c.
cl
on
e
6
i.m
.
cl
on
e
1
i.m
.L
cl
on
e
1
i.m
.R
200µm 50µm
200µm 50µm
200µm 50µm
200µm 50µm
200µm 50µm
ΜΙΒ1
1 
Supplemental Table 1: TaqMan® Gene Expression Assays (Life Technologies) 
Gene name TaqMan assay number 
ABCG2 Hs01053790_m1 
AFP Hs00173490_m1 
ALDH1A1 Hs00946916_m1 
AMY2A; AMY+ Hs00420710_g1 
AP2b (TFAP2b) Hs01560931_m1 
BRACHYURY T Hs00610080_m1 
CNR1 Hs01038522_s1 
DCX Hs00167057_m1 
DNMT3B Hs00171876_m1 
FGFR4 Hs01106908_m1 
GAPDH Hs02758991_g1 
GATA4 Hs00171403_m1 
HMBS Hs00609297_m1 
MSX1 Hs00427183_m1 
MYH3 Hs01074230_m1 
MYL1 Hs00984899_m1 
NANOG Hs02387400_g1 
OLIG2 Hs00300164_s1 
PAX3 Hs00992437_m1 
PAX3-FOXO1 Hs03024825_ft 
PAX6 Hs00240871_m1 
PAX7 Hs00242962_m1 
POU5F1 (OCT4) Hs04260367_gH 
REXO1 Hs00810654_m1 
SOX1 Hs01057642_s1 
SOX11 Hs00846583_s1 
SOX12 Hs00272869_s1 
SOX2 Hs04234836_s1 
SOX4 Hs00268388_s1 
SOX9 Hs01001343_g1 
TNNC1 Hs00896999_g1 
TUBB3 Hs00801390_s1 
2 
Supplemental Table 2: Antibodies list 
 Primary antibody (clone) Company Application (dilution) 
mouse anti-NANOG (hNanog.2) eBioscience WB (1:500), IF (1:50 aRMS & 1:200 iPSC) 
rabbit anti-OCT4 (C52G3) Cell Signaling WB (1:500), IF (1:50 aRMS & 1:200 iPSC) 
rabbit anti-SOX2 (D6D9) Cell Signaling WB (1:500), IF (1:50 aRMS) 
mouse anti-TUBULIN (B5-1-2) Sigma-Aldrich WB (1:40’000) 
mouse anti-SSEA4 (MC-813-70) Developmental 
Studies 
Hybridoma Bank 
IF (1:200) 
anti-human TRA-1-60 biotin eBioscience IF (1:200) 
polyclonal rabbit anti-AP2β Thermo Scientific IF (1:200) 
polyclonal rabbit anti-AMYLASE Sigma IF (1:1000) 
rabbit anti-GFAP (Z 0334) Dako Cytomotion IF (1:500) 
mouse anti-3βTUBULIN (TU-20) Cell Signaling IF (1:500) 
mouse anti-human Desmin (D33) DAKO IHC (1:20) 
mouse anti-Myf4 (L026) Novocastra 
Laboratories Ltd 
IHC (1:20) 
rabbit anti-mib1 (30-9) Ventana-Roche - 
phalloidin-FITC Enzo IF (1:2000) 
 Secondary antibody Company Application (dilution) 
anti-mouse HRP-linked 7076S Cell Signaling WB (1:2000) 
anti-rabbit HRP-linked 7074S Cell Signaling WB (1:2000) 
anti rabbit Alexa Fluor 594 Invitrogen IF (1:500) 
anti mouse Alexa Fluor 594 Invitrogen IF (1:500) 
anti mouse Alexa Fluor 488 Invitrogen IF (1:500) 
anti rabbit Alexa Fluor 488 Invitrogen IF (1:500) 
WB: Western Blotting; IF: Immunofluorescence; IHC: Immunohistochemistry 
